

APPLICATION  
FOR  
UNITED STATES LETTERS PATENT

TITLE: CD44 LIGANDS

APPLICANT: ISAAC J. RONDON, ALBERT EDGE AND  
RACHEL BARIBAULT KENT

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV332296680US

Date of Deposit September 15, 2003

## CD44-BINDING LIGANDS

### CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This application claims priority to U.S. Provisional Patent Applications Serial No. 60/410,758, filed on September 13, 2002, and 60/469,123, filed May 9, 2003, the contents of which are hereby incorporated by reference in their entireties.

### BACKGROUND

[002] *CD44* is a highly conserved gene found in mammals. Goodison *et al.* (1999) *Mol. Pathol.* 52(4):189-96. It encodes a type I transmembrane protein and is a member of the cartilage link protein family. Bajorath (2000) *Proteins* 39(2):103-11. Through alternative splicing, the *CD44* gene gives rise to many different CD44 protein isoforms, which tend to be expressed in a cell-specific manner and differentially glycosylated. CD44 is expressed in many different tissues, including white blood cells and metastatic cancer cells, where it functions in cell-cell and cell-matrix adhesion, as well as in signal transduction. A major endogenous ligand of CD44 is hyaluronic acid (HA), an integral component of the extracellular matrix. Other endogenous CD44 ligands include: osteopontin, serglycin, collagen, fibronectin, and laminin.

[003] Adhesive interactions between receptors on vascular endothelial cells (ECs) and circulating leukocytes regulate the extravasation of leukocytes at sites of inflammation. Activated CD44 can bind to hyaluronic acid (HA). The affinity of CD44 present on the surface of leukocytes for its ligand HA is subject to regulation. In resting leukocytes, the affinity of CD44 for HA is relatively low (about 150 $\mu$ M for murine CD44). Upon T cell receptor activation, CD44 becomes activated resulting in an increase in its affinity for HA (to about 5 $\mu$ M for murine CD44). The interaction between activated CD44 and HA can mediate the extravasation of activated leukocytes into an inflamed site. CD44 can mediate the adhesion and migration of metastatic tumor cells. See generally, e.g., Isacke and Yarwood (2002) *Int. J Biochem. Cell Biol.* 34(7):718-21; Siegelman *et al.* (1999) *J Leukoc. Biol.* 66(2):315-21; Pure and Cuff (2001) *Trends Mol Med* 7(5):213-21; and Yasuda *et al.* (2002) *Histol Histopathol* 17(3):945-50.

## SUMMARY

[004] The invention provides, *inter alia*, CD44-binding antibodies, antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments. Methods of using the antibodies to detect CD44 or to modulate a CD44-expressing cell, e.g., in a subject, are also described.

[005] In one aspect, the invention features a protein that interacts with, e.g., binds to CD44, e.g., human CD44, with high affinity and specificity. For example, the protein binds to human CD44 with an affinity constant of at least  $2 \times 10^7 \text{ M}^{-1}$ , e.g., at least  $10^8 \text{ M}^{-1}$ ,  $10^9 \text{ M}^{-1}$ , or  $10^{10} \text{ M}^{-1}$ . In one embodiment, the protein includes one or more human CDRs, e.g., one, two, three, four, five, or six human CDRs. For example, the LC CDRs can be human. In another example, HC CDR3 is human.

[006] In one embodiment, the protein binds to activated CD44 with an affinity ( $K_a$ ) higher (e.g., 1.2, 1.5, 1.8, 2, 3, 4, 5, 10, 20, 50, 100-fold higher) than their affinity for resting CD44. In one embodiment, the protein binds to deglycosylated CD44 (e.g., CD44 antigen produced in an activated lymphocyte or CD44 antigen that has been treated with a glycosidase enzyme, e.g., deglycosylated CD44Fc) with an affinity ( $K_a$ ) higher (e.g., 1.2, 1.5, 1.8, 2, 3, 4, 5, 10, 20, 50, 100-fold higher) than their affinity for resting CD44. In still another embodiment, the protein binds to high-affinity CD44 (i.e., CD44 that displays an increase in affinity for HA as compared to resting CD44) with an affinity ( $K_a$ ) higher (e.g., 1.2, 1.5, 1.8, 2, 3, 4, 5, 10, 20, 50, 100-fold higher) than their affinity for resting CD44.

[007] In one embodiment, the protein interacts with, e.g., binds to, the extracellular domain of CD44, e.g., a hyaluronic acid (HA) binding domain or fragment of human CD44 (e.g., about amino acids 21-649, or about amino acids 21-222, of SEQ ID NO:1). In some embodiments, the protein binds to the extracellular domain of human CD44 (e.g., the HA binding domain) and inhibits the binding of CD44 to HA. For example, the protein inhibits HA binding and includes one or more features (e.g., CDRs) of HAE-A3, HAE-G2, or HAE-H10.

**[008]** In one embodiment, the CD44-binding protein binds all or part of the epitope bound by a polypeptide or antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10 (also referred to as HH10), H1, HAE-A3, BE-H10 (also referred to as BH10), HAE-H9, or HAE-G2. For example, the CD44-binding protein can inhibit, e.g., competitively inhibit, the binding of a polypeptide or antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, to human CD44. The protein may bind to an epitope, e.g., a conformational or a linear epitope, which epitope when bound prevents binding of a polypeptide or antibody described herein, BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2. The epitope can be in close proximity spatially or functionally-associated, e.g., an overlapping or adjacent epitope in linear sequence or conformationally to the one recognized by the BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2 antibody. In one embodiment, the CD44-binding protein binds to an epitope located wholly or partially within the region of about amino acids 21 to 649, 40-200, 120-200, 120-170, or 22-222 of SEQ ID NO:1. In one embodiment, the protein binds to an epitope that does not include an amino acid encoded by the v6 exon.

**[009]** The protein can bind to a CD44-expressing cell. For example, Human CD44 is expressed on many different cell types, including white blood cells (e.g., B cells, T cells, macrophages, and neutrophils), parenchymal cells, and tumor cells (e.g., cancerous lung, liver, colon, breast, ovarian, epidermal, laryngeal, and cartilage cells, and particularly metastatic cells thereof). In some embodiments, the protein can be internalized with the CD44 by a living cell, thereby providing intracellular delivery of an agent conjugated to the antibody, e.g., a cytotoxic or a labeling agent.

**[0010]** In one embodiment, the protein is used to modulate the activity of a CD44-expressing cell, e.g., in a subject or in vitro. For example, the protein can be used to therapeutically target living normal, benign hyperplastic, and cancerous cells that express CD44 in a subject, e.g., a human subject. In one embodiment, the protein preferentially binds to CD44 expressed on activated lymphocytes or parenchymal cells (e.g., they bind with higher affinity ( $K_a$ ), e.g., at least 1.2, 1.5, 1.8, 2, 3, 4, 5, 10, 20, 50,

100-fold, or more, higher, to activated lymphocytes than they bind to resting lymphocytes). In some related embodiments, the protein binds to neuraminidase treated KG1a cells with an affinity ( $K_a$ ) at least 1.2, 1.5, 1.8, 2, 3, 4, 5, 10, 20, 50, 100-fold, or more, higher than their affinity for untreated KG1a cells. In one embodiment, the protein has an  $IC_{50}$  for inhibition of KG1a cells for binding to HA of less than  $10^{-7}$ ,  $10^{-8}$ ,  $10^{-9}$ ,  $10^{-10}$  or  $10^{-11}$  M. In another embodiment, the protein binds to CD44 present on activated lymphocytes and parenchymal cells and accumulate at sites of inflammation, e.g., *in vivo*. In another embodiment, the protein binds to CD44 on lymphocytes, e.g., activated lymphocytes, and thereby inhibit (e.g., partially or completely) lymphocyte rolling on endothelial cells, e.g., *in vivo*. In still another embodiment, the protein binds to CD44 present on living cells, e.g., white blood cells (e.g., activated lymphocytes) or cancer cells (e.g., metastatic cancer cells), and inhibit (e.g., partially or completely) migration and/or extravasation of such cells from endothelial vessels. In still another embodiment, the protein is a CD44 activity enhancing ligand, a CD44-binding cell agonist, e.g., a CD44-binding NK-cell agonist, or a CD44-binding cell sensitizing agent, e.g., a CD44-binding NK-cell sensitizing agent.

**[00011]** In one aspect, the invention features a protein that binds to CD44 ectodomain, e.g., with a  $K_d$  of less than  $5 \times 10^{-6}$  M or  $2 \times 10^{-7}$  M. The protein includes a heavy chain immunoglobulin variable domain and a light chain immunoglobulin variable domain. Such ligands are referred to as “CD44-binding antibodies” or “CD44-binding antibodies.”

**[0012]** In some embodiments, the protein includes one or more of the following features: (1) a HC CDR1 sequence motif that includes  $X_1$ -Y- $X_2$ -M- $X_3$  (SEQ ID NO:98), wherein  $X_1$  is any amino acid (e.g., E, L, K, H, N, W, or P),  $X_2$  is any amino acid (e.g., G, R, S, T, or L), and  $X_3$  is any amino acid (e.g., G, R, W, M, N, D, E, or S); (2) a HC CDR2 sequence that includes:  $X_1$ -I- $X_2$ - $X_3$ - $X_4$ -G-G- $X_5$ -T- $X_6$ -Y-A-D-S-V-K-G (SEQ ID NO:99), where  $X_1$  is any amino acid (e.g., S or R);  $X_2$  is any amino acid (e.g., V, S, Y, W, F, V, G, or S),  $X_3$  is any amino acid (e.g., S or P),  $X_4$  is S or absent,  $X_5$  is any amino acid (e.g., hydrophobic (e.g., F, I, L, W, or P) or uncharged polar (e.g., Q or T)), and  $X_6$  is any amino acid (e.g., F, E, D, R, L, or K); and (3) a HC CDR3 sequence that includes one of the following exemplary sequences: DVGVGAAAD (SEQ ID NO:100),

DGYDSSGYEGFD (SEQ ID NO:101), RSGSYPAD (SEQ ID NO:102), DRAAA (SEQ ID NO:103), GWSSQPA (SEQ ID NO:104), DYYDSSGYSYFD (SEQ ID NO:105), QKRSSLGAFD (SEQ ID NO:106), DSYGMD (SEQ ID NO:107), and GTRTVT (SEQ ID NO:108), or a sequence that is at least 85% identical to one of the foregoing.

**[0013]** In some embodiments, the protein includes one or more of the following features: (1) a LC CDR1 (e.g., a kappa LC) that includes R-A-S-Q-S-I-X<sub>1</sub>-S-X<sub>2</sub>-L-N (SEQ ID NO:109), wherein X<sub>1</sub> is any amino acid (e.g., G or S) and X<sub>2</sub> is any amino acid (e.g., Y or H), or a sequence that differs by no more than two or one amino acid substitutions; (2) a LC CDR2 (e.g., a kappa LC) that includes an amino acid sequence of at least 6 amino acids of which at least 5 or 6 amino acids are identical to ASSLQS (SEQ ID NO:110); and (3) a LC CDR3 (e.g., a kappa LC) that includes X<sub>1</sub>-Q-S-X<sub>2</sub>-S-T-P-X<sub>3</sub>-T (SEQ ID NO:111), where X<sub>1</sub> is any amino acid (e.g., hydrophilic, e.g., Q or H), and X<sub>2</sub> is any amino acid (e.g., Y or S), X<sub>3</sub> is any amino acid (e.g., R or P).

**[0014]** In some embodiments, the protein includes one or more of the following features: (1) a LC CDR1 (e.g., a lambda LC) that includes an amino acid sequence of at least 11, 12, or 14 amino acids of which at least 9, 10, 11, 12, 13, or 14 amino acids are identical to TGTSSDVGGYSYVS (SEQ ID NO:112); (2) a LC CDR2 (e.g., a lambda LC) that includes an amino acid sequence of at least 7 amino acids of which at least 5, 6 or 7 amino acids are identical to EVSNRP (SEQ ID NO:113); and (3) a LC CDR3 (e.g., a lambda LC) that includes an amino acid sequence of at least 9 or 10 amino acids of which at least 7, 8, 9, or 10 amino acids are identical to NSYTSSSTKM (SEQ ID NO:114).

**[0015]** In one embodiment, the protein includes a HC variable domain that includes a CDR<sub>1</sub> sequence motif of X<sub>1</sub>-Y-X<sub>2</sub>-M-X<sub>3</sub> (SEQ ID NO:98), wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid, or X<sub>1</sub> is E, L or P, X<sub>2</sub> is G, R, or L, and X<sub>3</sub> is G, R, or S; and/or one of the following exemplary sequences: LYRMR (SEQ ID NO:115), PYLMS (SEQ ID NO:116), and EYGMG (SEQ ID NO:117). Other exemplary CDR1 amino acid sequences have a length of at least 5 amino acids of which at least 3, 4, or 5 amino acids are identical to a HC CDR1 sequence described herein.

**[0016]** In one embodiment, the protein includes HC variable domain that includes a CDR2 sequence with the following motif: S-I-X<sub>1</sub>-X<sub>2</sub>-S-G-G-X<sub>3</sub>-T-X<sub>4</sub>-Y-A-D-S-V-K-G

(SEQ ID NO:118), where  $X_1$  is any amino acid (e.g., valine, serine, or tyrosine),  $X_2$  is any amino acid (e.g., proline or serine),  $X_3$  is hydrophobic (e.g., phenylalanine, isoleucine, leucine, valine, methionine, tryptophan, or tyrosine), and  $X_4$  is any amino acid (e.g., phenylalanine, aspartic acid, glutamic acid, or acidic or aromatic). Exemplary sequences that match this motif include: SISPSGGITEYADSVKG (SEQ ID NO:119), SIYSSGGLTDYADSVKG (SEQ ID NO:120), and SIVSSGGFTFYADSVKG (SEQ ID NO:121). Other exemplary CDR2 amino acid sequences have an amino acid sequence of at least 15, 16, or 17 amino acids of which at least 10, 12, 14, 15, 16, or 17 amino acids are identical to a HC CDR2 sequence described herein.

**[0017]** In one embodiment, the protein includes a HC variable domain that includes a CDR3 sequence including one of the following exemplary sequences: DVGVGAAAD (SEQ ID NO:100), DGYDSSGYEGFD (SEQ ID NO:101), and GTRTVT (SEQ ID NO: 108), and/or an amino acid sequence of at least 7 or 8 amino acids of which at least 5, 6, 7, or 8 amino acids are identical to DVGVGAAAD (SEQ ID NO:100); and/or an amino acid sequence of at least 11, 12, or 13 amino acids of which at least 8, 9, 10, 11, 12, or 13 amino acids are identical to DGYDSSGYEGFD (SEQ ID NO: 101); and/or an amino acid sequence of at least 5 or 6 amino acids of which at least 3, 4, 5, or 6 amino acids are identical to GTRTVT (SEQ ID NO:108). In some embodiments, the CDR3 sequence is less than 15, 13, 11, 9 or 7 amino acids in length.

**[0018]** In one embodiment, the protein includes a LC variable domain that includes a CDR1 sequence which includes: the sequence RSSQSLHSHNGYNYLD (SEQ ID NO:122) ; and/or an amino acid sequence of at least 13, 15 or 16 amino acids of which at least 11, 13, 14, 15, or 16 amino acids are identical to RSSQSLHSHNGYNYLD (SEQ ID NO:122).

**[0019]** In one embodiment, the protein includes a LC variable domain that includes a CDR2 sequence which includes: the sequence LGSNRAS (SEQ ID NO:123); and/or an amino acid sequence of at least 4, 6 or 7 amino acids of which at least 3, 5, 6, or 7 amino acids are identical to LGSNRAS (SEQ ID NO:123).

**[0020]** In one embodiment, the protein includes a LC variable domain that includes a CDR3 sequence which includes: the motif M-Q-A-L-Q- $X_1$ -P- $X_2$ -T (SEQ ID

NO:124), where X<sub>1</sub> is any amino acid, (e.g., threonine) or absent, and X<sub>2</sub> is any amino acid (e.g., hydrophobic, (e.g., tryptophan, proline or phenylalanine), tyrosine, or arginine) or absent; one of the following exemplary sequences: MQALQPYT (SEQ ID NO:125), MQALQTPWT (SEQ ID NO:126), or MQALQTPPT (SEQ ID NO:127); and/or an amino acid sequence of at least 6, 8 or 9 amino acids of which at least 5, 6, 7, 8, or 9 amino acids are identical to MQALQPYT (SEQ ID NO:125), MQALQTPWT (SEQ ID NO:126) or MQALQTPPT (SEQ ID NO:127).

**[0021]** In one embodiment, the CDR regions of the heavy or light chain variable domain (e.g., one or more of CDR1, CDR2, and CDR3) are at least 60, 70, 80, 90, 92, 95, 96, 97, 98, or 99% identical to a corresponding heavy or light CDR sequence described herein, e.g., a CDR in of the following antibodies: BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2.

**[0022]** In one embodiment, the framework regions of the heavy or light chain variable domain (e.g., one or more of FR1, FR2, FR3, and FR4) are at least 60, 70, 80, 90, 92, 95, 96, 97, 98, or 99% identical to a corresponding heavy or light FR sequence, e.g., a known sequence or a sequence described herein. For example, the framework region or the corresponding sequence to which the framework region is related is human.

**[0023]** In another embodiment, framework features can include one or more of the following features. For example, FR1-L can include D-I-Q-M-T-Q-S-P-X<sub>1</sub>-S-L-X<sub>2</sub>--X<sub>3</sub>-X<sub>4</sub>-X<sub>5</sub>-G-X<sub>6</sub>-X<sub>7</sub>-X<sub>8</sub>-X<sub>9</sub>-I-X<sub>10</sub>-C (SEQ ID NO:128), wherein X<sub>1</sub> is L or S, X<sub>2</sub> is P or S, X<sub>3</sub> is a small amino acid (e.g., fewer than four side chain carbons, e.g., A, V, or G), X<sub>4</sub> is T or S, X<sub>5</sub> is V or P, X<sub>6</sub> is E, D, or G, X<sub>7</sub> is P or R, X<sub>8</sub> is A or V, X<sub>9</sub> is S or T, X<sub>10</sub> is S or T; D-I-Q-M-T-Q-S-P-X<sub>1</sub>-S-L-P-X<sub>2</sub>-X<sub>3</sub>-X<sub>4</sub>-G-X<sub>5</sub>-X<sub>6</sub>-X<sub>7</sub>-X<sub>8</sub>-I-X<sub>9</sub>-C (SEQ ID NO:129), wherein X<sub>1</sub> is L or S, X<sub>2</sub> is a small amino acid (e.g., fewer than four side chain carbons, e.g., A, V, or G), X<sub>3</sub> is T or S, X<sub>4</sub> is V or P, X<sub>4</sub> is aliphatic (e.g., A, V, or I) is X<sub>5</sub> is E, D, or G, X<sub>6</sub> is P or R, X<sub>7</sub> is A or V, X<sub>8</sub> is S or T, X<sub>9</sub> is S or T; or a sequence which differs by at least one, but less than 6, 5, 3, or 2 amino acids from D-I-Q-M-T-Q-S-P-X<sub>1</sub>-S-L-X<sub>2</sub>-X<sub>3</sub>-X<sub>4</sub>-X<sub>5</sub>-G-X<sub>6</sub>-X<sub>7</sub>-X<sub>8</sub>-X<sub>9</sub>-I-X<sub>10</sub>-C (SEQ ID NO:128) at positions other than X (e.g., a substitution, e.g., a conservative substitution). FR1-L can include DIQMTQSPX<sub>1</sub>SLPVTGPX<sub>2</sub>PASISC (SEQ ID NO:130) wherein X<sub>1</sub> is any amino acid



(e. g., leucine or serine),  $X_2$  is any amino acid (e.g., glycine or glutamic acid), or a sequence which differs by at least one, but less than 7, 6, 5, 3, or 2 amino acids from DIQMTQSPX<sub>1</sub>SLPVTGPX<sub>2</sub>PASISC (SEQ ID NO:130) at positions other than X (e.g., a substitution, e.g., a conservative substitution).

**[0024]** FR2-L can include W-Y- $X_1$ - $X_2$ - $X_3$ -P-G- $X_4$ - $X_5$ -P- $X_6$ -L-L-I-Y (SEQ ID NO:131), wherein  $X_1$  is L or Q,  $X_2$  is Q or R,  $X_3$  is K or R,  $X_4$  is Q or K,  $X_5$  is S or A,  $X_6$  is Q or K, or a sequence which differs by at least one, but less than 5, 4, 3, or 2 amino acids from WYLQKPGQSPQLLIY (SEQ ID NO:132) or WYQRRPGKAPKLLIY (SEQ ID NO:133). FR2-L can include WYLQKPGQSPQLLIY (SEQ ID NO:132) or a sequence which differs by at least one, but less than 5, 4, 3, or 2 amino acids from SEQ ID NO:132 (e.g., a substitution, e.g., a conservative substitution).

**[0025]** FR3-L can include GVPX<sub>1</sub>RFSGSGSGTDF (SEQ ID NO:134), wherein  $X_1$  is any amino acid (e.g., D or S), or a sequence which differs by at least one, but less than 3, or 2 amino acids from GVPX<sub>1</sub>RFSGSGSGTDF (SEQ ID NO:134) at positions other than indicated by X (e.g., a substitution, e.g., a conservative substitution). FR3-L can include GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC (SEQ ID NO:135) or a sequence which differs by at least one, but less than 5, 4, 3, or 2 amino acids from GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC (SEQ ID NO:135) (e.g., a substitution, e.g., a conservative substitution) (e.g., a substitution, e.g., a conservative substitution).

**[0026]** FR3-L which comprises GVP- $X_1$ -RFSGSGSGTDF- $X_2$ -L- $X_3$ -I- $X_4$ - $X_5$ - $X_6$ - $X_7$ - $X_8$ -ED- $X_9$ - $X_{10}$ - $X_{11}$ -Y- $X_{12}$ -C (SEQ ID NO:136), wherein  $X_1$  is any amino acid (e.g., D or S),  $X_2$  is any amino acid (e.g., T or A),  $X_3$  is any amino acid (e.g., K or T),  $X_4$  is any amino acid (e.g., S or N),  $X_5$  is any amino acid (e.g., R, G, or S),  $X_6$  is any amino acid (e.g., V or L),  $X_7$  is any amino acid (e.g., E or Q),  $X_8$  is any amino acid (e.g., A or P),  $X_9$  is any amino acid (e.g., V or F),  $X_{10}$  is any amino acid (e.g., G or A),  $X_{11}$  is any amino acid (V, T, or A),  $X_{12}$  is aromatic, or a sequence which differs by at least one, but less than 3, or 2 amino acids from GVP- $X_1$ -RFSGSGSGTDF- $X_2$ -L- $X_3$ -I- $X_4$ - $X_5$ - $X_6$ - $X_7$ - $X_8$ -ED- $X_9$ - $X_{10}$ - $X_{11}$ -Y- $X_{12}$ -C (SEQ ID NO:136) at positions other than indicated by X (e.g., a substitution, e.g., a conservative substitution). FR4-L can include F-G- $X_1$ -G-T- $X_2$ - $X_3$ -

X<sub>4</sub>-I-K (SEQ ID NO:137), wherein X<sub>1</sub> is any amino acid (e.g., G, Q, or P), and X<sub>2</sub> is K, T, or R, X<sub>3</sub> is hydrophobic (e.g., aliphatic, e.g., V or L), X<sub>4</sub> is hydrophilic (e.g., E, D, or T), or a sequence which differs by at least one, but less than 3, or 2 amino acids from F-G-X<sub>1</sub>-G-T-X<sub>2</sub>-X<sub>3</sub>-X<sub>4</sub>-I-K (SEQ ID NO:137) at positions other than indicated by X (e.g., a substitution, e.g., a conservative substitution).

**[0027]** FR4-L can include FGX<sub>1</sub>GTKX<sub>2</sub>EIK (SEQ ID NO:138), wherein X<sub>1</sub> is glycine or glutamine, and X<sub>2</sub> is leucine or valine. FR4-L can include FGX<sub>1</sub>GTKX<sub>2</sub>EIK (SEQ ID NO:138), wherein X<sub>1</sub> is any amino acid (e.g., glycine or glutamine), and X<sub>2</sub> is hydrophobic (e.g., leucine or valine), or a sequence which differs by at least one, but less than 3, or 2 amino acids from FGX<sub>1</sub>GTKX<sub>2</sub>EIK (SEQ ID NO:138) at positions other than X<sub>1</sub> or X<sub>2</sub> (e.g., a substitution, e.g., a conservative substitution).

**[0028]** FR1-H can include EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO:139) or a sequence which differs by at least one, but less than 7, 6, 5, 3, or 2 amino acids from EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO:139)(e.g., a substitution, e.g., a conservative substitution).

**[0029]** FR2-H can include WVRQAPGKGLEWVS (SEQ ID NO:140), or a sequence which differs by at least one, but less than 5, 4, 3, or 2 amino acids from WVRQAPGKGLEWVS (SEQ ID NO:140)(e.g., a substitution, e.g., a conservative substitution).

**[0030]** FR3-H can include RFTISRDN SKNTLYLQMNSLRAEDTAVYX<sub>1</sub>CAX<sub>2</sub> (SEQ ID NO:141) where X<sub>1</sub> can be any amino acid, e.g., tyrosine or histidine and X<sub>2</sub> can be any amino acid, e.g., arginine, glycine or leucine, or a sequence that differs from RFTISRDN SKNTLYLQMNSLRAEDTAVYX<sub>1</sub>CAX<sub>2</sub> (SEQ ID NO: 141) by at least one, but less than 5, 4, 3, or 2 amino acids (e.g., a substitution, e.g., a conservative substitution).

**[0031]** FR4-H can include X<sub>1</sub>WGQGX<sub>2</sub>LVTVS (SEQ ID NO:142), wherein X<sub>1</sub> is any amino acid (e.g., asparagine or tyrosine), and X<sub>2</sub> is any amino acid (e.g., alanine or threonine), or a sequence that differs from YWGQGLTVTVSS (SEQ ID NO:143) by at least one, but less than 4, 3, or 2 amino acids (e.g., a substitution, e.g., a conservative substitution).

**[0032]** In one embodiment, a CD44-binding protein includes one or more of the following features: it (1) detectably binds to a CD44-expressing cell (e.g., as detected by a method described herein), at a concentration of less than 1000, 500, 200, 100, 50, 25, or 20 µg/ml; (2) inhibits HA binding to a CD44-expressing cell (e.g., CD44+ KG1a cells) by at least 20, 40, 60, or 80% inhibition at a concentration of less than 500, 200, 100, 50, or 20 µg/ml (e.g., in vitro or in vivo); (3) inhibits leukocyte-endothelial cell adhesion (e.g., adherence between HMEC cells and KG1a cells); (4) affects cell migration (e.g., endothelial cells, e.g., after wound infliction); and/or (5) affects wound healing (e.g., in an in vitro assay or in vivo).

**[0033]** The antibody is preferably monospecific, e.g., a monoclonal antibody, or antigen-binding fragment thereof. The term “monospecific antibody” refers to an antibody that displays a single binding specificity and affinity for a particular target, e.g., epitope. This term includes a “monoclonal antibody” or “monoclonal antibody composition,” which as used herein refer to a preparation of antibodies or fragments thereof of single molecular composition.

**[0034]** The CD44-binding antibodies can be full-length (e.g., an IgG (e.g., an IgG1, IgG2, IgG3, IgG4), IgM, IgA (e.g., IgA1, IgA2), IgD, and IgE) or can include only an antigen-binding fragment (e.g., a Fab, F(ab')<sub>2</sub> or scFv fragment). The antibody, or antigen-binding fragment thereof, can include two heavy chain immunoglobulins and two light chain immunoglobulins, or can be a single chain antibody. The antibodies can, optionally, include a constant region chosen from a kappa, lambda, alpha, gamma, delta, epsilon or a mu constant region gene. A CD44-binding antibody can include a heavy and light chain constant region substantially from a human antibody, e.g., a human IgG1 constant region or a portion thereof. As used herein, “isotype” refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

**[0035]** In a preferred embodiment, the antibody (or fragment thereof) is a recombinant CD44-binding antibody or modified CD44-binding antibody. For example, the antibody is a chimeric, a humanized, a deimmunized, or an *in vitro* generated antibody. The term “recombinant” or “modified” human antibody, as used herein, is intended to include all antibodies that are prepared, expressed, created or isolated by

recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, antibodies isolated from an animal (*e.g.*, a mouse) that is transgenic for human immunoglobulin genes or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant antibodies include humanized, CDR grafted, chimeric, deimmunized, *in vitro* generated antibodies, and may optionally include constant regions derived from human germline immunoglobulin sequences.

**[0036]** In one embodiment, the CD44-binding antibody binds to an epitope distinct from an epitope bound by known CD44-binding antibodies, *e.g.*, MAbs OS/37 (Cao et al., *Immunobiology*. 1995 **193**(1)1-14. and Murakami et al., *J Immunol*. 1994 **152**(2)467-77.), BU52 (Guo et al., *Int Immunol*. 1994 **6**(2)213-21. and Guy et al., *Immunology*. 1992 **75**(4)713-6.), Hermes-3 (de los Toyos et al., *Blood*. 1989 **74**(2)751-60. and Picker et al., *J Immunol*. 1989 **142**(6)2046-51.), AlG3 and A3D8 (Haynes et al. (1983) *J. Immunol*. 131:1195-1200, Telen et al. (1983) *J. Clin. Invest*. 71; 1878-1886), and TL-1 (Cao et al., *Immunobiology*. 1996-97 **196**(5)504-12. and Cao et al., *Immunobiology*. 1995 **193**(1):1-14.). In other embodiments, the CD44-binding antibody does not compete with known CD44-binding antibodies, *e.g.*, MAbs OS/37, BU52, Hermes-3, and TL-1, for binding to CD44. In still other embodiments, the CD44-binding antibody does not compete with a CD44-binding ligand described herein, *e.g.*, BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2.

**[0037]** In one embodiment, the CD44-binding antibody binds to an epitope that overlaps with or is identical to an epitope bound by a known CD44-binding antibody, *e.g.*, the S5 monoclonal antibody or the IM7 antibody.

**[0038]** In other embodiments, the CD44-binding antibody is a human antibody. In some embodiments, the antibody is produced by a cell that includes one or more nucleic acid molecules selected from the group consisting of nucleic acids encoding an immunoglobulin HC or LC of an antibody described herein, *e.g.*, BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or

HAE-G2; a nucleic acid that differs from one of these sequences by 5, 10, 15, 20, or 25 bases or less (e.g., by a substitution (e.g., a silent codon change), non-frameshifting insertion, or non-frameshifting deletion), a nucleic acid that hybridizes under high stringency conditions to such a nucleic acid sequence; or a nucleic acid that encodes a polypeptide that includes the amino acid sequence of an immunoglobulin HC or LC of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or a nucleic acid or polypeptide described herein (e.g., a homologous nucleic acid or polypeptide described herein), or a polypeptide that differs from one of these by 1, 2, 3, 5, 7, 10, 12, 15, or 20 amino acids or less (e.g., by a substitution (e.g., a conservative substitution), insertion, or deletion).

**[0039]** Also within the scope of the invention are antibodies, or antigen-binding fragments thereof, which bind overlapping epitopes of, or competitively inhibit, the binding of the CD44-binding antibodies disclosed herein to CD44, e.g., antibodies which bind overlapping epitopes of, or competitively inhibit, the binding of monospecific antibodies, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, to CD44. Any combination of CD44-binding antibodies is within the scope of the invention, e.g., two or more antibodies that bind to different regions of CD44, e.g., antibodies that bind to two different epitopes on the extracellular domain of CD44, e.g., a bispecific antibody.

**[0040]** In one embodiment, the CD44-binding antibody, or antigen-binding fragment thereof, includes at least one light or heavy chain immunoglobulin (or preferably, at least one light chain immunoglobulin and at least one heavy chain immunoglobulin). Preferably, each immunoglobulin includes a light or a heavy chain variable region having at least one, two and, preferably, three complementarity determining regions (CDR's) substantially identical to a CDR from a CD44-binding light or heavy chain variable region, respectively, e.g., from a light chain variable (VLC) region or a heavy chain variable (VHC) region from BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2. The light chain and heavy chain variable regions of such regions are shown in Table 1.

**Table 1**

<b>Antibody</b>	<b>Sequence</b>	<b>Identifier</b>
F2 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGGCCGT CACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTA GTGAAAGCCTCGTGACAGTGATGGAAACACCTACTTG GGTTGGTTTCAGCAGAGGCCAGGCCAATCTCCACGGCG CCTACTTTATAAGGTTTCTAACCGGGACTCTGGGGTCC CAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTT ACACTGCACATCAGCAGGGTGGAGGCTGAAGATGTTGG GGTTTATTACTGCATGCATTCTATACGCTGGCCGTGGA CGTTTCGGCCAAGGGACCACGGTGGAAATCAAG	SEQ ID NO:4
F2 VLC Amino Acid Sequence	DIQMTQSPLSLAVTLGQPASISCRSSESLVYSDGNTYL GWFQQRPGQSPRRLLYKVSNRDSGVPDRFSGSGSGTDF TLHISRVEAEDVGVYYCMHSIRWPWTFGQGTVEIK	SEQ ID NO:5
F2 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCCTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTCCTTACACTATGGCTTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTATCCTTCTGGTGGCACTACTCCTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGACATTTTACTG TGTATGATGGTTTTGATTTGTGGGGCCGAGGGACAATG GTCACCGTCTCAAGC	SEQ ID NO:6
F2 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYTMWVR QAPGKGLEWVSSIYPSSGTTTPYADSVKGRFTISRDNK NTLYLQMNSLR AEDTAVYYCARHFTVYDGF DLWGRGTM VTVSS	SEQ ID NO:7
H1 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTT GTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCA GTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAG CAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGG TGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCA GTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATC AGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTG TCAGCAGTATGGTAGCTCACCTCGAACGTTTCGGCCAAG GGACCAAGGTGGAAATCAAA	SEQ ID NO:8
H1 VLC Amino Acid Sequence	DIQMTQSPGTLSPGERATLSCRASQSVSSSYLAWYQ QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI SRLEPEDFAVYYCQYQGSSPRTFGQGTKVEIK	SEQ ID NO:9

H1 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTCATTACGGTATGTCTTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTCCTGGAT CGGTCTTCTGGTGGCGCTACTCTTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAAAGGAAGGTGGA ATAGGGGTGGCGCCTTTGACAACTGGGGCCAGGGAACC CTGGTCACCGTCTCAAGC	SEQ ID NO:10
H1 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYGMSWVR QAPGKGLEWVSWIGPSGGATLYADSVKGRFTISRDN SK NTLYLQMNSLRAEDTAVYYCAKGRWNRGGAFDNWGQGT LVTVSS	SEQ ID NO:11
H10 VLC Nucleic Acid Sequence  (aka HAE-H10)	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGT CACCCCTGGAGGGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAAC TATTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTC TAATCGGGCCTCCGGGGTCC CTGACAGGTTCA GTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTGCAACCGTACACTT TTGGCCAGGGGACCAAGCTGGAGATCAAA	SEQ ID NO:12
H10 VLC Amino Acid Sequence	DIQMTQSPLSLPVTPGGPASISCRSSQSLLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISRVEAEDVGVYYCMQALQPYTFGQGTKLEIK	SEQ ID NO:13
H10 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTCCTTACCTTATGTCTTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTCCTTCTAT CTATTCTTCTGGTGGCCTTACTGATTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACCATTGTGCGAGAGACGGTTACT ATGATAGTAGTGGTTACGAGGGTTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCAAGC	SEQ ID NO:14
H10 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYLMSWVR QAPGKGLEWVSSIIYSSGGLTDYADSVKGRFTISRDN SK NTLYLQMNSLRAEDTAVHYCARDGYDSSSGYEGFDYWG QGTLVTVSS	SEQ ID NO:15

A3 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCCGT CACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAAC TATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTCA GTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAAACTCCTCCCA CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA	SEQ ID NO:58
A3 VLC Amino Acid Sequence	DIQMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISRVEAEDVGVYYCMQALQTPPTFGGGTKVEIK	SEQ ID NO:59
A3 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCCTTACGTCTTTCTTGCGCTGCTTCCG GATTCAC TTTCTCTGAGTACGGTATGGGTTGGGTTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CGTTTCTTCTGGTGGCTTTACTTTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGGCACTCGTA CAGTAACCAACTGGGGCCAGGGAGCCCTGGTCACCGTC TCAAGC	SEQ ID NO:60
A3 VHC Amino Acid Sequence	EVQLLES GGLVQPGGSLRLSCAASGFTTFSEYGMGWR QAPGKGLEWVSSIVSSGGFTFYADSVKGRFTISRDN SK NTLYLQMNSLRAEDTAVYYCARGTRTVTNWGQALVTV SS	SEQ ID NO:61
G2 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCCGT CACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAAC TATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTCA GTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAAACCCCTTGA CTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	SEQ ID NO:62
G2 VLC Amino Acid Sequence	DIQMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISRVEAEDVGVYYCMQALQTPWTFGQGTKLEIK	SEQ ID NO:63



G2 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACTTTCTCTCTTTACCGTATGCGTTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTCTCCTTCTGGTGGCATTACTGAGTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGCTAGACGTGGGGG TGGGAGCTGCTGACTACTGGGGCCAGGGAACCCTGGTC ACCGTCTCAAGC	SEQ ID NO:64
G2 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYRMRWVR QAPGKGLEWVSSISPSGGITEYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCALDVGVAADYWGQGLV TVSS	SEQ ID NO:65
B12 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGT CACCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCGGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAACTGGGTACA CTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	SEQ ID NO:66
B12 VLC Amino Acid Sequence	DIQMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISGVEAEDVGVYYCMQALQTGYTFGQGTKLEIK	SEQ ID NO:67
B12 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACTTTCTCTAAGTACACTATGTGGTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTGGTCTTCTGGTGGCTTTACTCGTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGGGACGTAGTGGGA GCTACCCCGCTGATATCTGGGGCCAAGGGACAATGGTC ACCGTCTCAAGC	SEQ ID NO:68
B12 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYTMWWVR QAPGKGLEWVSSIWSSGGFTRYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCAGRSGSPADIWGQGTMV TVSS	SEQ ID NO:69

D7 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGT CACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAACATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CCGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAACTCCTAGGA CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA	SEQ ID NO:70
D7 VLC Amino Acid Sequence	DIQMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISRVEAEDVGVYYCMQALQTPRTFGGGTKVEIK	SEQ ID NO:71
D7 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTCATTACTCTATGATGTGGGTTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTTTCTGGTGGCTGGACTCTTTATGCTGACTCCGTTA AAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAAT ACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGA CACTGCAGTCTACTATTGTGCGAGAGATCGGGCAGCTG CCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC	SEQ ID NO:72
D7 VHC Amino Acid Sequence	EVQLLESQGLVQPGGSLRLSCAASGFTFSHYMMWVR QAPGKGLEWVSSIFPGGWTLYADSVKGRFTISRDN SKN TLYLQMNSLRAEDTAVYYCARDRAAAYWGQGLVTVSS	SEQ ID NO:73
BH10 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGT CACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAACATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAACTCCCTGGA CGTTTCGGCCAAGGGACCAAGGTGGAAATCAAA	SEQ ID NO:74
BH10 VLC Amino Acid Sequence	DIQMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKISRVEAEDVGVYYCMQALQTPWTFGQGTKVEIK	SEQ ID NO:75

BH10 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTAATTACACTATGAATTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CGTTTCTTCTGGTGGCTTTACTAAGTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACCTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGGCTGGTCTA GTCAGCCCCGCCATCTGGGGCCAGGGAAGCCTGGTCACC GTCTCAAGC	SEQ ID NO:76
BH10 VHC Amino Acid Sequence	EVQLLESGLVQPGGSLRLSCAASGFTFSNYTMNWVR QAPGKGLEWVSSIVSSGGFTKYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARGWSSQPAIWQGQSLVT VSS	SEQ ID NO:77
B8 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGC ATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAA GTCAGAGCATTTGGCAGCTATTTAAATTGGTATCAGCAG AAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGC ATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAAGTG GCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGC AGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCA ACAGAGTTACTCTACCCCTCGGACTTTCGGCCCTGGGA CCAAAGTGGATATCAAA	SEQ ID NO:78
B8 VLC Amino Acid Sequence	DIQMTQSPSSLSASVGDRTITCRASQSIGSYLNWYQQ KPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSYSTPRTFGPGTKVDIK	SEQ ID NO:79
B8 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTTGGTACTCTATGTCTTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CGGTCTTCTGGTGGCCAGACTCGTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACCTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGATTACTATG ATAGTAGTGGTTATTCGTACTTTGACTACTGGGGCCAG GGAACCCAGGTCACCGTCTCAAGC	SEQ ID NO:80
B8 VHC Amino Acid Sequence	EVQLLESGLVQPGGSLRLSCAASGFTFSWYSMSWVR QAPGKGLEWVSSIGPSGGQTRYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARDYYDSSGYSYFDYWGQ GTQVTVSS	SEQ ID NO:81

F1 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGTCTGC ATCTGTGGGAGACAGAGTCACCATCACTTGTCTGGGCAA GTCAGAGCATTAGCAGCCATTTAAATTGGTATCAGCGG AGACCAGGGAAAGCCCCCTAAGCTCCTGATTTATGCTGC ATCCAGTTTGCAAAGCGGGGTCCCATCAAGGTTTCAGTG GCAGTGGATCTGGGACAGATTTCTGCTCTCACCATCAGC AGTCTACAACCTGAAGATTTTGCAGCTTACTTCTGTCA CCAGAGTTCCAGTACGCCTCCGACTTTCGGCCAAGGGA CCACGGTGGAAATCAAA	SEQ ID NO:82
F1 VLC Amino Acid Sequence	DIQMTQSPLSLASVGDRTITCRASQSISSHLNWKYQR RPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTIS SLQPEDFAAYFCHQSSSTPPTFGQGTVEIK	SEQ ID NO:83
F1 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACTTTCTCTCCTTACGGTATGGATTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTCTCCTTCTGGTGGCACTACTCTTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACCTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGACAAAAAAGGT CCTCGTTAGGTGCTTTTGATATCTGGGGCCAAGGGACA ATGGTCACCGTCTCAAGC	SEQ ID NO:84
F1 VHC Amino Acid Sequence	EVQLLESGLLVQPGGSLRLSCAASGFTFSPYGMWVR QAPGKGLEWVSSISPSGGTTLYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARQKRSSLGAFDIWGQGT MVTVSS	SEQ ID NO:85
A11 VLC Nucleic Acid Sequence	GACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGT CGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTT GGTGGTTATAGCTATGTCTCCTGGTACCAACAGCACCC AGGCAAAGCCCCCAAACATGATTTATGAGGTCAGTA ATCGGCCCTCTGGGGTTTCTAATCGCTTCTCTGGCTCC AAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCT CCAGGCTGAAGACGAGGCTGATTATTACTGCAACTCAT ATACAAGCAGCAGCACTAAGATGTTCTGGCGGAGGGACC AGGCTGACCGTCCTA	SEQ ID NO:86
A11 VLC Amino Acid Sequence	QSVLTQPASVSGSPGQSITISCTGTSSDVGGYSYVSWY QQHPGKAPKLMIEVSNRPSGVSNRFSGSKSGNTASLT ISGLQAEDEADYYCNSYTSSSTKMFGGGTRLTVL	SEQ ID NO:87

A11 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTAAGTACTCTATGGAGTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTCCTCGTAT CTATCCTTCTGGTGGCCCTACTCTTTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGACTCTTACG GCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC TCAAGC	SEQ ID NO:88
A11 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYSMEWVR QAPGKGLEWVSRIYPSGGPTLYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARDYGMVWGQGTTVTV SS	SEQ ID NO:89
H9 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCATCCTCCCTGCCCGT CACCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAACCTATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTCAAGTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAACAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTACAACTCCGACGT TCGGCCAAGGGACCAAGGTGGAAATCAAA	SEQ ID NO:90
H9 VLC Amino Acid Sequence	DIQMTQSPSSLPVTPGEPASISCRSSQSLLSNGYNLYL DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF TLKINRVEAEDVGVYYCMQALQTPFTFGQGTKVEIK	SEQ ID NO:91
H9 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCTTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTTATTACGGTATGGGTGGGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTCCTCTAT CGGTCCTTCTGGTGGCCTTACTAATTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGGCACTCGTA CAGTAACCAACTGGGGCCAGGGAACCCTGGTCACCGTC TCAAGC	SEQ ID NO:92
H9 VHC Amino Acid Sequence	EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYGMGWVR QAPGKGLEWVSSIGPSGGLTNYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARGTRTVTNWGQGLVTV SS	SEQ ID NO:93

HH10 VLC Nucleic Acid Sequence	GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCCGT CACCCCTGGAGGGCCGGCCTCCATCTCCTGCAGGTCTA GTCAGAGCCTCCTGCATAGTAATGGATACAACATATTTG GATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCT CCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCC CTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTT ACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGG GGTTTATTACTGCATGCAAGCTCTGCAACCGTACACTT TTGGCCAGGGGACCAAGCTGGAGATCAAA	SEQ ID NO:94
HH10 VLC Amino Acid Sequence	DIQMTQSPLSLPVTTPGGPASISCRSSQSLHLSNGYNYL DWYLQKPGQSPQLLIYLGSNRASGVPDFRSGSGSGTDF TLKISRVEAEDVGVIYCMQALQPYTFGQGTKLEIK	SEQ ID NO:95
HH10 VHC Nucleic Acid Sequence	GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCA GCCTGGTGGTTCCTTACGTCTTTCTTGCGCTGCTTCCG GATTCACCTTCTCTCCTTACCTTATGTCTTGCGTTCGC CAAGCTCCTGGTAAAGGTTTGGAGTGGGTTTCTTCTAT CTATTCTTCTGGTGGCCTTACTGATTATGCTGACTCCG TTAAAGGTCGCTTCACTATCTCTAGAGACAACCTCTAAG AATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGA GGACACTGCAGTCTACTATTGTGCGAGAGACGGTTACT ATGATAGTAGTGGTTACGAGGGTTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCAAGC	SEQ ID NO:96
HH10 VHC Amino Acid Sequence	EVQLLESQGGLVQPGGSLRLSCAASGFTTFSPYLMWVR QAPGKGLEWVSSIYSSGGLTDYADSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCARDGYDSSGYEGFDYWG QGTLVTVSS	SEQ ID NO:97

Table 2

LIGHT CHAIN				
	SIGNAL SEQUENCE	FR1-L	CDR1-L	
HAE-A3-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
HAE-G2-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
HAE-H10-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGGPASISC	RSSQSLLHSNGYNYLD	
BE-B12-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
BE-D7-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
BE-H10-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
HAE-B8-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPSSLSASVGDRVTITC	RASQS....IGSYLN	
HAE-F1-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLSASVGDRVTITC	RASQS....ISSHLN	
BE-H9-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPSSLPVTTPGEPASISC	RSSQSLLHSNGYNYLD	
HAE-H-H10-k-light	MGWSCIIILFLVATATGVHS	DIQMTQSPLSLPVTTPGGPASISC	RSSQSLLHSNGYNYLD	
BE-A11-λ-light	MGWSCIIILFLVATATGVHS	.QSVLTQPASVSGSPGQSITISC	TGTSS..DVGGYSYVS	
	FR2-L	CDR2-L	FR3-L	
HAE-A3-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
HAE-G2-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
HAE-H10-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
BE-B12-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISGVEAEDVGVYYC	
BE-D7-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
BE-H10-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
HAE-B8-light	WYQQKPGKAPKLLIY	AASSLQS	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	
HAE-F1-light	WYQRRPGKAPKLLIY	AASSLQS	GVPSRFSGSGSGTDFALTISSLQPEDFAAYFC	
BE-H9-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKINRVEAEDVGVYYC	
HAE-H-H10-light	WYLQKPGQSPQLLIY	LGSNRRAS	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	
BE-A11-light	WYQQHPGKAPKLLMIY	EVSNNRPS	GVSNNRFSGSKSGNTASLTISGLQAEDVGVYYC	
	CDR3-L	FR4-L	CONSTANT REGION	
HAE-A3-light	MQALQT.PPT	FGGGTKVEIK	RTVAAPSVFIFPPSDEQLKSGTA	
HAE-G2-light	MQALQT.PWT	FGGGTKLEIK	RTVAAPSVFIFPPSDEQLKSGTA	
HAE-H10-light	MQALQ..PYT	FGGGTKLEIK	RTVAAPSVFIFPPSDEQLKSGTA	
BE-B12-light	MQALQT.GYT	FGGGTKLEIK	RTVAAPSVFIFPPSDEQLKSGTA	
BE-D7-light	MQALQT.PRT	FGGGTKVEIK	RTVAAPSVFIFPPSDEQLKSGTA	
BE-H10-light	MQALQT.PWT	FGGGTKVEIK	RTVAAPSVFIFPPSDEQLKSGTA	
HAE-B8-light	QQSYST.PRT	FGPGTKVDIK	RTVAAPSVFIFPPSDEQLKSGTA	
HAE-F1-light	HQSSST.PPT	FGGGTTVEIK	RTVAAPSVFIFPPSDEQLKSGTA	
BE-H9-light	MQALQT..PT	FGGGTKVEIK	RTVAAPSVFIFPPSDEQLKSGTA	
HAE-H-H10-light	MQALQ..PYT	FGGGTKLEIK	RTVAAPSVFIFPPSDEQLKSGTA	
BE-A11-light	NSYTSSSTKM	FGGGTRLTVL	GQPKAAPSVTLFPPSSEELQANK	
	CONSTANT REGION (contd)			
HAE-A3-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
HAE-G2-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
HAE-H10-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
BE-B12-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
BE-D7-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
BE-H10-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
HAE-B8-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
HAE-F1-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
BE-H9-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
HAE-H-H10-light	SVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTY			
BE-A11-light	ATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKY			
	CONSTANT REGION (contd)			
HAE-A3-light	SLSSTLTLSKADYEKKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQ ID NO:144)			
HAE-G2-light	SLSSTLTLSKADYEKKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQ ID NO:145)			
HAE-H10-light	SLSSTLTLSKADYEKKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQ ID NO:146)			
BE-B12-light	SLSSTLTLSKADYEKKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQ ID NO:147)			
BE-D7-light	SLSSTLTLSKADYEKKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQ ID NO:148)			

BE-H10-light	SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*	(SEQ ID NO:149)
HAE-B8-light	SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*	(SEQ ID NO:150)
HAE-F1-light	SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*	(SEQ ID NO:151)
BE-H9-light	SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*	(SEQ ID NO:152)
HAE-H-H10-light	SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*	(SEQ ID NO:153)
BE-A11-light	AASSYLSLTPEQWKSHRSYSCQVTHEG.STVEKTVAPAEC*	(SEQ ID NO:154)

## HEAVY CHAIN

	SIGNAL SEQUENCE	FR1-H
HAE-A3-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
HAE-G2-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
HAE-H10-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
BE-B12-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
BE-D7-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
BE-H10-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
HAE-B8-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
HAE-F1-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
BE-H9-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
HAE-H-H10-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS
BE-A11-heavy	MGWSCIIILFLVATATGAHS	EVQLLESGGGLVQPGGSLRLSCAASGFTFS

	CDR1-H	FR2-H	CDR2-H	FR3-H
HAE-A3-heavy	EYGMG	WVRQAPGKGLEWVS	SIVSSGGFTFYADSVKG	RFTISRDN SKNT
HAE-G2-heavy	LYRMR	WVRQAPGKGLEWVS	SISPSGGITEYADSVKG	RFTISRDN SKNT
HAE-H10-heavy	PYLMS	WVRQAPGKGLEWVS	SIYSSGGLTDYADSVKG	RFTISRDN SKNT
BE-B12-heavy	KYTMW	WVRQAPGKGLEWVS	SIWSSGGFTRYADSVKG	RFTISRDN SKNT
BE-D7-heavy	HYSMM	WVRQAPGKGLEWVS	SIFP.GGWTLYADSVKG	RFTISRDN SKNT
BE-H10-heavy	NYTMN	WVRQAPGKGLEWVS	SIVSSGGFTKYADSVKG	RFTISRDN SKNT
HAE-B8-heavy	WYSMS	WVRQAPGKGLEWVS	SIGPSGGQTRYADSVKG	RFTISRDN SKNT
HAE-F1-heavy	PYGMG	WVRQAPGKGLEWVS	SISPSGGTLYADSVKG	RFTISRDN SKNT
BE-H9-heavy	YYGMG	WVRQAPGKGLEWVS	SIGPSGGLTNYADSVKG	RFTISRDN SKNT
HAE-H-H10-heavy	PYLMS	WVRQAPGKGLEWVS	SIYSSGGLTDYADSVKG	RFTISRDN SKNT
BE-A11-heavy	KYSME	WVRQAPGKGLEWVS	RIYPSGGPTLYADSVKG	RFTISRDN SKNT

	FR3-H (contd)	CDR3-H	FR4-H
HAE-A3-heavy	LYLQMNSLRAEDTAVYYCAR	G.....TRVT	NWGQGLVTVSS
HAE-G2-heavy	LYLQMNSLRAEDTAVYYCAL	D.....VGGAAD	YWGGTLVTVSS
HAE-H10-heavy	LYLQMNSLRAEDTAVYHCAR	DGYDSSGYEGFD	YWGGTLVTVSS
BE-B12-heavy	LYLQMNSLRAEDTAVYYCAG	R.....SGSYPAD	IWGQGTMTVTVSS
BE-D7-heavy	LYLQMNSLRAEDTAVYYCAR	D.....RAAA	YWGGTLVTVSS
BE-H10-heavy	LYLQMNSLRAEDTAVYYCAR	G.....WSSQPA	IWGQGLVTVSS
HAE-B8-heavy	LYLQMNSLRAEDTAVYYCAR	D.YYDSSGSYF	YWGGTQVTVSS
HAE-F1-heavy	LYLQMNSLRAEDTAVYYCAR	Q...KRSSLGAFD	IWGQGTMTVTVSS
BE-H9-heavy	LYLQMNSLRAEDTAVYYCAR	G.....TRVT	NWGQGLVTVSS
HAE-H-H10-heavy	LYLQMNSLRAEDTAVYYCAR	DGYDSSGYEGFD	YWGGTLVTVSS
BE-A11-heavy	LYLQMNSLRAEDTAVYYCAR	D.....SYGMD	VWGQGTMTVTVSS

	CONSTANT REGION-H IgG4
HAE-A3-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
HAE-G2-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
HAE-H10-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
BE-B12-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
BE-D7-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
BE-H10-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
HAE-B8-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
HAE-F1-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
BE-H9-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
HAE-H-H10-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
BE-A11-heavy	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF

	CONSTANT REGION-H (contd)
HAE-A3-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
HAE-G2-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
HAE-H10-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
BE-B12-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
BE-D7-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
BE-H10-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
HAE-B8-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC
HAE-F1-heavy	PAVLQSSGLYSLSVVTVPSSSLGKTQYTCNVDHKPSNTKVDKRVESKYGPPC



BE-H9-heavy	PAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDRVESKYGPPC
HAE-H-H10-heavy	PAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDRVESKYGPPC
BE-A11-heavy	PAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDRVESKYGPPC

## CONSTANT REGION-H (contd)

HAE-A3-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
HAE-G2-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
HAE-H10-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
BE-B12-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
BE-D7-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
BE-H10-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
HAE-B8-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
HAE-F1-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
BE-H9-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
HAE-H-H10-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV
BE-A11-heavy	PSCPAPEFLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYV

## CONSTANT REGION-H (contd)

HAE-A3-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
HAE-G2-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
HAE-H10-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
BE-B12-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
BE-D7-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
BE-H10-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
HAE-B8-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
HAE-F1-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
BE-H9-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
HAE-H-H10-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI
BE-A11-heavy	DGVEVHNAKTKPREEQFNSTYRVVSVLT VLVHQLDNLNGKEYCKVSNKGLPSSI

## CONSTANT REGION-H (contd)

HAE-A3-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
HAE-G2-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
HAE-H10-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
BE-B12-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
BE-D7-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
BE-H10-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
HAE-B8-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
HAE-F1-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
BE-H9-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
HAE-H-H10-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
BE-A11-heavy	EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG

## CONSTANT REGION-H (contd)

HAE-A3-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
HAE-G2-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
HAE-H10-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
BE-B12-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
BE-D7-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
BE-H10-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
HAE-B8-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
HAE-F1-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
BE-H9-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
HAE-H-H10-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ
BE-A11-heavy	QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQ

HAE-A3-heavy	KSLSLSLGK* (SEQ ID NO:155)
HAE-G2-heavy	KSLSLSLGK* (SEQ ID NO:156)
HAE-H10-heavy	KSLSLSLGK* (SEQ ID NO:157)
BE-B12-heavy	KSLSLSLGK* (SEQ ID NO:158)
BE-D7-heavy	KSLSLSLGK* (SEQ ID NO:159)
BE-H10-heavy	KSLSLSLGK* (SEQ ID NO:160)
HAE-B8-heavy	KSLSLSLGK* (SEQ ID NO:161)
HAE-F1-heavy	KSLSLSLGK* (SEQ ID NO:162)
BE-H9-heavy	KSLSLSLGK* (SEQ ID NO:163)
HAE-H-H10-heavy	KSLSLSLGK* (SEQ ID NO:164)
BE-A11-heavy	KSLSLSLGK* (SEQ ID NO:165)

**Table 3**

<b>Antibody</b>	<b>Sequence</b>	<b>Identifier</b>
F2 VLC CDR1	RSSESLVYSDGNTYLG	SEQ ID NO:16
F2 VLC CDR2	KVSNRDS	SEQ ID NO:17
F2 VLC CDR3	MHSIRWPWT	SEQ ID NO:18
F2 VLC FR1	DIQMTQSPLSLAVTLGQPASISC	SEQ ID NO:19
F2 VLC FR2	WFQQRPGQSPRRLLY	SEQ ID NO:20
F2 VLC FR3	GVPDRFSGSGSGTDFTLHISRVEAEDVGVYYC	SEQ ID NO:21
F2 VLC FR4	FGQGT TVEIK	SEQ ID NO:22
F2 VHC CDR1	PYTMA	SEQ ID NO:23
F2 VHC CDR2	SIYPSGGTTPYADSVKG	SEQ ID NO:24
F2 VHC CDR3	HFTVYDGF D	SEQ ID NO:25
F2 VHC FR1	EVQLLES G GGLVQPGGSLRLSCAASGFTFS	SEQ ID NO:26
F2 VHC FR2	WVRQAPGKGLEWVS	SEQ ID NO:27
F2 VHC FR3	RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	SEQ ID NO:28
F2 VHC FR4	LWGRGTMVTVSS	SEQ ID NO:29
H1 VLC CDR1	RASQSVSSSYLA	SEQ ID NO:30
H1 VLC CDR2	GASSRAT	SEQ ID NO:31
H1 VLC CDR3	QQYGSSPRT	SEQ ID NO:32
H1 VLC FR1	DIQMTQSPGTL SLSPGERATLSC	SEQ ID NO:33
H1 VLC FR2	WYQQKPGQAPRL LIY	SEQ ID NO:34
H1 VLC FR3	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC	SEQ ID NO:35
H1 VLC FR4	FGQGTKVEIK	SEQ ID NO:36
H1 VHC CDR1	HYGMS	SEQ ID NO:37
H1 VHC CDR2	WIGPSGGATLYADSVKG	SEQ ID NO:38
H1 VHC CDR3	GRWNRGGAFD	SEQ ID NO:39
H1 VHC FR1	EVQLLES G GGLVQPGGSLRLSCAASGFTFS	SEQ ID NO:40
H1 VHC FR2	WVRQAPGKGLEWVS	SEQ ID NO:41

H1 VHC FR3	RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK	SEQ ID NO:42
H1 VHC FR4	NWGQGT LVT VSS	SEQ ID NO:43
H10 VLC CDR1	RSSQSL LHSNGYNYLD	SEQ ID NO:44
H10 VLC CDR2	LGSNRAS	SEQ ID NO:45
H10 VLC CDR3	MQALQPYT	SEQ ID NO:46
H10 VLC FR1	DIQMTQSPLSLPVT PGGPASISC	SEQ ID NO:47
H10 VLC FR2	WYLQKPGQSPQLLIY	SEQ ID NO:48
H10 VLC FR3	GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC	SEQ ID NO:49
H10 VLC FR4	FGQG TKLEIK	SEQ ID NO:50
H10 VHC CDR1	PYLMS	SEQ ID NO:51
H10 VHC CDR2	SIYSSGGLTDYADSVKG	SEQ ID NO:52
H10 VHC CDR3	DGYDSSGYEGFD	SEQ ID NO:53
H10 VHC FR1	EVQLLES GGLVQP GGSRLSCAASGFTFS	SEQ ID NO:54
H10 VHC FR2	WVRQAPGKGLEWVS	SEQ ID NO:55
H10 VHC FR3	RFTISRDN SKNTLYLQMNSLRAEDTAVYH CAR	SEQ ID NO:56
H10 VHC FR4	YWGQGT LVT VSS	SEQ ID NO:57

\* Additional CDRs and Framework regions are detailed in Table 2, above.

**[0041]** In a preferred embodiment, the antibody includes at least one, two and preferably three CDR's from the light or heavy chain variable region of an antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, or a sequence substantially identical thereto. In other embodiments, the antibody can have at least one, two and preferably three CDR's from the light or heavy chain variable region of an antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, as produced by their respective clones. In one preferred embodiment, the antibody includes all six CDR's from a human CD44-binding antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2. The CDR and framework sequences of antibodies F2, H1, and H10 are shown,

e.g., in Table 3; the CDR and framework sequences of antibodies G2, H10, and A3 and other antibodies are shown, e.g., in Table 2. Note that the heavy chains of HAE-H10 and HAE-H-H10 differ by one amino acid in FR3. In one embodiment, the constant region of a CD44-binding antibody differs from the constant region shown in Table 2.

**[0042]** In another preferred embodiment, the antibody includes at least one, two and preferably three CDR's from the light or heavy chain variable region of an antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, having an amino acid sequence that differs by no more than 3, 2.5, 2, 1.5, 1, or 0.5 substitutions, insertions or deletions for every 10 amino acids relative to the corresponding CDRs of the disclosed antibody. Further, the antibody, or antigen-binding fragment thereof, can include six CDR's, each of which differs by no more than 3, 2.5, 2, 1.5, 1, or 0.5 substitutions, insertions or deletions for every 10 amino acids relative to the corresponding CDRs of a human CD44-binding antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2.

**[0043]** In another embodiment, the light or heavy chain immunoglobulin of the CD44-binding antibody, can further include a light or a heavy chain variable framework that has no more than 3, 2.5, 2, 1.5, 1, or 0.5 substitutions, insertions or deletions for every 10 amino acids in FR1, FR2, FR3, or FR4 relative to the corresponding frameworks of an antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2. In a preferred embodiment, the light or heavy chain immunoglobulin of the CD44-binding antibody, or antigen-binding fragment thereof, further includes a light or a heavy chain variable framework, e.g., FR1, FR2, FR3, or FR4, that is identical to a framework of an antibody disclosed herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2.

**[0044]** In one embodiment, the light or the heavy chain variable framework can be chosen from: (a) a light or heavy chain variable framework including at least 80%, 90%, 95%, or preferably 100% of the amino acid residues from a human light or heavy chain variable framework, e.g., a light or heavy chain variable framework residue from a

human mature antibody or a human germline sequence (e.g., VH3, e.g., 3/23), or a consensus sequence (see, e.g., U.S. 6,300,064); (b) a light or heavy chain variable framework including from 20% to 80%, 40% to 80%, or 60% to 90% of the amino acid residues from a human light or heavy chain variable framework, e.g., a light or heavy chain variable framework residue from a human mature antibody or a human germline sequence, or a consensus sequence; (c) a non-human framework (e.g., a rodent framework); (d) a non-human framework that has been modified, e.g., to remove antigenic or cytotoxic determinants, e.g., deimmunized, or partially humanized. In a preferred embodiment, the antibody does not induce an immune response (e.g., a response that is detectable and/or adverse) in a human subject; or (e) an immunoglobulin framework of any species that includes an amino acid of human origin at one or more of the following positions: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, and/or 92H (according to the Kabat numbering), or a human consensus amino acid at one or more of the following positions (preferably at least five, ten, twelve, or all): (in the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, and/or (in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 78H, 91H, 92H, 93H, and/or 103H (according to the Kabat numbering).

**[0045]** In one embodiment, the heavy chain framework includes an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical (e.g., 100%) to the heavy chain framework of, e.g., an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G; or which differs by at least 1 to 5, but by less than 40, 30, 20, 10, or 6 residues from the heavy chain framework sequence of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G. In another embodiment, the light chain framework includes an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical (e.g., 100%) to the light chain framework of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10,

HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2; or which differs by at least 1 to 5, but by less than 40, 30, 20, 10, or 6 residues from the light chain framework sequence of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

**[0046]** In other embodiments, the modified heavy chain variable region of the CD44 antibody has an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or more (e.g., 100%), identical to, e.g., a corresponding region of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G; or which differs by at least 1 to 5, but by less than 40, 30, 20, 10, or 6 residues from the amino acid sequence of a corresponding region of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G. In other embodiments, the modified light chain variable region of the CD44 antibody has an amino acid sequence, which is at least 80%, 85%, 90%, 95%, 97%, 98%, 99%, or more (e.g., 100%), identical to, e.g., a corresponding region of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G; or which differs by at least 1 to 5, but by less than 40, 30, 20, or 10 residues from the amino acid sequence of a corresponding region of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

**[0047]** Preferred CD44-binding antibodies include at least one, preferably two, light chain variable regions having the amino acid sequence of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G, and at least one, preferably two, heavy chain variable regions having the amino acid sequence of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

**[0048]** In other embodiments, the light or heavy chain variable framework of the CD44-binding antibody, or antigen-binding fragment thereof, includes at least one, two,

three, four, five, six, seven, eight, nine, ten, fifteen, sixteen, or seventeen amino acid residues from a human light or heavy chain variable framework, e.g., a light or heavy chain variable framework residue from a human mature antibody, a human germline sequence, or a consensus sequence. In one embodiment, the amino acid residue from the human light chain variable framework is the same as the residue found at the same position in a human germline. Preferably, the amino acid residue from the human light chain variable framework is the most common residue in the human germline at the same position.

**[0049]** Also within the scope of the invention are antibodies, or antigen-binding fragments thereof, which bind overlapping epitopes of, or competitively inhibit, the binding of the CD44-binding peptides or antibodies disclosed herein to CD44, e.g., antibodies which bind overlapping epitopes of, or competitively inhibit, the binding of monospecific antibodies, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2, to CD44. Any combination of CD44-binding antibodies is within the scope of the invention, e.g., two or more antibodies that bind to different regions of CD44, e.g., antibodies that bind to two different epitopes on the extracellular domain of CD44, e.g., a bispecific antibody.

**[0050]** In one embodiment, the CD44-binding antibody, or antigen-binding fragment thereof, includes at least one light or heavy chain immunoglobulin (or preferably, at least one light chain immunoglobulin and at least one heavy chain immunoglobulin). Preferably, each immunoglobulin includes a light or a heavy chain variable region having at least one, two and, preferably, three complementarity determining regions (CDR's) substantially identical to a CDR from a CD44-binding light or heavy chain variable region, respectively, i.e., from a variable region of an antibody described herein, e.g. BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G2.

**[0051]** An CD44-binding ligand described herein can be used alone, e.g., can be administered to a subject or used *in vitro* in non-derivatized or unconjugated forms. In other embodiments, the CD44-binding ligand can be derivatized, modified or linked to another functional molecule, e.g., another polypeptide, protein, isotope, cell, or insoluble support. For example, the CD44-binding ligand can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecular entities, such as an antibody (e.g., if the ligand is an antibody to form a bispecific or a multispecific antibody), a toxin, a radioisotope, a therapeutic (e.g., a cytotoxic or cytostatic) agent or moiety, among others. For example, the CD44-binding ligand can be coupled to a radioactive ion (e.g., an  $\alpha$ -,  $\gamma$ -, or  $\beta$ -emitter), e.g., iodine ( $^{131}\text{I}$  or  $^{125}\text{I}$ ), yttrium ( $^{90}\text{Y}$ ), lutetium ( $^{177}\text{Lu}$ ), actinium ( $^{225}\text{Ac}$ ), rhenium ( $^{186}\text{Re}$ ), or bismuth ( $^{212}\text{Bi}$  or  $^{213}\text{Bi}$ ).

**[0052]** In another aspect, the invention features a nucleic acid that includes a coding sequence that encodes a polypeptide comprising an immunoglobulin heavy chain variable domain that binds to CD44, e.g., an immunoglobulin heavy chain variable domain described herein. For example, the immunoglobulin heavy chain variable domain can include: (a) a CDR1 sequence motif comprising  $X_1$ -Y- $X_2$ -M- $X_3$  (SEQ ID NO:\_\_\_), wherein  $X_1$  is E, L or P,  $X_2$  is G, R, or L, and  $X_3$  is G, R, or S, (b) a CDR2 sequence comprising: S-I- $X_1$ - $X_2$ -S-G-G- $X_3$ -T- $X_4$ -Y-A-D-S-V-K-G, where  $X_1$  is any amino acid,  $X_2$  is any amino acid,  $X_3$  is hydrophobic, and  $X_4$  is any amino acid, and/or (c) a CDR3 sequence comprising one of the following exemplary sequences: DVGVGAAAD (SEQ ID NO:\_\_\_), DGYDSSGYEGFD (SEQ ID NO:\_\_\_), and GTRTVT (SEQ ID NO:\_\_\_). In another example, the immunoglobulin heavy chain variable domain can include: a HC CDR1 sequence motif comprising  $X_1$ -Y- $X_2$ -M- $X_3$  (SEQ ID NO:\_\_\_), wherein  $X_1$  is any amino acid (e.g., E, L, K, H, N, W, or P),  $X_2$  is any amino acid (e.g., G, R, S, T, or L), and  $X_3$  is any amino acid (e.g., G, R, W, M, N, D, E, or S); a HC CDR2 sequence comprising:  $X_1$ -I- $X_2$ - $X_3$ - $X_4$ -G-G- $X_5$ -T- $X_6$ -Y-A-D-S-V-K-G (SEQ ID NO:\_\_\_), where  $X_1$  is any amino acid (e.g., S or R);  $X_2$  is any amino acid (e.g., V, S, Y, W, F, V, G, or S),  $X_3$  is any amino acid (e.g., S or P),  $X_4$  is S or absent,  $X_5$  is hydrophobic (e.g., F, I, L, W, or P) or Q or T, and  $X_6$  is any amino acid (e.g., F, E, D, R, L, or K); and/or a HC CDR3 sequence comprising one of the following exemplary sequences: DVGVGAAAD



(SEQ ID NO:\_\_\_), DGYDSSGYEGFD (SEQ ID NO:\_\_\_), RSGSYPAD (SEQ ID NO:\_\_\_), DRAAA (SEQ ID NO:\_\_\_), GWSSQPA (SEQ ID NO:\_\_\_), DYYDSSGYSYFD (SEQ ID NO:\_\_\_), QKRSSLGAFD (SEQ ID NO:\_\_\_), DSYGMD (SEQ ID NO:\_\_\_) and GTRTVT (SEQ ID NO:\_\_\_), or a sequence that is at least 85% identical to one of the foregoing. The immunoglobulin heavy chain variable domain can include a framework region described herein. In one example, the variable domain is a heavy chain variable domain is at least 75, 80, 85, 90, 92, 95, 96, 97, 98, or 99% identical to a heavy chain variable domain of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

**[0053]** In another aspect, the invention features a nucleic acid that includes a coding sequence that encodes a polypeptide comprising an immunoglobulin light chain variable domain that binds to CD44, e.g., an immunoglobulin light chain variable domain described herein. For example, the immunoglobulin light chain variable domain can include: (a) a CDR1 comprising an amino acid sequence of at least 13 amino acids of which at least 11 amino acids are identical to RSSQSLLHSNGYNYLD (SEQ ID NO:\_\_\_); (b) a CDR2 comprising an amino acid sequence of at least 7 amino acids of which at least 5 amino acids are identical to LGSNRAS (SEQ ID NO:\_\_\_); and/or (c) a CDR3 comprising M-Q-A-L-Q-X1-P-X2-T (SEQ ID NO:\_\_\_), where X1 is any amino acid or no amino acid, and X2 is any amino acid (e.g., hydrophobic, R, or Y) or absent.

**[0054]** The immunoglobulin light chain variable domain can include a framework region described herein. In one example, the variable domain is a light chain variable domain is at least 75, 80, 85, 90, 92, 95, 96, 97, 98, or 99% identical a corresponding light chain variable domain of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

**[0055]** A nucleic acid described herein can further include a promoter operably linked to the coding sequence. A nucleic acid can include a first and second coding sequence, e.g., wherein the first coding sequence encodes a polypeptide that includes an immunoglobulin heavy chain variable domain and the second coding sequence encodes a polypeptide that includes an immunoglobulin light chain variable domain.

**[0056]** In another aspect, the invention features a host cell that contains a first nucleic acid encoding a polypeptide comprising a heavy chain variable region and a second nucleic acid encoding a polypeptide comprising a light chain variable region. The heavy chain variable region and the light chain variable region can associate to form a CD44 binding protein. These sequences encoding variable regions can have one or more properties described herein, e.g., at least 75, 80, 85, 90, 92, 95, 96, 97, 98, or 99% identity (e.g., 100%) to a sequence described herein, or the ability to hybridize to a nucleic acid sequence described herein or a complement thereof, or can encode a variable region described herein. The invention also includes a method of providing a CD44-binding antibody. The method can include providing a host cell described herein; and expressing said first and second nucleic acids in the host cell under conditions that allow assembly of said light and heavy chain variable regions to form an antigen binding protein that interacts with CD44.

**[0057]** In one embodiment, the protein ligand at the concentration corresponding to its  $K_d$  for CD44 causes at least 2, 4, 8, or 20 fold greater lysis in the CD44 agonist assay (as defined herein) than the amount of lysis observed in the absence of the protein ligand.

**[0058]** In another aspect, the invention features a protein that includes a human (or humanized) heavy chain immunoglobulin variable domain and a human (or humanized) light chain immunoglobulin variable domain. The protein binds to human CD44 ectodomain with a  $K_d$  of less than  $5 \cdot 10^{-6}$  or  $2 \cdot 10^{-7}$  M and has one or more of the following features: (i) it agonizes human NK cells, (ii) it causes at least 2, 4, 8, or 20 fold greater lysis in the CD44 agonist assay (as defined herein) than the amount of lysis observed in the absence of the protein ligand, (iii) it is a CD44 activity enhancing ligand, a CD44-binding cell agonist, e.g., a CD44-binding NK-cell agonist, and (iv) it is a CD44-

binding cell sensitizing agent, e.g., a CD44-binding NK-cell sensitizing agent. The protein can include one or more additional features described herein. For example, the protein can include one or more features (e.g., CDRs) of BE-B12, BE-D7, BE-H10 (aka BH10), HAE-B8, HAE-F1, BE-H9, HAE-H-H10 (aka HH10), or BE-A11. A

“humanized” immunoglobulin variable region is an immunoglobulin variable region that includes sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human. Descriptions of “humanized” immunoglobulins include, for example, US 6,407,213 and US 5,693,762.

**[0059]** In another aspect, the invention features a method of administering a heterologous cells to a subject. The method includes administering to the subject an effective amount of a CD44 binding ligand (e.g., a CD44 binding ligand described herein), optionally, ablating or irradiating cells of the subject, and introducing heterologous cells into the subject, wherein the heterologous cells have a different HLA type from the subject or are from a different animal species than the subject.

**[0060]** In another aspect, the invention provides compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier, excipient or stabilizer, and at least one of the CD44-binding ligands (e.g., antibodies or fragments thereof) described herein. In one embodiment, the compositions, e.g., the pharmaceutical compositions, include a combination of two or more of the aforesaid CD44-binding ligands.

**[0061]** In another aspect, the invention features a kit that includes a CD44-binding antibody (or fragment thereof), e.g., a CD44-binding antibody (or fragment thereof) as described herein, for use alone or in combination with other therapeutic modalities, e.g., a cytotoxic or labeling agent, e.g., a cytotoxic or labeling agent as described herein, along with instructions on how to use the CD44 antibody or the combination of such agents to treat, prevent or detect cancerous lesions.

**[0062]** In another aspect, the protein ligand that binds to CD44 is a polypeptide that is not an immunoglobulin. For example, the polypeptide can be of variable length, e.g., 4 to 100 amino acid residues in length, preferably 5 to 75, 6 to 50, or 7 to 40 amino

acid residues in length, or more preferably 8 to 30 or 10 to 25 amino acid residues in length. In some embodiments, the polypeptide includes non-standard or synthetic amino acid residues, e.g., norleucine, selenocysteine, pyrrolysine, etc. In some embodiments, the polypeptide includes cross-linking groups, e.g., two cysteine residues that can form a disulfide bond or some other type of chemical cross-linking moieties that can be used to cyclize the peptide. In other preferred embodiments, the polypeptide can be modified, e.g., using polyethylene glycol or fusion to a soluble protein, so as to increase the solubility of the polypeptide.

**[0063]** In another aspect, the invention features a method of identifying a protein that specifically binds to CD44. For example, the method includes: providing a CD44 antigen; providing a display library (e.g., a phage display library member); identifying a member present in the library, wherein the member expresses a protein that specifically binds to the CD44 antigen. In preferred embodiments, the CD44 antigen is of human origin and includes, e.g., the extracellular domain of human CD44 or some fragment thereof, e.g., the HA binding domain of CD44. The CD44 antigen can be a recombinant polypeptide optionally fused to another polypeptide, e.g., CD44Fc, or it can be a cell that expresses CD44 (e.g., lymphocytes, particularly activated lymphocytes, or cancerous cells) on its surface. In other preferred embodiments, the CD44 antigen has an activated conformation. For example, a CD44 polypeptide antigen can be deglycosylated (e.g., by treating the polypeptide with a glycosidase, e.g., *V. cholerae* neuraminidase or any other glycosidase that acts upon CD44 so as to render an active conformation) or, alternatively, expressed in a cell line that produces CD44 in an activated conformation, e.g., an activated lymphocyte cell line. A CD44 antigen consisting of cells (e.g., live cells or fixed cells) that express CD44 will preferentially express an activated form of CD44, e.g., activated lymphocytes.

**[0064]** The methods described here are, for example, applicable to libraries that are based on bacteriophage with a substantially complete genome (e.g., including a modified gene III) and to libraries that are based on bacteriophage particles that include a phagemid nucleic acid. The terms “bacteriophage library member” and “phage” encompass members of both types of libraries. The term “bacteriophage particle” refers to a particle formed of bacteriophage coat proteins that packages a nucleic acid. The

packaged nucleic acid can be a modified bacteriophage genome or a phagemid, e.g., a nucleic acid that includes a bacteriophage origin of replication but lacks essential phage genes and cannot propagate in *E. coli* without help from "helper phage" or phage genes supplied *in trans*.

**[0065]** In other embodiments, the invention features a method of identifying a protein that specifically binds to CD44. The method includes: providing a CD44 antigen; immunizing a mouse with the CD44 antigen; producing hybridoma cells from the spleen of the immunized mouse; and identifying individual hybridoma cell lines expressing an antibody that specifically binds to the CD44 antigen.

**[0066]** In preferred embodiments, the CD44 antigen is of human origin and includes, e.g., the extracellular domain of human CD44 or some fragment thereof, e.g., the HA binding domain of CD44. The CD44 antigen can be a recombinant polypeptide optionally fused to another polypeptide, e.g., CD44Fc, or it can be a cell that expresses CD44 (e.g., lymphocytes, particularly activated lymphocytes, or cancerous cells) on its surface. In other preferred embodiments, the CD44 antigen has an activated conformation. For example, a CD44 polypeptide antigen can be deglycosylated (e.g., by treating the polypeptide with a glycosidase, e.g., *V. cholerae* neuraminidase or any other glycosidase that acts upon CD44 so as to render an active conformation) or, alternatively, expressed in a cell line that produces CD44 in an activated conformation, e.g., an activated lymphocyte cell line. A CD44 antigen consisting of cells (e.g., live cells or fixed cells) that express CD44 will preferentially express an activated form of CD44, e.g., activated lymphocytes.

**[0067]** In preferred embodiments, the methods further include isolating a nucleic acid molecule from the identified phage or hybridoma, wherein the nucleic acid molecule encodes the polypeptide or antibody that specifically binds to the CD44 antigen. The isolated nucleic acid molecules can be used to produce therapeutic agents, as described herein.

**[0068]** In another aspect, the invention features nucleic acids that encode proteins identified by the methods described herein. In preferred embodiments, the nucleic acids include sequences encoding a heavy and light chain immunoglobulin or immunoglobulin

fragment described herein. For example, the invention features a first and second nucleic acid encoding a heavy and light chain variable region, respectively, of a CD44-binding antibody molecule as described herein. Sequences encoding a heavy and light chain that function together can be present on separate nucleic acid molecules or on the same nucleic acid molecule. In another aspect, the invention features host cells and vectors containing a nucleic acid described herein or encoding a protein described herein.

**[0069]** In yet another aspect, the invention features a method of producing a CD44-binding antibody, or antigen-binding fragment thereof. The method includes: providing a host cell that contains a first nucleic acid encoding a polypeptide comprising a heavy chain variable region, e.g., a heavy chain variable region as described herein; providing a second nucleic acid encoding a polypeptide comprising a light chain variable region, e.g., a light chain variable region as described herein; and expressing said first and second nucleic acids in the host cell under conditions that allow assembly of said light and heavy chain variable regions to form an antigen binding protein that interacts with CD44. The first and second nucleic acids can be linked or unlinked, e.g., expressed on the same or different vector, respectively. The first and second nucleic acids can be components of the same molecule or can reside on different molecules (e.g., different chromosomes or plasmids).

**[0070]** The host cell can be a eukaryotic cell, e.g., a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, e.g., *E. coli*. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. For example, nucleic acids encoding the antibodies described herein can be expressed in a transgenic animal. In one embodiment, the nucleic acids are placed under the control of a tissue-specific promoter (e.g., a mammary specific promoter) and the antibody is produced in the transgenic animal. For example, the antibody molecule is secreted into the milk of the transgenic animal, such as a transgenic cow, pig, horse, sheep, goat or rodent. To produce a single chain antibody, the nucleic acid is configured to encode a single polypeptide that comprises both the heavy and light chain variable domains.

**[0071]** In another aspect, the invention features a method of inhibiting the adhesion, migration or extravasation of a cell, e.g., an activated white blood cell (e.g., an B cell, T cell, macrophage, or neutrophil), parenchymal cell, or benign or hyperplastic cell (e.g., a cell found in laryngeal, epidermal, pulmonary, breast, renal, urothelial, colonic, prostatic, or hepatic cancer and/or metastasis). The method can include contacting the cell with a CD44-binding ligand, in an amount sufficient to inhibit the adhesion, migration, or extravasation of the cell. Methods of the invention can be used, for example, to treat or prevent a disorder, e.g., an inflammatory disorder (e.g., rheumatoid arthritis, lupus, restenosis, graft v. host response, or multiple sclerosis), or a cancerous disorder (e.g., a malignant or metastatic disorder), by administering to a subject (e.g., an experimental animal or a human patient) a CD44-binding ligand in an amount effective to treat or prevent such disorder.

**[0072]** In another aspect, the invention features a method of contacting a cell (in vitro, ex vivo, or in vivo), e.g., an activated white blood cell (e.g., an B cell, T cell, macrophage, or neutrophil), parenchymal cell, or benign or hyperplastic cell (e.g., a cell found in laryngeal, epidermal, pulmonary, breast, renal, urothelial, colonic, prostatic, or hepatic cancer and/or metastasis). The method can include providing a ligand that interacts with CD44, e.g., a ligand described herein, and contacting the cell with the ligand, in an amount sufficient to form at least one detectable ligand-cell complex. The ligand can include, for example, a label or cytotoxic entity, e.g., an immunoglobulin Fc domain or a cytotoxic drug.

**[0073]** In another aspect, the invention features a method of treating, e.g., inhibiting or killing, a cell. The method includes providing a CD44-binding ligand, e.g. a ligand described herein, and contacting the cell with the ligand, in an amount sufficient to ablate or kill the cell. The contacting can be in vitro or in vivo. For example, the cell can be an activated white blood cell (e.g., an B cell, T cell, macrophage, or neutrophil), parenchymal cell, or benign or hyperplastic cell (e.g., a cell found in laryngeal, epidermal, pulmonary, breast, renal, urothelial, colonic, prostatic, or hepatic cancer and/or metastasis). The ligand can include a cytotoxic entity. The method can be used, for example, to treat or prevent a disorder, e.g., an inflammatory disorder (e.g., rheumatoid arthritis, lupus, restenosis, graft v. host response, or multiple sclerosis), or a

cancerous disorder (e.g., a malignant or metastatic disorder), by administering to a subject (e.g., an experimental animal or a human patient) a CD44-binding ligand in an amount effective to treat or prevent such disorder.

**[0074]** The subject methods can be used on cells in culture, e.g. *in vitro* or *ex vivo*. For example, white blood cells (e.g., B cells, T cells, macrophages, or neutrophils), parenchymal cells, or cancerous or metastatic cells (e.g., laryngeal, epidermal, pulmonary, breast, renal, urothelial, colonic, prostatic, or hepatic cancer or metastatic cells) can be cultured *in vitro* in culture medium and the contacting step can be effected by adding the CD44-binding ligand to the culture medium. The method can be performed on cells (e.g., cancerous or metastatic cells) present in a subject, as part of an *in vivo* (e.g., therapeutic or prophylactic) protocol. For *in vivo* embodiments, the contacting step is effected in a subject and includes administering the CD44-binding ligand to the subject under conditions effective to permit both binding of the ligand to the cell, and the inhibition of adhesion, migration, or extravasation of the cell, or the treating, e.g., the killing or ablating, of the cell.

**[0075]** The method can be used to treat or prevent cancerous disorders, e.g., including but are not limited to, solid tumors, soft tissue tumors, and metastatic lesions. Examples of solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary tract (e.g., renal, urothelial cells), pharynx, as well as adenocarcinomas which include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. In particular, metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods or compositions described herein.

**[0076]** The subject can be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of, a disorder described herein, e.g., cancer).



**[0077]** The CD44-binding antibody or fragment thereof, e.g., a CD44-binding antibody or fragment thereof as described herein, can be administered to the subject systemically (e.g., orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation), topically, or by application to mucous membranes, such as the nose, throat and bronchial tubes.

**[0078]** The methods can further include the step of monitoring the subject, e.g., for a reduction in one or more of: a reduction in tumor size; reduction in cancer markers, e.g., levels of cancer specific antigen; reduction in the appearance of new lesions, e.g., in a bone scan; a reduction in the appearance of new disease-related symptoms; or decreased or stabilization of size of soft tissue mass; or any parameter related to improvement in clinical outcome. The subject can be monitored in one or more of the following periods: prior to beginning of treatment; during the treatment; or after one or more elements of the treatment have been administered. Monitoring can be used to evaluate the need for further treatment with the same CD44-binding ligand or for additional treatment with additional agents. Generally, a decrease in one or more of the parameters described above is indicative of the improved condition of the subject.

**[0079]** The CD44-binding ligand can be used alone in unconjugated form to thereby inhibit adhesion, migration, or extravasation of the CD44-expressing cells, or ablate or kill the CD44-expressing cells. If the ligand is an antibody, the ablation or killing can be mediated, e.g., by an antibody-dependent cell killing mechanisms such as complement-mediated cell lysis and/or effector cell-mediated cell killing. In other embodiments, the CD44-binding ligand can be bound to a substance, e.g., a cytotoxic agent or moiety, effective to kill or ablate the CD44-expressing cells. For example, the CD44-binding ligand can be coupled to a radioactive ion (e.g., an  $\alpha$ -,  $\gamma$ -, or  $\beta$ -emitter), e.g., iodine ( $^{131}\text{I}$  or  $^{125}\text{I}$ ), yttrium ( $^{90}\text{Y}$ ), lutetium ( $^{177}\text{Lu}$ ), actinium ( $^{225}\text{Ac}$ ), or bismuth ( $^{213}\text{Bi}$ ). The methods and compositions described herein can be used in combination with other therapeutic modalities. In one embodiment, the method includes administering to the subject a CD44-binding ligand, e.g., a CD44-binding antibody or fragment thereof, in combination with a cytotoxic agent, in an amount effective to treat or prevent said disorder. The ligand and the cytotoxic agent can be administered simultaneously or

sequentially. In other embodiments, the methods and compositions described herein are used in combination with surgical and/or radiation procedures.

**[0080]** In another aspect, the invention features methods for detecting the presence of a CD44 protein, in a sample, *in vitro* (e.g., a biological sample, a tissue biopsy, e.g., a cancerous lesion). The subject method can be used to evaluate, e.g., diagnose or stage a disorder described herein, e.g., a cancerous disorder. The method includes: (i) contacting the sample (and optionally, a reference, e.g., control, sample) with a CD44-binding ligand, as described herein, under conditions that allow interaction of the CD44-binding ligand and the CD44 protein to occur; and (ii) detecting formation of a complex between the CD44-binding ligand, and the sample (and optionally, the reference, e.g., control, sample). Formation of the complex is indicative of the presence of CD44 protein (e.g., activated CD44 protein), and can indicate the suitability or need for a treatment described herein. For example, a statistically significant change in the formation of the complex in the sample relative to the reference sample, e.g., the control sample, is indicative of the presence of CD44 (e.g., activated CD44) in the sample.

**[0081]** In yet another aspect, the invention provides a method for detecting the presence of CD44 (e.g., activated CD44) *in vivo* (e.g., *in vivo* imaging in a subject). The subject method can be used to evaluate, e.g., diagnose, localize, or stage a disorder described herein, e.g., a cancerous disorder. The method includes: (i) administering to a subject (and optionally a control subject) a CD44-binding ligand (e.g., an antibody or antigen binding fragment thereof), under conditions that allow interaction of the CD44-binding ligand and the CD44 protein to occur; and (ii) detecting formation of a complex between the ligand and CD44, wherein a statistically significant change in the formation of the complex in the subject relative to the reference, e.g., the control subject or subject's baseline, is indicative of the presence of the CD44. The presence of activated CD44 in particular locations within a subject (e.g., in the joints or in close proximity to a solid tumor) can be indicative of an inflammatory disorder or cancer, e.g., metastatic cancer.

**[0082]** In other embodiments, a method of diagnosing or staging, a disorder as described herein (e.g., an inflammatory or cancerous disorder), is provided. The method

includes: (i) identifying a subject having, or at risk of having, the disorder; (ii) obtaining a sample of a tissue or cell affected with the disorder; (iii) contacting said sample or a control sample with a CD44-binding ligand, under conditions that allow interaction of the binding agent and the CD44 protein to occur, and (iv) detecting formation of a complex. A statistically significant increase in the formation of the complex between the ligand with respect to a reference sample, e.g., a control sample, is indicative of the disorder or the stage of the disorder. For example, the finding of activated CD44 on tumor cells located in a solid tumor can indicate that the tumor is progressing into a metastatic tumor.

**[0083]** Preferably, the CD44-binding ligand used in the *in vivo* and *in vitro* diagnostic methods is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound binding agent. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. In one embodiment, the CD44-binding ligand is coupled to a radioactive ion, e.g., indium ( $^{111}\text{In}$ ), iodine ( $^{131}\text{I}$  or  $^{125}\text{I}$ ), yttrium ( $^{90}\text{Y}$ ), actinium ( $^{225}\text{Ac}$ ), bismuth ( $^{213}\text{Bi}$ ), sulfur ( $^{35}\text{S}$ ), carbon ( $^{14}\text{C}$ ), tritium ( $^3\text{H}$ ), rhodium ( $^{188}\text{Rh}$ ), or phosphorous ( $^{32}\text{P}$ ). In another embodiment, the ligand is labeled with an NMR contrast agent.

**[0084]** In another aspect, the invention provides a ligand (e.g., a ligand that includes one or more immunoglobulin variable domains, e.g., domains that form an immunoglobulin antigen binding site) that interacts with CD44 and which functions as a CD44 agonist. For example, interaction between the ligand and an NK cell can sensitize the NK cell to radiation or increase CD44 protein levels on the cell. Exemplary ligands may include BE-B12, BE-D7, BE-H10 (aka BH10), HAE-B8, HAE-F1, BE-H9, HAE-H-H10 (aka HH10), and BE-A11, and related antibodies.

**[0085]** In one embodiment, the ligand competes with the monoclonal S5 which binds to canine CD44 for binding to a CD44, e.g., to a human or canine CD44. (See, e.g., Sandmaier *et al.* (1998) *Blood* 91:3494-3502). In one embodiment, the ligand binds to an epitope that overlaps with an epitope bound by monoclonal S5. The invention also includes methods of preparing and administering such ligands, e.g., in an amount effective to aid a subject (e.g., to increase the engraftment rate of bone marrow). For

example, the ligand can be administered at a dose of between 0.05 to 10 mg/kg/day, e.g., 0.05 to 2 mg/kg/day.

**[0086]** In another aspect, the invention provides a ligand (e.g., a ligand that includes one or more immunoglobulin variable domains, e.g., domains that form an immunoglobulin antigen binding site) that interacts with CD44 and that increases the engraftment rate of a HLA-nonidentical bone marrow. In one embodiment, the ligand does not elicit a substantial (e.g., a detectable or an adverse) immune response in a human subject. In one embodiment, the ligand is a CD44 activity enhancing ligand, a CD44-binding cell agonist, e.g., a CD44-binding NK-cell agonist, or a CD44-binding cell sensitizing agent, e.g., a CD44-binding NK-cell sensitizing agent.

**[0087]** In another aspect, the invention provides a protein that competes with the monoclonal S5 for binding to a CD44, e.g., to a human or canine CD44. (See, e.g., Sandmaier *et al.* (1998) *Blood* 91:3494-3502). For example, the protein includes one or more immunoglobulin variable domains, e.g., domains that form an immunoglobulin antigen binding site, e.g., domains with human framework regions, e.g., one, two, three, four, five, six, seven or eight human framework regions. The protein can include one or more human CDRs, e.g., one, two, three, four, five, or six human CDRs. For example, the LC CDRs can be human. In another example, HC CDR3 is human. In one embodiment, the antibody includes at least three human CDRs. The antibody can also include one or two synthetic CDRs.

**[0088]** In one embodiment, one or more the CDRs of the immunoglobulin variable domains differs from a respective CDR of the S5 monoclonal by at least one amino acid, e.g., at least one, two, three, four, five, or seven. For example, each CDR differs from a respective CDR of the S5 monoclonal by at least one, two, or three amino acids. In one embodiment, the protein binds to human CD44 with a  $K_d$  of less than  $10^{-6}$ ,  $10^{-7}$ ,  $10^{-8}$ ,  $10^{-9}$ , or  $10^{-10}$  M. In one embodiment, the protein induces lysis of NK cells *in vitro*, e.g., at least 2, 3, 4, 5, 10, or 20 more % lysis relative to a parallel control, or, e.g., at least 15, 20, 35, 40, 50, 60, 65, 70, or 85% lysis.

**[0089]** Certain CD44 agonists may increase CD44 binding affinity for HA, e.g., at least 0.2, 0.5, 0.7, 1.0, 1.2, 1.5, 2.0, 4, 5, or 10 fold increase, e.g., using a cell-free or cell-based assay.

**[0090]** In another aspect, the invention provides a method of grafting cells into a subject. The method includes administering to the subject a ligand described herein, e.g., a CD44 agonist, and then grafting cells (e.g., bone marrow cells) into the subject. The method can also include killing, impairing, or attenuating hematopoietic cells in the subject. For example, the method can include irradiating the subject or cells of the subject, e.g., to kill NK cells in the subject. The ligand can be administered in an amount effective to sensitize NK cells in the subject to the killing, impairing, or attenuating, e.g., to irradiation. For example, the ligand can be administered in an amount of between 0.05 to 10 mg/kg/day, e.g., 0.05 to 2 mg/kg/day. In one embodiment, the subject is human and ligand includes an immunoglobulin antigen binding site formed by immunoglobulin variable domains, e.g., with human framework regions. In one embodiment, HLA type of the grafted cells is non-identical to the HLA type of the subject.

**[0091]** The invention also provides polypeptides and nucleic acids that encompass a range of amino acid and nucleic acid sequences. In addition, the invention features a host cell that includes a nucleic acid described herein. The cell can express a protein described herein, e.g., on its surface.

**[0092]** As used herein, the term “antibody” refers to a protein comprising at least one immunoglobulin variable domain. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (FR). The extent of the framework region and CDR's has been precisely defined (see, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication

No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). Kabat definitions are used herein. Each VH and VL is composed of three CDR's and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

**[0093]** As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may omit one, two or more N- or C-terminal amino acids, or may include other alterations.

**[0094]** The VH or VL chain of the antibody can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter-connected by, e.g., disulfide bonds. The heavy chain constant region includes three domains, CH1, CH2 and CH3. The light chain constant region includes a CL domain. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The term “antibody” includes intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof), wherein the light chains of the immunoglobulin may be of types kappa or lambda. In one embodiment, the antibody is glycosylated. An antibody can be functional for antibody-dependent cytotoxicity and/or complement-mediated cytotoxicity.

**[0095]** All or part of an antibody can be encoded by an immunoglobulin gene or a segment thereof. Exemplary human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin “light chains” (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda

constant region gene at the COOH--terminus. Full-length immunoglobulin “heavy chains” (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

**[0096]** The term “antigen-binding fragment” of a full length antibody (or simply “antibody portion,” or “fragment”), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to CD44 (e.g., human CD44). Examples of binding fragments encompassed within the term “antigen-binding fragment” of a full length antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment including two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR) that retains functionality. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (scFv). See *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883. The term “antibody” encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab fragments, F(ab')<sub>2</sub>, a Fd fragment, a Fv fragments, and dAb fragments) as well as complete antibodies. Antibody fragments can be obtained using any appropriate technique including conventional techniques known to those with skill in the art.

**[0097]** As used herein, “activated” CD44 refers to the predominant form of CD44 present on activated white blood cells. As used herein, “resting” CD44 or CD44 that is “not activated” refers to the predominant form of CD44 present on resting white blood cells. White blood cells is a term of art that encompasses, e.g., lymphocytes (e.g., B- and T-cells and their precursors), monocytes, and neutrophils. Functionally, activated CD44 can be distinguished from non-activated forms of CD44 by its higher (e.g., 10%, 20%,

30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 500%, 1000%, or higher) affinity for hyaluronan (HA). Activated CD44 can be distinguished from non-activated CD44 on the basis of a structural property, e.g., glycosylation (e.g., reduced glycosylation), additional polypeptide sequences resulting from alternative splicing (e.g., inclusion of exons v4-v7), conformational changes induced by protein-protein interactions (e.g., the clustering of CD44 on the cell surface), or some combination thereof. The term “CD44 ectodomain” refers to any extracellular region of a CD44 protein.

**[0098]** As used herein, “deglycosylated” CD44 refers to CD44 proteins exhibiting a decrease in glycosylation as compared to CD44 present on resting white blood cells. Decreases in CD44 glycosylation can be cell specific, e.g., cell-type specific (a function of the cell type in which the CD44 protein is expressed (e.g., a metastatic tumor cell)), or cell-state specific (a function of the state of the cell in which the CD44 protein is expressed (e.g., an activated lymphocyte)). The degree of glycosylation of CD44 can be determined by its mobility, e.g., following electrophoresis, or by assaying for particular glycosylation epitopes, e.g., by ELISA. The deglycosylated form may include at least one, two, four, or six or more amino acids that lack a glycosyl modification at positions that are glycosylated in a CD44 molecule in a resting cell.

**[0099]** As used herein, “high-affinity” CD44 refers to CD44 that has a higher affinity for HA as compared to CD44 present on resting white blood cells. The higher affinity can be a reflection of molecular changes in the protein, e.g., arising from alternative splicing or changes in glycosylation, it can be a reflection of the cell in which the CD44 is expressed (e.g., an activated white blood cell or a metastatic cell), or both.

**[00100]** As used herein, “activation” used with respect to white blood cells refers to cellular changes triggered by T cell receptor and/or cytokine stimulation associated with their recruitment to a site of, or response to, inflammation.

**[00101]** As used herein, “binding affinity” refers to the apparent association constant or  $K_a$ . The  $K_a$  is the reciprocal of the dissociation constant ( $K_d$ ). A ligand may, for example, have a binding affinity of at least  $10^{-5}$ ,  $10^{-6}$ ,  $10^{-7}$  or  $10^{-8}$  M for a particular target molecule. Higher affinity binding of a ligand to a first target relative to a second target can be indicated by a higher  $K_a$  (or a smaller numerical value  $K_d$ ) for binding the



first target than the  $K_a$  (or numerical value  $K_d$ ) for binding the second target. In such cases the ligand has specificity for the first target relative to the second target.

**[00102]** Binding affinity can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g., using a fluorescence assay). These techniques can be used to measure the concentration of bound and free ligand as a function of ligand (or target) concentration. The concentration of bound ligand ( $[Bound]$ ) is related to the concentration of free ligand ( $[Free]$ ) and the concentration of binding sites for the ligand on the target where ( $N$ ) is the number of binding sites per target molecule by the following equation:

$$[Bound] = N \cdot [Free] / ((1/K_a) + [Free]).$$

**[00103]** It is not always necessary to make an exact determination of  $K_a$ , though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to  $K_a$ , and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher. Exemplary conditions for evaluating binding affinity are in PBS (phosphate buffered saline) at pH 7.2 at 30°C.

**[00104]** An “isolated composition” refers to a composition that is removed from at least 90% of at least one component of a natural sample from which the isolated composition can be obtained. Compositions produced artificially or naturally can be “compositions of at least” a certain degree of purity if the species or population of species of interests is at least 5, 10, 25, 50, 75, 80, 90, 92, 95, 98, or 99% pure on a weight-weight basis.

**[00105]** An “epitope” refers to the site on a target compound that is bound by a ligand, e.g., a polypeptide ligand or an antigen-binding ligand (e.g., an antibody such as a Fab or full length antibody). In the case where the target compound is a protein, the site can be entirely composed of amino acid components, entirely composed of chemical modifications of amino acids of the protein (e.g., glycosyl moieties), or composed of combinations thereof. Overlapping epitopes include at least one common amino acid residue.

**[00106]** A “CD44 activity enhancing ligand” is a ligand that increase CD44 affinity for HA by at least 10%. For example, some CD44-binding antibodies may increase CD44 affinity for HA. For example, a CD44-binding antibody may increase affinity of an interaction between by at least 10, 15, 20, 30, 50, 75, 100, or 110%, e.g., when present at a concentration of between 0.1 µg/ml to 10 µg/ml.

**[00107]** A “CD44-binding cell agonist” is a CD44-binding protein that activates a CD44-expressing cells as determined by an assay described herein. A “CD44-binding cell sensitizing agent” is a CD44-binding molecule that can reduce the amount of total body irradiation required to kill a CD44-expressing cells in a subject. A “CD44-binding NK-cell agonist” is a CD44-binding protein that activates NK cells as determined by an assay described herein. A “CD44-binding NK-cell sensitizing agent” is a CD44-binding molecule that can reduce the amount of total body irradiation required to kill NK cells in a subject.

**[00108]** A “CD44 antagonist” refers to a CD44 interacting molecule that reduces the ability of CD44 to bind to HA. For example, the antagonist may reduce the affinity of CD44 to HA, e.g., by reducing the  $K_a$  at least 20, 40, 50, 60, 70, 80, 90, or 95%.

**[00109]** A “S5-like antibody” refers to an antibody that competes with S5 for binding to canine CD44 or an antibody that binds to a corresponding epitope of human CD44. A “S5-like engraftment enhancing antibody” refers to an S5-like antibody that enhances hematopoietic cell engraftment in a canine model or a human subject.

**[00110]** “An immunosuppressive agent capable of inactivating thymic or lymph node T cells”, as used herein, is an agent other than an antibody, e.g., a chemical agent, e.g., a drug, that, when administered at an appropriate dosage, results in the inactivation of thymic or lymph node T cells. Examples of such agents are cyclosporine, FK-506, and rapamycin. Such agents can be used in conjunction with a CD44-binding NK-cell agonist, e.g., prior to or after transfer of exogenous cells.

**[00111]** “Tolerance”, as used herein, refers to the inhibition of a graft recipient's immune response which would otherwise occur, e.g., in response to the introduction of a nonself MHC antigen into the recipient. Tolerance can involve humoral, cellular, or both humoral and cellular responses.

**[00112]** “Hematopoietic stem cell”, as used herein, refers to a cell, e.g., a bone marrow cell which is capable of developing into a mature myeloid and/or lymphoid cell. Stem cells derived from the cord blood of the recipient or the donor can be used in certain implementations, e.g., as a source of exogenous cells for transfer.

**[00113]** “Graft”, as used herein, refers to a body part, organ, tissue, or cells. Grafts may consist of organs such as liver, kidney, heart or lung; body parts such as bone or skeletal matrix; tissue such as skin, intestines, endocrine glands; or progenitor stem cells of various types.

**[00114]** Calculations of “homology” or “sequence identity” between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.

**[00115]** In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence.

**[00116]** The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J. Mol. Biol.* 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

**[00117]** As used herein, the term “substantially identical” (or “substantially homologous”) is used herein to refer to a first amino acid or nucleotide sequence that contains a sufficient number of identical or equivalent (e.g., with a similar side chain, e.g., conserved amino acid substitutions) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have similar activities. In the case of antibodies, the second antibody has the same specificity and has at least 50% of the affinity relative to the same antigen.

**[0118]** Sequences similar or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiment, the sequence identity can be about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

**[0119]** As used herein, the term “homologous” is synonymous with “similarity” and means that a sequence of interest differs from a reference sequence by the presence of one or more amino acid substitutions (although modest amino acid insertions or deletions) may also be present. In addition to the GAP program described above, a variety of means of calculating degrees of homology or similarity to a reference sequence

are available. One method uses the BLAST algorithms (available from the National Center of Biotechnology Information (NCBI), National Institutes of Health, Bethesda MD), in each case, using the algorithm default or recommended parameters for determining significance of calculated sequence relatedness. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) *CABIOS*, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

**[0120]** As used herein, the term “hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions” describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified. The invention includes nucleic acids that hybridize with low, medium, high, or very high stringency to a nucleic acid described herein or to a complement thereof. The nucleic acids can be the same length or within 30, 20, or 10% of the length of the reference nucleic acid.

**[0121]** It is understood that a CD44-binding ligand may have mutations relative to a CD-binding ligand described herein (e.g., a conservative or non-essential amino acid

substitutions), which do not have a substantial effect on the polypeptide functions. Whether or not a particular substitution will be tolerated, i.e., will not adversely affect desired biological properties, such as binding activity can be determined as described in Bowie, et al. (1990) *Science* 247:1306-1310. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). It is possible for many framework and CDR amino acid residues to include one or more conservative substitutions.

**[0122]** A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of the binding agent, e.g., the antibody, without abolishing or more preferably, without substantially altering a biological activity, whereas an “essential” amino acid residue results in such a change.

**[0123]** The terms “polypeptide” or “peptide” (which may be used interchangeably) refer to a polymer of three or more amino acids linked by a peptide bond, e.g., between 3 and 30, 12 and 60, or 30 and 300, or over 300 amino acids in length. The polypeptide may include one or more unnatural amino acids. Typically, the polypeptide includes only natural amino acids. A “protein” can include one or more polypeptide chains. Accordingly, the term “protein” encompasses polypeptides. A protein or polypeptide can also include one or more modifications, e.g., a glycosylation, amidation, phosphorylation, and so forth. The term “small peptide” can be used to describe a polypeptide that is between 3 and 30 amino acids in length, e.g., between 8 and 24 amino acids in length. The term “ligand” refers to a protein that can interact, e.g., specifically interact, with a target molecule, e.g., CD44.

[0124] Other features and advantages of the instant invention will become more apparent from the following detailed description and claims. Embodiments of the invention can include any combination of features described herein. The contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference, inclusive of U.S. Serial No. 60/410,758, filed September 13, 2002 and 60/469,123, filed May 9, 2003.

## DETAILED DESCRIPTION

[0125] CD44 is a cell surface protein. It is accessible and susceptible to targeting by the antibodies and other ligands described herein. CD44 participates, e.g., in adhesion, migration, and extravasation by certain CD44-expressing cells.

[0126] The invention provides, *inter alia*, proteins that bind to CD44, e.g., the extracellular region of mature CD44. In one embodiment, the protein is a CD44 antagonist. In another embodiment, the protein is a CD44 activity enhancing ligand, a CD44 binding cell agonist, or a CD44-binding cell sensitizing agent.

[0127] CD44-binding proteins can be used to modulate a CD44-expressing cell or a function of CD44, e.g., cell adhesion, migration, or extravasation. For example, a CD44-binding protein can be used to treat diseases, e.g., particularly diseases in which CD44-expressing cells contribute to pathology, e.g., inflammatory diseases and cancer. The recruitment of lymphocytes to sites of inflammation can be inhibited by blocking the interaction between activated CD44 and HA. Likewise, blocking the interaction between CD44 and HA can inhibit the metastasis of tumor cells that depend upon the CD44/HA interaction for cellular migration and/or extravasation from the vascular system.

[0128] In one embodiment, the CD44-binding protein is an antibody, e.g., a full length-antibody, or an antigen-binding fragment of a full length antibody. In another embodiment, the protein is a modified scaffold polypeptide (or peptide). In still another preferred embodiment, the protein ligand is a cyclic peptide or a linear peptide, e.g., of less than 30 or 25 amino acids. Whereas some examples described herein refer to antibody ligands or fragments thereof, it is understood, that the invention can be practiced

using any protein ligand (e.g., antibody and non-antibody ligand, e.g., a ligand having a structural fold described herein).

**[0129]** It is appreciated that there can be naturally occurring or artificial genetic variation in genes encoding the CD44 amino acid sequence that may result in a variety of CD44 amino acid sequences, typically at least 96%, 97%, 98%, or 99% homologous to a CD44 amino acid sequence provided herein, e.g., differing by fewer than ten, five, or three amino acid substitutions. For example, one natural variation is at position 46 of SEQ ID NO:1 (PRO-46 or ARG-46). Preferably, the CD44 amino acid sequence is a functional CD44 amino acid sequence, e.g., the sequence of an HA binding fragment of a mature, full-length CD44 protein. The protein may be functional for extravasation and/or cell migration.

**[0130]** Alternative splicing can lead to a variety of CD44 amino acid sequences. Screaton *et al.* (1992), *Proc. Natl. Acad. Sci. USA* 89:12160-4. Exemplary CD44 amino acid sequences are as follows:

**[0131]** CD44 Isoform: Exons 1-17 and 19:

MDKFWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL  
PTMAQMEKALSIGFETCRYGFIEGHVVIPIRIHPNSICAANNTGVYILTSNTSQYDITYCFN  
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGRYVQKGEYRTNPEDIYPSNPTDDDVS  
GSSSERSSTSGGYIFYTFSTVHPIPEDDSPWITDSTDRI PATTL MST SATATETATKRQE  
TWDWFSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDD  
EDFISSTISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTRMTDVRNGTTAYEGNWN  
PEAHPPLIHHEHHEEEETPHSTSTIQATPSSTTEETATQKEQWFGNRWHEGYRQTPREDS  
HSTTGTAASAHTSHPMQGRTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSTT  
LQPTANPNTGLVEDLDRTGPLSMTTQQSNSQSFSSTHEGLEEDKDHPTTSTLTSSNRNDV  
TGRRDPNHSEGSTTLLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNR  
SLSGDQDTFHPSGGSHHTHGESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLAL  
ALILAVCIAVNSRRRCGQKKLVINSNGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSET  
PDQFMTADETRNLQNVDMKIGV (SEQ ID NO:1)

**[0132]** Exons 1-5, 12-17 and 19:

MDKFWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL  
PTMAQMEKALSIGFETCRYGFIEGHVVIPIRIHPNSICAANNTGVYILTSNTSQYDITYCFN  
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGRYVQKGEYRTNPEDIYPSNPTDDDVS  
GSSSERSSTSGGYIFYTFSTVHPIPEDDSPWITDSTDRI PATNMDSSHSTTLQPTANPNT  
GLVEDLDRTGPLSMTTQQSNSQSFSSTHEGLEEDKDHPTTSTLTSSNRNDVTGRRDPNH  
SEGSTTLLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLSGDQDTF  
HPSGGSHHTHGESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIA



VNSRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADE  
TRNLQNVDKIGV (SEQ ID NO:2)

[0133] Exons 1-5, 15-17 and 19:

MDKFWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL  
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN  
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS  
GSSSERSSSTSGGYIFYTFSTVHPIPEDDSPWITDSTDRIPATRDQDTFHPSGGSHHTHGS  
ESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKK  
LVINSGNGAVEDRKPIGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDKIG  
V (SEQ ID NO:3)

[0134] In one embodiment, the protein ligands can bind to an epitope present in at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, including epitopes arising from the glycosylation of such sequences.

[0135] Exemplary epitopes include the IM7 binding site and the S5 monoclonal binding site. Epitopes can include one or more amino acids in the sequence: DLPNAFDGPITIT, e.g., the sequence at about amino acid residue 134 to 147 of SEQ ID NO:1. For example, the epitope can include one or more amino acids between 22-150, 22-75, 76-150, 130-200, 140-190, 145-185, or 150-300 of SEQ ID NO:1. The epitope may include determinants that are N-terminal of amino acid 400, 300, 250, 200, or 150 of SEQ ID NO:1.

[0136] An exemplary mature CD44 amino acid sequence is 21-742 of SEQ ID NO:1. An exemplary extracellular domain is 21-649 of SEQ ID NO:1. Exemplary glycosylation sites include amino acid positions 25, 57, 100, 120, 548, 599, and 636 of SEQ ID NO:1. In some CD44 variants, these positions are not glycosylated, either alone or in combination.

[0137] The CD44-binding proteins bind to human CD44 with high affinity and specificity, and thus can be used as diagnostic, prophylactic, or therapeutic agents *in vivo* and *in vitro*. Preferably the ligands specifically bind to the CD44. As used herein, "specific binding" refers to the property of the antibody: (1) to bind to CD44, e.g., human

CD44, with an affinity of at least  $2 \times 10^7 \text{ M}^{-1}$ , and (2) to preferentially bind to CD44, e.g., human CD44, with an affinity that is at least two-fold, 50-fold, 100-fold, or more, greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than CD44. (The terms “CD44-binding ligands” and “CD44 ligands” are used interchangeably to refer to ligands that can interact with CD44).

#### [0138] CD44 Agonists

**[0139]** CD44 agonists can be used to modulate immune cells in a subject. For example, CD44 agonists can be used to sensitize NK cells. The sensitized cells can then be ablated, e.g., using radiation, a cytotoxin directed against the cells, or other drug that triggers ablation. Without intending to be bound by theory, a CD44 agonist can be used to increase CD44 protein levels on target cells or CD44 activity. See, e.g., Sandmaier *et al.* (1998) *Blood* 91:3494-3502). Modulation of an immune system with a CD44 ligand can be appropriate prior, during, or after introduction of antigenic material into a subject, e.g., introducing a HLA-nonidentical cell or tissue, e.g., bone marrow or prior, during, or after treatment of graft-versus-host disease (GVHD). Thus, treatment with a CD44 agonist can be used, e.g., before a transplant, e.g., an organ or bone marrow transplant. Bone marrow transplantation can be used to treat a wide variety of diseases, including hematological malignancies, aplastic anemia, red cell disorders and congenital immunodeficiencies.

**[0140]** CD44 antibodies can be evaluated for agonist activity in an NK cell assay. Sandmaier *et al.* (1998) *Blood* 91(9):3494-502. Canine peripheral blood monocyctic cell (PBMC) effector populations are incubated with CD44 antibody, then aliquotted into wells of round-bottom 96-well plates containing an equal volume of medium (spontaneous release) or of 2% Triton-X (maximum release). NK-sensitive target canine thyroid adenocarcinoma cells (CTAC) are loaded with chromium-51 (5 mCi/mL of medium) in a 1 hr, 37°C, 5% CO<sub>2</sub> incubation, then washed three times with 10-fold excess cold medium, resuspended to  $5 \times 10^4$  to  $10^5$  cells/mL, and  $5 \times 10^3$  to  $10^4$  cells are added to the effector cells. After 16 hr incubation at 37°C, 5% CO<sub>2</sub>, plates are

centrifuged and supernatants are obtained for measurement of released radioactivity in a gamma scintillation counter. Percent specific lysis is calculated:

$$\text{Specific lysis (\%)} = \frac{\text{cpm (experimental)} - \text{cpm (spontaneous release)}}{\text{cpm (maximum release)} - \text{cpm (spontaneous release)}} \times 100.$$

**[0141]** The extent of specific lysis after CD44 antibody incubation compared to lysis after incubation in medium alone is an indication of CD44 antibody agonist activity. A similar assay can be done with human peripheral blood monocytic cells if the antibody is specific for humans, relative to canine CD44. It is appreciated that the ability of a CD44 antibody to be a CD44 activity enhancing ligand, a CD44-binding cell agonist, e.g., a CD44-binding NK-cell agonist, or a CD44-binding cell sensitizing agent, e.g., a CD44-binding NK-cell sensitizing agent, may be empirical and may not require a particular result in a particular assay to be useful as such.

**[0142]** Identifying a CD44-binding ligand

**[0143]** In one implementation, proteins that bind to CD44, e.g., activated CD44, deglycosylated CD44, or high-affinity CD44, are identified by a method that includes: providing a library of coding nucleic acids and selecting from the library one or more members that encode a protein that binds to the CD44 antigen. The selection can be performed in a number of ways. For example, the library can be a display library. Similarly, a CD-44 binding protein can be isolated from a library of proteins, e.g., proteins on a protein array.

**[0144]** The CD44 can be tagged and recombinantly expressed. The CD44 is purified and attached to a support, e.g., to affinity beads, or paramagnetic beads or other magnetically responsive particles.

[0145] The CD44 can also be expressed on the surface of a cell. Members of the display library that specifically bind to the cell, e.g., only if the CD44 is activated, can be selected.

**[0146]** Display Libraries

[0147] In one embodiment, a display library is used to identify proteins that bind to CD44. A display library is a collection of entities; each entity includes an accessible polypeptide component and a recoverable component that encodes or identifies the polypeptide component. The polypeptide component can be of any length, e.g. from three amino acids to over 300 amino acids. In a selection, the polypeptide component of each member of the library is probed with CD44 protein and if the polypeptide component binds to CD44, the display library member is identified, typically by retention on a support.

[0148] Retained display library members are recovered from the support and analyzed. The analysis can include amplification and a subsequent selection under similar or dissimilar conditions. For example, positive and negative selections can be alternated. The analysis can also include determining the amino acid sequence of the polypeptide component and purification of the polypeptide component for detailed characterization.

[0149] A variety of formats can be used for display libraries. Examples include the following.

[0150] **Phage Display.** One format utilizes viruses, particularly bacteriophages. This format is termed “phage display.” The polypeptide component is typically covalently linked to a bacteriophage coat protein. The linkage results from translation of a nucleic acid encoding the polypeptide component fused to the coat protein. The linkage can include a flexible peptide linker, a protease site, or an amino acid incorporated as a result of suppression of a stop codon. Phage display is described, for example, in Ladner *et al.*, U.S. Patent No. 5,223,409; Smith (1985) *Science* 228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791; WO 92/15679; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; de Haard *et al.* (1999) *J. Biol. Chem* 274:18218-30;

Hoogenboom *et al.* (1998) *Immunotechnology* 4:1-20; Hoogenboom *et al.* (2000) *Immunol Today* 2:371-8; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Rebar *et al.* (1996) *Methods Enzymol.* 267:129-49; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; and Barbas *et al.* (1991) *PNAS* 88:7978-7982.

**[0151]** Phage display systems have been developed for filamentous phage (phage f1, fd, and M13) as well as other bacteriophage (e.g. T7 bacteriophage and lambdoid phages; see, e.g., Santini (1998) *J. Mol. Biol.* 282:125-135; Rosenberg *et al.* (1996) *Innovations* 6:1-6; Houshmet *et al.* (1999) *Anal Biochem* 268:363-370). The filamentous phage display systems typically use fusions to a minor coat protein, such as gene III protein, and gene VIII protein, a major coat protein, but fusions to other coat proteins such as gene VI protein, gene VII protein, gene IX protein, or domains thereof can also been used (see, e.g., WO 00/71694). In one embodiment, the fusion is to a domain of the gene III protein, e.g., the anchor domain or “stump,” (see, e.g., U.S. Patent No. 5,658,727 for a description of the gene III protein anchor domain). Phagemid and other modifications of the fundamental technology are also available.

**[0152]** Bacteriophage displaying the polypeptide component can be grown and harvested using standard phage preparatory methods, e.g. PEG precipitation from growth media.

**[0153]** After selection of individual display phages, the nucleic acid encoding the selected polypeptide components, by infecting cells using the selected phages. Individual colonies or plaques can be picked, the nucleic acid isolated and sequenced.

**[0154]** **Cell-based Display.** In still another format the library is a cell-display library. Proteins are displayed on the surface of a cell, e.g., a eukaryotic or prokaryotic cell. Exemplary prokaryotic cells include *E. coli* cells, *B. subtilis* cells, spores (see, e.g., Lu *et al.* (1995) *Biotechnology* 13:366). Exemplary eukaryotic cells include yeast (e.g., *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Hansenula*, or *Pichia pastoris*).

Yeast surface display is described, e.g., in Boder and Wittrup (1997) *Nat. Biotechnol.* 15:553-557 and WO 03/029456 which describes a yeast display system that can be used to display immunoglobulin proteins such as Fab fragments, and the use of mating to generate combinations of heavy and light chains.

**[0155]** In one embodiment, diverse nucleic acid sequences are cloned into a vector for yeast display. The cloning joins the diverse sequence with a domain (or complete) yeast cell surface protein, e.g., Aga2, Aga1, Flo1, or Gas1. A domain of these proteins can anchor the polypeptide encoded by the diverse nucleic acid sequence by a transmembrane domain (e.g., Flo1) or by covalent linkage to the phospholipid bilayer (e.g., Gas1). The vector can be configured to express two polypeptide chains on the cell surface such that one of the chains is linked to the yeast cell surface protein. For example, the two chains can be immunoglobulin chains.

**[0156]** In one embodiment, nucleic acids encoding immunoglobulin heavy chains that have been mutagenized based on an initial CD44-binding immunoglobulin are introduced into yeast cells of one cell type, and nucleic acids encoding immunoglobulin light chains that have been mutagenized based on an initial CD44-binding immunoglobulin are introduced into yeast cells of the other cell type. These two populations of cells can be combined to form diploid yeast that each express an immunoglobulin heavy and light chain. The yeast cells can be selected and/or screened for cells that bind to CD44, e.g., bind with improved affinity.

**[0157] Ribosome Display.** RNA and the polypeptide encoded by the RNA can be physically associated by stabilizing ribosomes that are translating the RNA and have the nascent polypeptide still attached. Typically, high divalent  $Mg^{2+}$  concentrations and low temperature are used. See, e.g., Mattheakis *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:9022 and Hanes *et al.* (2000) *Nat Biotechnol.* 18:1287-92; Hanes *et al.* (2000) *Methods Enzymol.* 328:404-30; and Schaffitzel *et al.* (1999) *J Immunol Methods.* 231(1-2):119-35.

**[0158] Protein-Nucleic Acid Fusions.** Another format utilizes protein-nucleic acid fusions. Protein-nucleic acid fusions can be generated by the in vitro translation of mRNA that include a covalently attached puromycin group, e.g., as described in Roberts

and Szostak (1997) *Proc. Natl. Acad. Sci. USA* 94:12297-12302, and U.S. Patent No. 6,207,446. The mRNA can then be reverse transcribed into DNA and crosslinked to the protein.

**[0159] Other Display Formats.** Yet another display format is a non-biological display in which the polypeptide component is attached to a non-nucleic acid tag that identifies the polypeptide. For example, the tag can be a chemical tag attached to a bead that displays the polypeptide or a radiofrequency tag (see, e.g., U.S. Patent No. 5,874,214).

**[0160] Scaffolds.** Scaffolds for display can include: antibodies (e.g., Fab fragments, single chain Fv molecules (scFV), single domain antibodies, camelid antibodies, and camelized antibodies); T-cell receptors; MHC proteins; extracellular domains (e.g., fibronectin Type III repeats, EGF repeats); protease inhibitors (e.g., Kunitz domains, ecotin, BPTI, and so forth); TPR repeats; trifoil structures; zinc finger domains; DNA-binding proteins; particularly monomeric DNA binding proteins; RNA binding proteins; enzymes, e.g., proteases (particularly inactivated proteases), RNase; chaperones, e.g., thioredoxin, and heat shock proteins; and intracellular signaling domains (such as SH2 and SH3 domains).

**[0161]** Appropriate criteria for evaluating a scaffolding domain can include: (1) amino acid sequence, (2) sequences of several homologous domains, (3) 3-dimensional structure, and/or (4) stability data over a range of pH, temperature, salinity, organic solvent, oxidant concentration. In one embodiment, the scaffolding domain is a small, stable protein domains, e.g., a protein of less than 100, 70, 50, 40 or 30 amino acids. The domain may include one or more disulfide bonds or may chelate a metal, e.g., zinc.

**[0162]** Examples of small scaffolding domains include: Kunitz domains (58 amino acids, 3 disulfide bonds), *Cucurbita maxima* trypsin inhibitor domains (31 amino acids, 3 disulfide bonds), domains related to guanylin (14 amino acids, 2 disulfide bonds), domains related to heat-stable enterotoxin IA from gram negative bacteria (18 amino acids, 3 disulfide bonds), EGF domains (50 amino acids, 3 disulfide bonds), kringle domains (60 amino acids, 3 disulfide bonds), fungal carbohydrate-binding domains (35 amino acids, 2 disulfide bonds), endothelin domains (18 amino acids, 2

disulfide bonds), and Streptococcal G IgG-binding domain (35 amino acids, no disulfide bonds).

**[0163]** Examples of small intracellular scaffolding domains include SH2, SH3, and EVH domains. Generally, any modular domain, intracellular or extracellular, can be used.

**[0164]** A display library of variants of a scaffold domain can be screened, e.g., to identify an epitope specific ligand that binds to CD44. For example, the epitope can be an epitope bound by a ligand described herein, e.g., the S5 antibody. In one embodiment, the scaffold domain is other than an antibody domain. An exemplary method for identifying an epitope specific ligand includes using competing non-target molecules that lack the particular epitope or are mutated within the epitope, e.g., with alanine. Such non-target molecules can be used in a negative selection procedure as described below, as competing molecules when binding a display library to the target, or as a pre-elution agent, e.g., to capture in a wash solution dissociating display library members that are not specific to the target. Another exemplary method includes using a ligand that binds to the epitope of interest as an eluant to elute display library members bound to CD44.

**[0165]** **Iterative Selection.** In one preferred embodiment, display library technology is used in an iterative mode. A first display library is used to identify one or more ligands for a target. These identified ligands are then varied using a mutagenesis method to form a second display library. Higher affinity ligands are then selected from the second library, e.g., by using higher stringency or more competitive binding and washing conditions.

**[0166]** In some implementations, the mutagenesis is targeted to regions known or likely to be at the binding interface. If, for example, the identified ligands are antibodies, then mutagenesis can be directed to the CDR regions of the heavy or light chains as described herein. Further, mutagenesis can be directed to framework regions near or adjacent to the CDRs, e.g., framework regions, particular within ten, five, or three amino acids of a CDR junction.. In the case of antibodies, mutagenesis can also be limited to one or a few of the CDRs, e.g., to make precise step-wise improvements.



**[0167]** Some exemplary mutagenesis techniques include: error-prone PCR (Leung *et al.* (1989) *Technique* 1:11-15), recombination (see, e.g., USSN 10/279,633, filed October 24, 2002), DNA shuffling using random cleavage (Stemmer (1994) *Nature* 389:391; termed “nucleic acid shuffling”), RACHITT™ (Coco *et al.* (2001) *Nature Biotech.* 19:354), site-directed mutagenesis (Zoller *et al.* (1987) *Nucl Acids Res* 10:6487-6504), cassette mutagenesis (Reidhaar-Olson (1991) *Methods Enzymol.* 208:564-586) and incorporation of degenerate oligonucleotides (Griffiths *et al.* (1994) *EMBO J* 13:3245).

**[0168]** In one example of iterative selection, the methods described herein are used to first identify a protein ligand from a display library that binds a CD44 with at least a minimal binding specificity for a target or a minimal activity, e.g., an equilibrium dissociation constant for binding of greater than 1 nM, 10 nM, or 100 nM. The nucleic acid sequence encoding the initial identified protein ligand are used as a template nucleic acid for the introduction of variations, e.g., to identify a second protein ligand that has enhanced properties (e.g., binding affinity, kinetics, or stability) relative to the initial protein ligand.

**[0169] Off-Rate Selection.** Since a slow dissociation rate can be predictive of high affinity, particularly with respect to interactions between polypeptides and their targets, the methods described herein can be used to isolate ligands with a desired kinetic dissociation rate (i.e. reduced) for a binding interaction to a target.

**[0170]** To select for slow dissociating ligands from a display library, the library is contacted to an immobilized target. The immobilized target is then washed with a first solution that removes non-specifically or weakly bound biomolecules. Then the immobilized target is eluted with a second solution that includes a saturation amount of free target, i.e., replicates of the target that are not attached to the particle. The free target binds to biomolecules that dissociate from the target. Rebinding is effectively prevented by the saturating amount of free target relative to the much lower concentration of immobilized target.

**[0171]** The second solution can have solution conditions that are substantially physiological or that are stringent. Typically, the solution conditions of the second solution are identical to the solution conditions of the first solution. Fractions of the

second solution are collected in temporal order to distinguish early from late fractions. Later fractions include biomolecules that dissociate at a slower rate from the target than biomolecules in the early fractions.

**[0172]** Further, it is also possible to recover display library members that remain bound to the target even after extended incubation. These can either be dissociated using chaotropic conditions or can be amplified while attached to the target. For example, phage bound to the target can be contacted to bacterial cells.

**[0173]        **Selecting and Screening for Specificity.**** “Selection” refers to a process in which many members of a display library are allowed to contact the target and those that bind are recovered and propagated. Here, selection was from a library having more than  $10^{10}$  members. “Screening” refers to a process in which isolated members of the library are tested singly for binding to the target. Through automation, thousands of candidates may be screened in a highly parallel process. The display library selection methods described herein can include a selection process that discards display library members that bind to a non-target molecule. Examples of non-target molecules include, e.g., the Fc domain of the CD44Fc antigen. In one implementation, a so-called “negative selection” step is used to discriminate between the target and related non-target molecule and a related, but distinct non-target molecules. The display library or a pool thereof is contacted to the non-target molecule. Members of the sample that do not bind the non-target are collected and used in subsequent selections for binding to the target molecule or even for subsequent negative selections. The negative selection step can be prior to or after selecting library members that bind to the target molecule.

**[0174]** In another implementation, a screening step is used. After display library members are isolated for binding to the target molecule, each isolated library member is tested for its ability to bind to a non-target molecule (e.g., a non-target listed above). For example, a high-throughput ELISA screen can be used to obtain this data. The ELISA screen can also be used to obtain quantitative data for binding of each library member to the target. The non-target and target binding data are compared (e.g., using a computer and software) to identify library members that specifically bind to CD44.

**[0175]** The display library selection and screening methods described herein can include a selection or screening process that selects for display library members that bind to specific sites on the target molecule. For example, elution with high concentration of HA selects for phage that bind to the HA-binding site of CD44. One can screen for a phage that binds to the HA-binding site of CD44 by performing ELISAs with and without HA in the buffer.

**[0176]** Diversity

**[0177]** Display libraries include variation at one or more positions in the displayed polypeptide. The variation at a given position can be synthetic or natural. For some libraries, both synthetic and natural diversity are included.

**[0178]** **Synthetic Diversity.** Libraries can include regions of diverse nucleic acid sequence that originate from artificially synthesized sequences. Typically, these are formed from degenerate oligonucleotide populations that include a distribution of nucleotides at each given position. The inclusion of a given sequence is random with respect to the distribution. One example of a degenerate source of synthetic diversity is an oligonucleotide that includes NNN wherein N is any of the four nucleotides in equal proportion.

**[0179]** Synthetic diversity can also be more constrained, e.g., to limit the number of codons in a nucleic acid sequence at a given trinucleotide to a distribution that is smaller than NNN. For example, such a distribution can be constructed using less than four nucleotides at some positions of the codon. In addition, trinucleotide addition technology can be used to further constrain the distribution.

**[0180]** So-called “trinucleotide addition technology” is described, e.g., in Wells *et al.* (1985) *Gene* 34:315-323, U.S. Patent No. US 4,760,025 and 5,869,644. Oligonucleotides are synthesized on a solid phase support, one codon (i.e., trinucleotide) at a time. The support includes many functional groups for synthesis such that many oligonucleotides are synthesized in parallel. The support is first exposed to a solution containing a mixture of the set of codons for the first position. The unit is protected so additional units are not added. The solution containing the first mixture is washed away

and the solid support is deprotected so a second mixture containing a set of codons for a second position can be added to the attached first unit. The process is iterated to sequentially assemble multiple codons. Trinucleotide addition technology enables the synthesis of a nucleic acid that at a given position can encode a number of amino acids. The frequency of these amino acids can be regulated by the proportion of codons in the mixture. Further the choice of amino acids at the given position is not restricted to quadrants of the codon table as is the case if mixtures of single nucleotides are added during the synthesis. Synthetic oligonucleotides including randomized or spiked codons can be also be used for producing a library for an affinity maturation selection.

**[0181] Natural Diversity.** Libraries can include regions of diverse nucleic acid sequence that originate (or are synthesized based on) from different naturally-occurring sequences. An example of natural diversity that can be included in a display library is the sequence diversity present in immune cells (see also below). Nucleic acids are prepared from these immune cells and are manipulated into a format for polypeptide display. Another example of naturally diversity is the diversity of sequences among different species of organisms. For example, diverse nucleic acid sequences can be amplified from environmental samples, such as soil, and used to construct a display library. De Wildt J Mol Biol. 1999 Dec 3;294(3):701-10 describe some exemplary characteristics of human immunoglobulin sequences.

**[0182] Antibody Display Libraries**

**[0183]** In one embodiment, the display library presents a diverse pool of polypeptides, each of which includes an immunoglobulin domain, e.g., an immunoglobulin variable domain. Display libraries are particular useful, for example for identifying human or “humanized” antibodies that recognize human antigens. Such antibodies can be used as therapeutics to treat human disorders such as cancer. Since the constant and framework regions of the antibody are human, these therapeutic antibodies may avoid themselves being recognized and targeted as antigens. The constant regions are also optimized to recruit effector functions of the human immune system. The *in vitro* display selection process surmounts the inability of a normal human immune system to generate antibodies against self-antigens.

**[0184]** A typical antibody display library displays a polypeptide that includes a VH domain and a VL domain. An “immunoglobulin domain” refers to a domain from the variable or constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain two  $\beta$ -sheets formed of about seven  $\beta$ -strands, and a conserved disulphide bond (see, e.g., A. F. Williams and A. N. Barclay 1988 *Ann. Rev Immunol.* 6:381-405). The display library can display the antibody as a Fab fragment (e.g., using two polypeptide chains) or a single chain Fv (e.g., using a single polypeptide chain). Other formats can also be used.

**[0185]** As in the case of the Fab and other formats, the displayed antibody can include a constant region as part of a light or heavy chain. In one embodiment, each chain includes one constant region, e.g., as in the case of a Fab. In other embodiments, additional constant regions are displayed.

**[0186]** Antibody libraries can be constructed by a number of processes (see, e.g., de Haard *et al.* (1999) *J. Biol. Chem* 274:18218-30; Hoogenboom *et al.* (1998) *Immunotechnology* 4:1-20. and Hoogenboom *et al.* (2000) *Immunol Today* 21:371-8. Further, elements of each process can be combined with those of other processes. The processes can be used such that variation is introduced into a single immunoglobulin domain (e.g., VH or VL) or into multiple immunoglobulin domains (e.g., VH and VL). The variation can be introduced into an immunoglobulin variable domain, e.g., in the region of one or more of CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4, referring to such regions of either and both of heavy and light chain variable domains. In one embodiment, variation is introduced into all three CDRs of a given variable domain. In another preferred embodiment, the variation is introduced into CDR1 and CDR2, e.g., of a heavy chain variable domain. Any combination is feasible. In one process, antibody libraries are constructed by inserting diverse oligonucleotides that encode CDRs into the corresponding regions of the nucleic acid. The oligonucleotides can be synthesized using monomeric nucleotides or trinucleotides. For example, Knappik *et al.* (2000) *J. Mol. Biol.* 296:57-86 describe a method for constructing CDR encoding oligonucleotides using trinucleotide synthesis and a template with engineered restriction sites for accepting the oligonucleotides.

**[0187]** In another process, an animal, e.g., a rodent, is immunized with the CD44. The animal is optionally boosted with the antigen to further stimulate the response. Then spleen cells are isolated from the animal, and nucleic acid encoding VH and/or VL domains is amplified and cloned for expression in the display library.

**[0188]** In yet another process, antibody libraries are constructed from nucleic acid amplified from naïve germline immunoglobulin genes. The amplified nucleic acid includes nucleic acid encoding the VH and/or VL domain. Sources of immunoglobulin-encoding nucleic acids are described below. Amplification can include PCR, e.g., with primers that anneal to the conserved constant region, or another amplification method.

**[0189]** Nucleic acid encoding immunoglobulin domains can be obtained from the immune cells of, e.g., a human, a primate, mouse, rabbit, camel, or rodent. In one example, the cells are selected for a particular property. B cells at various stages of maturity can be selected. In another example, the B cells are naïve.

**[0190]** In one embodiment, fluorescent-activated cell sorting (FACS) is used to sort B cells that express surface-bound IgM, IgD, or IgG molecules. Further, B cells expressing different isotypes of IgG can be isolated. In another preferred embodiment, the B or T cell is cultured *in vitro*. The cells can be stimulated *in vitro*, e.g., by culturing with feeder cells or by adding mitogens or other modulatory reagents, such as antibodies to CD40, CD40 ligand or CD20, phorbol myristate acetate, bacterial lipopolysaccharide, concanavalin A, phytohemagglutinin or pokeweed mitogen.

**[0191]** In still another embodiment, the cells are isolated from a subject that has an immunological disorder, e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, Sjogren syndrome, systemic sclerosis, or anti-phospholipid syndrome. The subject can be a human, or an animal, e.g., an animal model for the human disease, or an animal having an analogous disorder. In yet another embodiment, the cells are isolated from a transgenic non-human animal that includes a human immunoglobulin locus.

**[0192]** In one preferred embodiment, the cells have activated a program of somatic hypermutation. Cells can be stimulated to undergo somatic mutagenesis of immunoglobulin genes, for example, by treatment with anti-immunoglobulin, anti-CD40, and anti-CD38 antibodies (see, e.g., Bergthorsdottir *et al.* (2001) *J Immunol.* 166:2228). In another embodiment, the cells are naïve.

**[0193]** The nucleic acid encoding an immunoglobulin variable domain can be isolated from a natural repertoire by the following exemplary method. First, RNA is isolated from the immune cell. Full length (i.e., capped) mRNAs are separated (e.g. by dephosphorylating uncapped RNAs with calf intestinal phosphatase). The cap is then removed with tobacco acid pyrophosphatase and reverse transcription is used to produce the cDNAs.

**[0194]** The reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, e.g., de Haard *et al.* (1999) *J. Biol. Chem* 274:18218-30. The primer binding region can be constant among different immunoglobulins, e.g., in order to reverse transcribe different isotypes of immunoglobulin. The primer binding region can also be specific to a particular isotype of immunoglobulin. Typically, the primer is specific for a region that is 3' to a sequence encoding at least one CDR. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes).

**[0195]** A synthetic sequence can be ligated to the 3' end of the reverse transcribed strand. The synthetic sequence can be used as a primer binding site for binding of the forward primer during PCR amplification after reverse transcription. The use of the synthetic sequence can obviate the need to use a pool of different forward primers to fully capture the available diversity.

**[0196]** The variable domain-encoding gene is then amplified, e.g., using one or more rounds. If multiple rounds are used, nested primers can be used for increased fidelity. The amplified nucleic acid is then cloned into a display library vector.

**[0197]** Any method for amplifying nucleic acid sequences may be used for amplification. Methods that maximize and do not bias diversity are preferred. A variety of techniques can be used for nucleic acid amplification. The polymerase chain reaction

(PCR; U.S. Patent Nos. 4,683,195 and 4,683,202, Saiki, *et al.* (1985) *Science* 230, 1350-1354) utilizes cycles of varying temperature to drive rounds of nucleic acid synthesis. Transcription-based methods utilize RNA synthesis by RNA polymerases to amplify nucleic acid (U.S. Pat. No 6,066,457; U.S. Pat. No 6,132,997; U.S. Pat. No 5,716,785; Sarkar *et al.*, *Science* (1989) 244: 331-34 ; Stofler *et al.*, *Science* (1988) 239: 491). NASBA (U.S. Patent Nos. 5,130,238; 5,409,818; and 5,554,517) utilizes cycles of transcription, reverse-transcription, and RNaseH-based degradation to amplify a DNA sample. Still other amplification methods include rolling circle amplification (RCA; U.S. Patent Nos. 5,854,033 and 6,143,495) and strand displacement amplification (SDA; U.S. Patent Nos. 5,455,166 and 5,624,825).

#### **[0198]**      Secondary Screening Methods

**[0199]**      After selecting candidate display library members that bind to a target, each candidate display library member can be further analyzed, e.g., to further characterize its binding properties for the target. Each candidate display library member can be subjected to one or more secondary screening assays. The assay can be for a binding property, a catalytic property, a physiological property (e.g., cytotoxicity, renal clearance, immunogenicity), a structural property (e.g., stability, conformation, oligomerization state) or another functional property. The same assay can be used repeatedly, but with varying conditions, e.g., to determine pH, ionic, or thermal sensitivities.

**[0200]**      As appropriate, the assays can use the display library member directly, a recombinant polypeptide produced from the nucleic acid encoding a displayed polypeptide, or a synthetic peptide synthesized based on the sequence of a displayed polypeptide. Exemplary assays for binding properties include the following.

**[0201]**      **ELISA.** Polypeptides encoded by a display library can also be screened for a binding property using an ELISA assay. For example, each polypeptide is contacted to a microtitre plate whose bottom surface has been coated with the target, e.g., a limiting amount of the target. The plate is washed with buffer to remove non-specifically bound polypeptides. Then the amount of the polypeptide bound to the plate is determined by probing the plate with an antibody that can recognize the polypeptide, e.g., a tag or



constant portion of the polypeptide. The antibody is linked to an enzyme such as alkaline phosphatase, which produces a colorimetric product when appropriate substrates are provided. The polypeptide can be purified from cells or assayed in a display library format, e.g., as a fusion to a filamentous bacteriophage coat. Alternatively, cells (e.g., live or fixed) that express the target molecule, e.g., activated CD44, can be plated in a microtitre plate and used to test the affinity of the peptides/antibodies present in the display library or obtained by selection from the display library.

**[0202]** In another version of the ELISA assay, each polypeptide of a diversity strand library is used to coat a different well of a microtitre plate. The ELISA then proceeds using a constant target molecule to query each well.

**[0203] Homogeneous Binding Assays.** The binding interaction of candidate polypeptide with a target can be analyzed using a homogenous assay, i.e., after all components of the assay are added, additional fluid manipulations are not required. For example, fluorescence resonance energy transfer (FRET) can be used as a homogenous assay (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first molecule (e.g., the molecule identified in the fraction) is selected such that its emitted fluorescent energy can be absorbed by a fluorescent label on a second molecule (e.g., the target) if the second molecule is in proximity to the first molecule. The fluorescent label on the second molecule fluoresces when it absorbs to the transferred energy. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. A binding event that is configured for monitoring by FRET can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter). By titrating the amount of the first or second binding molecule, a binding curve can be generated to estimate the equilibrium binding constant.

**[0204]** Another example of a homogenous assay is Alpha Screen (Packard Bioscience, Meriden CT). Alpha Screen uses two labeled beads. One bead generates

singlet oxygen when excited by a laser. The other bead generates a light signal when singlet oxygen diffuses from the first bead and collides with it. The signal is only generated when the two beads are in proximity. One bead can be attached to the display library member, the other to the target. Signals are measured to determine the extent of binding.

**[0205]** The homogenous assays can be performed while the candidate polypeptide is attached to the display library vehicle, e.g., a bacteriophage.

**[0206] Surface Plasmon Resonance (SPR).** The binding interaction of a molecule isolated from a display library and a target can be analyzed using SPR. SPR or Biomolecular Interaction Analysis (BIA) detects biospecific interactions in real time, without labeling any of the interactants. Changes in the mass at the binding surface (indicative of a binding event) of the BIA chip result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)). The changes in the refractivity generate a detectable signal, which are measured as an indication of real-time reactions between biological molecules. Methods for using SPR are described, for example, in U.S. Patent No. 5,641,640; Raether (1988) *Surface Plasmons* Springer Verlag; Sjolander and Urbaniczky (1991) *Anal. Chem.* 63:2338-2345; Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705 and on-line resources provide by BIAcore International AB (Uppsala, Sweden).

**[0207]** Information from SPR can be used to provide an accurate and quantitative measure of the equilibrium dissociation constant ( $K_d$ ), and kinetic parameters, including  $K_{on}$  and  $K_{off}$ , for the binding of a biomolecule to a target. Such data can be used to compare different biomolecules. For example, proteins encoded by nucleic acid selected from a library of diversity strands can be compared to identify individuals that have high affinity for the target or that have a slow  $K_{off}$ . This information can also be used to develop structure-activity relationships (SAR). For example, the kinetic and equilibrium binding parameters of matured versions of a parent protein can be compared to the parameters of the parent protein. Variant amino acids at given positions can be identified that correlate with particular binding parameters, e.g., high affinity and slow  $K_{off}$ . This information can be combined with structural modeling (e.g., using homology modeling,

energy minimization, or structure determination by crystallography or NMR). As a result, an understanding of the physical interaction between the protein and its target can be formulated and used to guide other design processes.

**[0208] Protein Arrays.** Polypeptides identified from the display library can be immobilized on a solid support, for example, on a bead or an array. For a protein array, each of the polypeptides is immobilized at a unique address on a support. Typically, the address is a two-dimensional address. Protein arrays are described below (see, e.g., Diagnostics).

**[0209] Functional Assays**

**[0210] Cellular Assays.** Candidate polypeptides can be selected from a library by transforming the library into a host cell; the library could have been previously identified from a display library. For example, the library can include vector nucleic acid sequences that include segments that encode the polypeptides and that direct expression, e.g., such that the polypeptides are produced within the cell, secreted from the cell, or attached to the cell surface. The cells can be screened or selected for polypeptides that bind to the CD44, e.g., as detected by a change in a cellular phenotype or a cell-mediated activity. For example, in the case of an antibody that binds to the CD44, the activity may be cell or complement-mediated cytotoxicity.

**[0211]** In another embodiment, the library of cells is in the form of a cellular array. The cellular array can likewise be screened for any appropriate detectable activity.

**[0212]** In other embodiments, cellular assays can be used to test the effects of proteins/antibodies obtained from the display library. Such assays can be used, e.g., to measure cellular adhesion or migration, or lymphocyte rolling. Techniques for measuring cellular adhesion, migration, and lymphocyte rolling are well known in the art. See, e.g., Siegelman *et al.* (1999), *J Leukoc Biol* 66(2):315-21; Hidalgo *et al.* (2002), *J Hematother Stem Cell Res* 11(3):539-47; Bourguignon *et al.* (2002), *J Biol Chem* July 26 (published online); and Zhang *et al.* (2002), *Cancer Res* 62(14):3962-5.

**[0213]** An exemplary *in vitro* cell proliferation assay is the Cell Titer 96® Aqueous non-radioactive cell proliferation assay (Promega, Wisconsin). In an exemplary implementation, cells are seeded into a well of a microtitre plate. The test compound, e.g., a CD44-binding antibody described herein, is added to the well. The cells are incubated for 4 days at 37°C in 5% CO<sub>2</sub> atmosphere. After the incubation MTS/PMS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine formazan) is added according to the kit instructions. Absorbance is monitored at 490 nm. An IC<sub>50</sub> value for the cells is calculated based on the fraction of surviving cells. Cells that can be used include CD44 expressing cells, e.g., A431 cells (ATCC # CRL 1555; epidermoid carcinoma of the vulva) and FaDu cells (ATCC # HTB 43; squamous cell carcinoma of the pharynx).. Controls for comparison can include wells that lack the test compound or wells that include a cell that does not express CD44, e.g., A459 cells.

**[0214]** Exemplary *in vivo* assays to evaluate the anti-tumor effect of a CD44-binding antibody includes nude mouse tumor models. In an exemplary implementation, a nude mouse is xenografted with a human tumor that includes CD44-expressing cells. For example, 10<sup>6</sup> tumor cells can be transplanted subcutaneously into the flank of a nude mouse, e.g., the NMRI-nu/nu mouse. Exemplary human tumor cells include carcinoma cells, e.g., A431 (ATCC # CRL 1555) and breast carcinoma cells, e.g., MDA-MB 453 (ATCC# HTB-131). When the tumor reaches an average size of between 100-180 mm<sup>3</sup>, the test compound or control composition is administered to the mouse, e.g., by intravenous injection. It is possible to use this assay to monitor the effect of different dosages, e.g., about 0.1, 0.5, 1.0, 5.0, 10, 20 or 25 mg/kg/day or ranges therebetween. Animals are monitored by evaluating tumor size. For example, a tumor response can be rated as complete if the tumor entirely disappears or as a partial response if the tumor volume decreases after treatment, but then begins regrowing. The animals can also be monitored to evaluate tolerability of the treatment, e.g., by monitoring animal weight.

**[0215]** Ligand Production

**[0216]** Standard recombinant nucleic acid methods can be used to construct nucleic acids that encode a protein ligand that binds to CD44 and to express the protein ligand.

**[0217]** Methods well known to those skilled in the art can be used to construct vectors containing a polynucleotide encoding a ligand and appropriate transcriptional/translational control signals. These methods can include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Sambrook & Russell, *Molecular Cloning: A Laboratory Manual*, 3<sup>rd</sup> Edition, Cold Spring Harbor Laboratory, N.Y. (2001) and Ausubel *et al.*, *Current Protocols in Molecular Biology* (Greene Publishing Associates and Wiley Interscience, N.Y. (1989).

**[0218]** Some antibodies, e.g., Fabs, can be produced in bacterial cells, e.g., *E. coli* cells. For example, if the Fab is encoded by sequences in a phage display vector that includes a suppressible stop codon between the display entity and a bacteriophage protein (or fragment thereof), the vector nucleic acid can be shuffled into a bacterial cell that cannot suppress a stop codon. In this case, the Fab is not fused to the gene III protein and is secreted into the media.

**[0219]** Antibodies can also be produced in eukaryotic cells. In one embodiment, the antibodies (e.g., scFv's) are expressed in a yeast cell such as *Pichia* (see, e.g., Powers *et al.* (2001) *J Immunol Methods*. 251:123-35), *Hansenula*, or *Saccharomyces*.

**[0220]** In one embodiment, antibodies are produced in mammalian cells. Preferred mammalian host cells for expressing the clone antibodies or antigen-binding fragments thereof include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin (1980) *Proc. Natl. Acad. Sci. USA* 77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) *Mol. Biol.* 159:601-621), lymphocytic cell lines, e.g., NS0 myeloma cells and SP2 cells, COS cells, and a cell from a transgenic animal, e.g., a transgenic mammal. For example, the cell is a mammary epithelial cell.

**[0221]** In addition to the nucleic acid sequence encoding the protein ligand, the recombinant expression vectors may carry additional sequences, such as sequences that regulate replication of the vector in host cells (*e.g.*, origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see *e.g.*, U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in *dhfr*<sup>-</sup> host cells with methotrexate selection/amplification) and the *neo* gene (for G418 selection).

**[0222]** In an exemplary system for recombinant expression of an antibody, or antigen-binding portion thereof, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into *dhfr*<sup>-</sup> CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (*e.g.*, derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium. For example, some antibodies can be isolated by affinity chromatography with a Protein A or Protein G.

**[0223]** For antibodies that include an Fc domain, the antibody production system preferably synthesizes antibodies in which the Fc region is glycosylated. For example, the Fc domain of IgG molecules is glycosylated at asparagine 297 in the CH2 domain. This asparagine is the site for modification with biantennary-type oligosaccharides. It has been demonstrated that this glycosylation is required for effector functions mediated

by Fcγ receptors and complement C1q (Burton and Woof (1992) *Adv. Immunol.* 51:1-84; Jefferis *et al.* (1998) *Immunol. Rev.* 163:59-76). In one embodiment, the Fc domain is produced in a mammalian expression system that appropriately glycosylates the residue corresponding to asparagine 297. The Fc domain can also include other eukaryotic post-translational modifications.

**[0224]** Antibodies can also be produced by a transgenic animal. For example, U.S. Patent No. 5,849,992 describes a method of expressing an antibody in the mammary gland of a transgenic mammal. A transgene is constructed that includes a milk-specific promoter and nucleic acids encoding the antibody of interest and a signal sequence for secretion. The milk produced by females of such transgenic mammals includes, secreted therein, the antibody of interest. The antibody can be purified from the milk, or for some applications, used directly.

**[0225]** It is also possible to produce antibodies that bind to CD44 by immunization, e.g., using an animal, e.g., with natural, human, or partially human immunoglobulin loci. Non-human antibodies can also be modified to include substitutions for human immunoglobulin sequences, e.g., consensus human amino acid residues at particular positions, e.g., at one or more of the following positions (preferably at least five, ten, twelve, or all): (in the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, and/or (in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 78H, 91H, 92H, 93H, and/or 103H (according to the Kabat numbering). See, e.g., U.S. 6,407,213.

**[0226] CD44 production.** Method for producing CD44 ectodomain protein, CD44 protein, and CD44-containing liposomes are known in the art. See, e.g., US 6,432,405.

**[0227] Pharmaceutical Compositions**

**[0228]** A CD44-binding protein ligand can be a component of a composition, e.g., a pharmaceutically acceptable composition. To prepare one such composition, the ligand

is formulated together with a pharmaceutically acceptable carrier. As used herein, “pharmaceutical compositions” encompass labeled ligands for in vivo imaging as well as therapeutic compositions.

**[0229]** As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (*e.g.*, by injection or infusion). Depending on the route of administration, the active compound, *i.e.*, protein ligand may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

**[0230]** A “pharmaceutically acceptable salt” refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see *e.g.*, Berge, S.M., *et al.* (1977) *J. Pharm. Sci.* 66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

**[0231]** The compositions described herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (*e.g.*, injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for administration of humans with antibodies. The preferred mode of administration is



parenteral (*e.g.*, intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the CD44-binding ligand is administered by intravenous infusion or injection. In another preferred embodiment, the CD44-binding ligand is administered by intramuscular or subcutaneous injection.

**[0232]** The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

**[0233]** Pharmaceutical compositions typically must be sterile and stable under the conditions of manufacture and storage. A pharmaceutical composition can also be tested to insure it meets regulatory and industry standards for administration. For example, endotoxin levels in the preparation can be tested using the Limulus amebocyte lysate assay (*e.g.*, using the kit from Bio Whittaker lot # 7L3790, sensitivity 0.125 EU/mL) according to the USP 24/NF 19 methods. Sterility of pharmaceutical compositions can be determined using thioglycollate medium according to the USP 24/NF 19 methods. For example, the preparation is used to inoculate the thioglycollate medium and incubated at 35°C for 14 or more days. The medium is inspected periodically to detect growth of a microorganism.

**[0234]** The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound (*i.e.*, the ligand) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a

previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

**[0235]** The CD44-binding protein ligands described herein can be administered by a variety of methods known in the art, although for many applications, the preferred route/mode of administration is intravenous injection or infusion. For example, for therapeutic applications, the CD44-binding ligand can be administered by intravenous infusion at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m<sup>2</sup> or 7 to 25 mg/m<sup>2</sup>. The route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known. *See, e.g., Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

**[0236]** In certain embodiments, the ligand may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer a compound by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with a material that prevents its inactivation.

**[0237]** Pharmaceutical compositions can be administered with medical devices known in the art. For example, a pharmaceutical composition can be administered with a needleless hypodermic injection device, such as the devices disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of implants and modules include: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering medicants through the skin; U.S. Patent No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. Of course, many other such implants, delivery systems, and modules are also known.

**[0238]** In certain embodiments, a CD44-binding protein ligand can be formulated to ensure proper distribution *in vivo*. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that a therapeutic compound crosses the BBB (if desired), it can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Patents 4,522,811; 5,374,548; and 5,399,331. The liposomes may include one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., V.V. Ranade (1989) *J. Clin. Pharmacol.* 29:685).

**[0239]** Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The

specification for the dosage unit forms can be dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

**[0240]** An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of a CD44-binding antibody is 0.1-20 mg/kg, more preferably 1-10 mg/kg. The CD44-binding antibody can be administered by intravenous infusion at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m<sup>2</sup> or about 5 to 30 mg/m<sup>2</sup>. For ligands smaller in molecular weight than an antibody, appropriate amounts can be proportionally less. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

**[0241]** A pharmaceutical composition may include a “therapeutically effective amount” or a “prophylactically effective amount” of a CD44-binding antibody. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the protein ligand to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects. A “therapeutically effective dosage” preferably inhibits a measurable parameter, e.g., inflammation or tumor growth rate by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to inhibit a measurable parameter, e.g., cancer, can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, this property of a

composition can be evaluated by examining the ability of the compound to inhibit, such inhibition *in vitro* by assays known to the skilled practitioner.

**[0242]** A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

**[0243]** Kits can be prepared that include a CD44-binding antibody and instructions for use, e.g., treatment, prophylactic, or diagnostic use. In one embodiment, the instructions for diagnostic applications include the use of the CD44-binding antibody (e.g., antibody or antigen-binding fragment thereof, or other polypeptide or peptide) to detect CD44, *in vitro*, e.g., in a sample, e.g., a biopsy or cells from a patient having an inflammatory disorder or a cancer or neoplastic disorder, or *in vivo*. In another embodiment, the instructions for therapeutic applications include suggested dosages and/or modes of administration in a patient with a cancer or neoplastic disorder. The kit can further contain a least one additional reagent, such as a diagnostic or therapeutic agent, e.g., a diagnostic or therapeutic agent as described herein, and/or one or more additional CD44-binding ligands, formulated as appropriate, in one or more separate pharmaceutical preparations.

**[0244]** Stabilization and Retention

**[0245]** In one embodiment, a CD44 ligand (e.g., a CD44 binding antibody described herein) is physically associated with a moiety that improves its stabilization and/or retention in circulation, e.g., in blood, serum, lymph, or other tissues.

**[0246]** For example, a CD44 ligand can be associated with a polymer, e.g., a substantially non-antigenic polymers, such as polyalkylene oxides or polyethylene oxides. Suitable polymers will vary substantially by weight. The polymers can have average molecular weights in the ranges of from about 200 to about 35,000 Daltons, from about 1,000 to about 15,000 and 2,000 to about 12,500 Daltons.

**[0247]** For example, a CD44 ligand can be conjugated to a water soluble polymer, e.g., hydrophilic polyvinyl polymers, e.g. polyvinylalcohol and polyvinylpyrrolidone.. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained. Additional useful polymers include polyoxyalkylenes such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; branched or unbranched polysaccharides which comprise the saccharide monomers D-mannose, D- and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (e.g. polymannuronic acid, or alginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminic acid including homopolysaccharides and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextrane sulfate, dextran, dextrans, glycogen, or the polysaccharide subunit of acid mucopolysaccharides, e.g. hyaluronic acid; polymers of sugar alcohols such as polysorbitol and polymannitol; heparin or heparon.

**[0248]** Other compounds can also be attached to the same polymer, e.g., a cytotoxin, a label, or another targeting agent, e.g., another CD44 ligand or an unrelated ligand. Mono-activated, alkoxy-terminated polyalkylene oxides (PAO's), e.g., monomethoxy-terminated polyethylene glycols (mPEG's); C<sub>1-4</sub> alkyl-terminated polymers; and bis-activated polyethylene oxides (glycols) can be used for crosslinking. See, e.g., U.S. 5,951,974.

**[0249]** In one embodiment, the polymer prior to cross-linking need not be, but preferably is, water soluble. Generally, after crosslinking, the product is water soluble, e.g., exhibits a water solubility of at least about 0.01 mg/ml, and more preferably at least about 0.1 mg/ml, and still more preferably at least about 1 mg/ml. In addition, the polymer should not be highly immunogenic in the conjugate form, nor should it possess viscosity that is incompatible with intravenous infusion or injection if the conjugate is intended to be administered by such routes.

**[0250]** In one embodiment, the polymer contains only a single group which is reactive. This helps to avoid cross-linking of protein molecules. However, it is within the scope herein to maximize reaction conditions to reduce cross-linking, or to purify the reaction products through gel filtration or ion exchange chromatography to recover substantially homogenous derivatives. In other embodiments, the polymer contains two or more reactive groups for the purpose of linking multiple ligands to the polymer backbone. Again, gel filtration or ion exchange chromatography can be used to recover the desired derivative in substantially homogeneous form.

**[0251]** The molecular weight of the polymer can range up to about 500,000 D, and preferably is at least about 20,000 D, or at least about 30,000 D, or at least about 40,000 D. The molecular weight chosen can depend upon the effective size of the conjugate to be achieved, the nature (e.g. structure, such as linear or branched) of the polymer, and the degree of derivatization.

**[0252]** The covalent crosslink can be used to attach a CD44 ligand to a polymer, for example, by crosslinking the polymer to the N-terminal amino group and epsilon amino groups found on lysine residues, as well as other amino, imino, carboxyl, sulfhydryl, hydroxyl or other hydrophilic groups. The polymer may be covalently bonded directly to the CD44 ligand without the use of a multifunctional (ordinarily bifunctional) crosslinking agent. Covalent binding to amino groups is accomplished by known chemistries based upon cyanuric chloride, carbonyl diimidazole, aldehyde reactive groups (PEG alkoxide plus diethyl acetal of bromoacetaldehyde; PEG plus DMSO and acetic anhydride, or PEG chloride plus the phenoxide of 4-hydroxybenzaldehyde, activated succinimidyl esters, activated dithiocarbonate PEG, 2,4,5-trichlorophenylchloroformate or P-nitrophenylchloroformate activated PEG.) Carboxyl groups can be derivatized by coupling PEG-amine using carbodiimide. Sulfhydryl groups can be derivatized by coupling to maleimido-substituted PEG (e.g. alkoxy-PEG amine plus sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) WO 97/10847 or PEG-maleimide commercially available from Shearwater Polymers, Inc., Huntsville, Ala.). Alternatively, free amino groups on the ligand (e.g. epsilon amino groups on lysine residues) can be thiolated with 2-imino-thiolane (Traut's

reagent) and then coupled to maleimide-containing derivatives of PEG, e.g., as described in Pedley et al., Br. J. Cancer, 70: 1126-1130 (1994).

**[0253]** Functionalized PEG polymers that can be attached to a CD44 ligand are available, e.g., from Shearwater Polymers, Inc. (Huntsville, Ala.). Such commercially available PEG derivatives include, e.g., amino-PEG, PEG amino acid esters, PEG-hydrazide, PEG-thiol, PEG-succinate, carboxymethylated PEG, PEG-propionic acid, PEG amino acids, PEG succinimidyl succinate, PEG succinimidyl propionate, succinimidyl ester of carboxymethylated PEG, succinimidyl carbonate of PEG, succinimidyl esters of amino acid PEGs, PEG-oxycarbonylimidazole, PEG-nitrophenyl carbonate, PEG tresylate, PEG-glycidyl ether, PEG-aldehyde, PEG vinylsulfone, PEG-maleimide, PEG-orthopyridyl-disulfide, heterofunctional PEGs, PEG vinyl derivatives, PEG silanes, and PEG phospholides. The reaction conditions for coupling these PEG derivatives may vary depending on the CD44 ligand, the desired degree of PEGylation, and the PEG derivative utilized. Some factors involved in the choice of PEG derivatives include: the desired point of attachment (such as lysine or cysteine R-groups), hydrolytic stability and reactivity of the derivatives, stability, toxicity and antigenicity of the linkage, suitability for analysis, etc. Specific instructions for the use of any particular derivative are available from the manufacturer.

**[0254]** The conjugates of a CD44-binding ligand and a polymer can be separated from the unreacted starting materials, e.g., by gel filtration or ion exchange chromatography, e.g., HPLC. Heterologous species of the conjugates are purified from one another in the same fashion. Resolution of different species (e.g. containing one or two PEG residues) is also possible due to the difference in the ionic properties of the unreacted amino acids. See, e.g., WO 96/34015.

**[0255]** A conjugate of a CD44-binding ligand and a polymer can be administered to the subject in an amount effective to maintain a desired concentration in a subject for at least 4, 8, 12, 24, or 72 hours. Because the conjugate is stabilized and may have an extended circulatory half-life, it may be possible to administer the conjugate as part of a regimen no more than once every 12, 24, 48, or 72 hours or no more than once every three, four, five, six, ten, twelve, or fourteen days. The conjugate may have a beta phase



half life of at least 4, 6, 8, 8.5, 9, 10, 12, 20, 24, 30, 42, 48, or 50 hours. The beta phase may be at least 40, 50, 60, 70, or 80% of the amplitude.

**[0256]** Treatments

**[0257]** Protein ligands that bind to CD44 (e.g., those described herein) have therapeutic and prophylactic utilities. For example, these ligands can be administered to cells in culture, e.g. *in vitro* or *ex vivo*, or in a subject, e.g., *in vivo*, to treat, prevent, and/or diagnose a variety of disorders, such as inflammatory diseases and cancers.

**[0258]** As used herein, the term “treat” or “treatment” is defined as the application or administration of a CD44-binding antibody, alone or in combination with, a second agent to a subject, e.g., a patient, or application or administration of the agent to an isolated tissue or cell, e.g., cell line, from a subject, e.g., a patient, who has a disorder (e.g., a disorder as described herein), a symptom of a disorder or a predisposition toward a disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, the symptoms of the disorder or the predisposition toward the disorder. Treating a cell refers to the inhibition, ablation, killing of a cell *in vitro* or *in vivo*, or otherwise reducing capacity of a cell, e.g., an aberrant cell, to mediate a disorder, e.g., a disorder as described herein (e.g., a cancerous disorder). In one embodiment, “treating a cell” refers to a reduction in the activity and/or proliferation of a cell, e.g., a hyperproliferative cell. Such reduction does not necessarily indicate a total elimination of the cell, but a reduction, e.g., a statistically significant reduction, in the activity or the number of the cell.

**[0259]** As used herein, an amount of a CD44-binding ligand effective to treat a disorder, or a “therapeutically effective amount” refers to an amount of the ligand which is effective, upon single or multiple dose administration to a subject, in treating a cell, e.g., white blood cell (e.g., a B cell, T cell, macrophage, or neutrophil), parenchymal cell, or cancer cell (e.g., a CD44-expressing cancer cell, particularly a metastatic cell thereof), or in prolonging curing, alleviating, relieving or improving a subject with a disorder as described herein beyond that expected in the absence of such treatment. As used herein,

“inhibiting the growth” of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and metastases and does not necessarily indicate a total elimination of the neoplastic growth.

**[0260]** As used herein, an amount of a CD44-binding ligand effective to prevent a disorder, or a “a prophylactically effective amount” of the ligand refers to an amount of a CD44-binding ligand, e.g., a CD44-binding antibody described herein, which is effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder, e.g., an inflammatory disorder or a cancer.

**[0261]** The terms “induce”, “inhibit”, “potentiate”, “elevate”, “increase”, “decrease” or the like, e.g., which denote quantitative differences between two states, refer to a difference, e.g., a statistically significant difference, between the two states. For example, “an amount effective to inhibit the proliferation of the CD44-expressing hyperproliferative cells” means that the rate of growth of the cells will be different, e.g., statistically significantly different, from the untreated cells.

**[0262]** As used herein, the term “subject” is intended to include human and non-human animals. Preferred human animals include a human patient having a disorder characterized by abnormal cell proliferation or cell differentiation. The term “non-human animals” includes all non-human vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and non-human mammals, such as non-human primates, sheep, dog, cow, pig, etc.

**[0263]** In one embodiment, the subject is a human subject. Alternatively, the subject can be a mammal expressing a CD44-like antigen with which an antibody cross-reacts. A CD44-binding antibody can be administered to a human subject for therapeutic purposes (see, e.g., below). Moreover, a CD44-binding ligand can be administered to a non-human mammal expressing the CD44-like antigen to which the ligand binds (e.g., a primate, pig or mouse) for veterinary purposes or as an animal model of human disease. Regarding the latter, such animal models may be useful for evaluating the therapeutic efficacy of the ligand (e.g., testing of dosages and time courses of administration).

**[0264]** In one embodiment, the CD-44 binding antibody is used to treat (e.g., ablating or killing) a cell (e.g., a non-cancerous cell, e.g., a normal, benign or hyperplastic cell, or a cancerous cell, e.g., a malignant cell, e.g., cell found in a solid tumor, a soft tissue tumor, or a metastatic lesion (e.g., a cell found in renal, urothelial, colonic, rectal, pulmonary, breast or hepatic, cancers and/or metastasis)). The methods can include the steps of contacting the cell with a CD44-binding ligand, e.g., a CD44-binding antibody described herein, in an amount sufficient to treat, e.g., ablate or kill, the cell.

**[0265]** The subject method can be used on cells in culture, e.g. *in vitro* or *ex vivo*. For example, cancerous or metastatic cells (e.g., renal, urothelial, colon, rectal, lung, breast, ovarian, prostatic, or liver cancerous or metastatic cells) can be cultured *in vitro* in culture medium and the contacting step can be effected by adding the CD44-binding ligand to the culture medium. The method can be performed on cells (e.g., cancerous or metastatic cells) present in a subject, as part of an *in vivo* (e.g., therapeutic or prophylactic) protocol. For *in vivo* embodiments, the contacting step is effected in a subject and includes administering the CD44-binding ligand to the subject under conditions effective to permit both binding of the ligand to the cell and the treating, e.g., the killing or ablating of the cell.

**[0266]** The method can be used to treat a cancer. As used herein, the terms “cancer”, “hyperproliferative”, “malignant”, and “neoplastic” are used interchangeably, and refer to those cells an abnormal state or condition characterized by rapid proliferation or neoplasm. The terms include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth.

**[0267]** The common medical meaning of the term “neoplasia” refers to “new cell growth” that results as a loss of responsiveness to normal growth controls, e.g. to neoplastic cell growth. A “hyperplasia” refers to cells undergoing an abnormally high rate of growth. However, as used herein, the terms neoplasia and hyperplasia can be used interchangeably, as their context will reveal, referring generally to cells experiencing

abnormal cell growth rates. Neoplasias and hyperplasias include “tumors,” which may be benign, premalignant or malignant.

**[0268]** Examples of cancerous disorders include, but are not limited to, solid tumors, soft tissue tumors, and metastatic lesions. Examples of solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary tract (e.g., renal, urothelial cells), pharynx, prostate, ovary as well as adenocarcinomas which include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and so forth. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the CD44-binding antibodies described herein. The CD44-binding antibodies that antagonize CD44 activity can be particularly useful for treating cancers that include CD44-expressing cells.

**[0269]** The subject method can be useful in treating malignancies of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary tract, prostate, ovary, pharynx, as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. Exemplary solid tumors that can be treated include: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma,

acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

**[0270]** The term “carcinoma” is recognized by those skilled in the art and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues. An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.

**[0271]** The term “sarcoma” is recognized by those skilled in the art and refers to malignant tumors of mesenchymal derivation.

**[0272]** The subject method can also be used to inhibit the proliferation of hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. For instance, the CD44-binding protein can be used to treat various myeloid disorders including, but not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) *Crit Rev. in Oncol./Hematol.* 11:267-97). Lymphoid malignancies which may be treated by the subject method include, but are not limited to acute lymphoblastic leukemia (ALL), which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to, non-Hodgkin's lymphoma and variants thereof, peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF) and Hodgkin's disease.

**[0273]** Methods of administering CD44-binding ligands are also described in “Pharmaceutical Compositions”. Suitable dosages of the molecules used will depend on

the age and weight of the subject and the particular drug used. The ligands can be used as competitive agents to inhibit, reduce an undesirable interaction, e.g., between a natural or pathological agent and the CD44.

**[0274]** In one embodiment, the CD44-binding ligands are used to kill or ablate cancerous cells and normal, benign hyperplastic, and cancerous cells *in vivo*. The ligands can be used by themselves or conjugated to an agent, e.g., a cytotoxic drug or radioisotope. This method includes: administering the ligand alone or attached to a cytotoxic drug, to a subject requiring such treatment.

**[0275]** The terms “cytotoxic agent” and “cytostatic agent” and “anti-tumor agent” are used interchangeably herein and refer to agents that have the property of inhibiting the growth or proliferation (e.g., a cytostatic agent), or inducing the killing, of hyperproliferative cells, e.g., an aberrant cancer cell. In cancer therapeutic embodiment, the term “cytotoxic agent” is used interchangeably with the terms “anti-cancer” or “anti-tumor” to mean an agent, which inhibits the development or progression of a neoplasm, particularly a solid tumor, a soft tissue tumor, or a metastatic lesion.

**[0276]** Nonlimiting examples of anti-cancer agents include, e.g., antimicrotubule agents, topoisomerase inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway, agents that promote apoptosis, radiation, and antibodies against other tumor-associated antigens (including naked antibodies, immunotoxins and radioconjugates). Examples of the particular classes of anti-cancer agents are provided in detail as follows: antitubulin/antimicrotubule, e.g., paclitaxel, vincristine, vinblastine, vindesine, vinorelbin, taxotere; topoisomerase I inhibitors, e.g., topotecan, camptothecin, doxorubicin, etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, merbarone, piroxantrone hydrochloride; antimetabolites, e.g., 5-fluorouracil (5-FU), methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine/Ara-C, trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L-Asparate=PALA, pentostatin, 5-azacitidine, 5-Aza 2'-deoxycytidine, ara-A, cladribine, 5 - fluorouridine, FUDR, tiazofurin, N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl)methyl)-N-methylamino]-2-thenoyl]-L-glutamic acid; alkylating

agents, e.g., cisplatin, carboplatin, mitomycin C, BCNU=Carmustine, melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol; agents acting via other mechanisms of action, e.g., dihydrolenperone, spiromustine, and desipeptide; biological response modifiers, e.g., to enhance anti-tumor responses, such as interferon; apoptotic agents, such as actinomycin D; and anti-hormones, for example anti-estrogens such as tamoxifen or, for example antiandrogens such as 4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide.

**[0277]** In one embodiment, the CD44-binding antibody is conjugated to a maytansinoid, e.g., a derivative of maytansine (CAS 35846538) or a C-3 ester of maytansinol. For example, the maytansinoid can be linked by a covalent bond such as a disulfide moiety. It is also possible to link multiple maytansinoid moieties to a single antibody molecule, e.g., at least 2, 3, or 4 maytansinoid moieties. Maytansinoids suitable for conjugating to antibodies for use in cancer therapy and methods for preparing such are known; see, e.g., Chari R V J, et al. Cancer Research 52:127-31, 1992; Liu C. et al., Proc Natl Acad Sci USA 93:8618-23, 1996; U.S. Pat. No. 5,208,020. In one embodiment, the CD44-binding antibody is conjugated to N<sup>2'</sup>-deacetyl- N<sup>2'</sup>-(3-mercapto-1-oxopropyl)-Maytansine (CAS Number 139504-50-0, e.g., DM1). The maytansinoid can be a maytansinol derivative linked to the antibody molecule via a disulfide bridge at the C-3 position of maytansinol.

**[0278]** Since the CD44-binding ligands recognize CD44-expressing cancer cells, e.g., cancerous lung, liver, colon, breast, ovarian, epidermal, laryngeal, and cartilage cells, and particularly metastatic cells thereof, any such cells to which the ligands bind are destroyed. Alternatively, the ligands bind to cells in the vicinity of the cancerous cells and kill them, thus indirectly attacking the cancerous cells which may rely on surrounding cells for nutrients, growth signals and so forth. Thus, the CD44-binding ligands (e.g., modified with a cytotoxin) can selectively kill or ablate cells in cancerous tissue (including the cancerous cells themselves).

**[0279]** The ligands may be used to deliver a variety of cytotoxic drugs including therapeutic drugs, a compound emitting radiation, molecules of plants, fungal, or

bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short-range radiation emitters, including, for example, short-range, high-energy  $\alpha$ -emitters, as described herein.

**[0280]** Enzymatically active toxins and fragments thereof are exemplified by diphtheria toxin A fragment, nonbinding active fragments of diphtheria toxin, exotoxin A (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain,  $\alpha$ -sacrin, certain *Aleurites fordii* proteins, certain Dianthin proteins, *Phytolacca americana* proteins (PAP, PAPII and PAP-S), *Morodica charantia* inhibitor, curcin, crotin, *Saponaria officinalis* inhibitor, gelonin, mitogillin, restrictocin, phenomycin, and enomycin. Procedures for preparing enzymatically active polypeptides of the immunotoxins are described in W084/03508 and W085/03508, and in the appended Examples below. Examples of cytotoxic moieties that can be conjugated to the antibodies include adriamycin, chlorambucil, daunomycin, methotrexate, neocarzinostatin, and platinum.

**[0281]** In the case of polypeptide toxins, recombinant nucleic acid techniques can be used to construct a nucleic acid that encodes the ligand (or a polypeptide component thereof) and the cytotoxin (or a polypeptide component thereof) as translational fusions. The recombinant nucleic acid is then expressed, e.g., in cells and the encoded fusion polypeptide isolated.

**[0282]** Procedures for conjugating protein ligands (e.g., antibodies) with the cytotoxic agents have been previously described. Procedures for conjugating chlorambucil with antibodies are described by Flechner (1973) *European Journal of Cancer*, 9:741-745; Ghose et al. (1972) *British Medical Journal*, 3:495-499; and Szekerke, et al. (1972) *Neoplasma*, 19:211-215. Procedures for conjugating daunomycin and adriamycin to antibodies are described by Hurwitz, E. et al. (1975) *Cancer Research*, 35:1175-1181 and Arnon et al. (1982) *Cancer Surveys*, 1:429-449. Procedures for preparing antibody-ricin conjugates are described in U.S. Patent No. 4,414,148 and by Osawa, T., et al. (1982) *Cancer Surveys*, 1:373-388 and the references cited therein. Coupling procedures as also described in EP 86309516.2. For example, antibody molecules can be modified with crosslinking reagents such as N-succinimidyl 3-(2-



pyridyldithio)propionate (SPDP), 4-succinimidyl-oxycarbonyl-.alpha.-methyl-.alpha.-(2-pyridyldithio)-toluene (SMPT), N-succinimidyl-3-(2-pyridyldithio)-butyrate (SDPB), N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-5-(2-pyridyldithio)pentanoate, 2-iminothiolane, or acetylsuccinic anhydride by known methods. See, Carlsson et al, Biochem. J. 173:723-737, 1978; Blattler, et al. Biochem. 24:1516-1524, 1985; Lambert et al. Biochem. 22:3913-3920, 1983; Klotz et al, Arch. Biochem. Biophys. 96:605, 1962; Liu et al, Biochem. 18:690, 1979; Blakey and Thorpe, Immunoconjugates and Radiopharmaceuticals 1:1-16, 1988; Worrell et al. Anti-Cancer Drug Design 1:179-184, 1986. In one embodiment, the linker moiety is a 4-thiopentanoate derived from SPP.

**[0283]** To kill or ablate normal, benign hyperplastic, or cancerous cells, a first protein ligand is conjugated with a prodrug which is activated only when in close proximity with a prodrug activator. The prodrug activator is conjugated with a second protein ligand, preferably one which binds to a non-competing site on the target molecule. Whether two protein ligands bind to competing or non-competing binding sites can be determined by conventional competitive binding assays. Blakely et al., (1996) *Cancer Research*, 56:3287-3292 described some suitable drug-prodrug pairs.

**[0284]** Alternatively, the CD44-binding ligand can be coupled to high energy radiation emitters, for example, a radioisotope, such as  $^{131}\text{I}$ , a  $\gamma$ -emitter, which, when localized at the tumor site, results in a killing of several cell diameters. See, e.g., S.E. Order, "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", *Monoclonal Antibodies for Cancer Detection and Therapy*, R.W. Baldwin et al. (eds.), pp 303-316 (Academic Press 1985). Other suitable radioisotopes include  $\alpha$ -emitters, such as  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ , and  $^{211}\text{At}$ , and  $\beta$ -emitters, such as  $^{186}\text{Re}$  and  $^{90}\text{Y}$ . Moreover,  $\text{Lu}^{117}$  may also be used as both an imaging and cytotoxic agent.

**[0285]** Radioimmunotherapy (RIT) using antibodies labeled with  $^{131}\text{I}$ ,  $^{90}\text{Y}$ , and  $^{177}\text{Lu}$  is under intense clinical investigation. There are significant differences in the physical characteristics of these three nuclides and as a result, the choice of radionuclide is very critical in order to deliver maximum radiation dose to the tumor. The higher beta

energy particles of  $^{90}\text{Y}$  may be good for bulky tumors. The relatively low energy beta particles of  $^{131}\text{I}$  are ideal, but *in vivo* dehalogenation of radioiodinated molecules is a major disadvantage for internalizing antibody. In contrast,  $^{177}\text{Lu}$  has low energy beta particle with only 0.2-0.3 mm range and delivers much lower radiation dose to bone marrow compared to  $^{90}\text{Y}$ . In addition, due to longer physical half-life (compared to  $^{90}\text{Y}$ ), the tumor residence times are higher. As a result, higher activities (more mCi amounts) of  $^{177}\text{Lu}$  labeled agents can be administered with comparatively less radiation dose to marrow. There have been several clinical studies investigating the use of  $^{177}\text{Lu}$  labeled antibodies in the treatment of various cancers. (Mulligan T et al. (1995) *Clin Cancer Res.* 1:1447-1454; Meredith RF, et al. (1996) *J Nucl Med* 37:1491-1496; Alvarez RD, et al. (1997) *Gynecologic Oncology* 65: 94-101).

**[0286]** The CD44-binding ligands can be used directly *in vivo* to eliminate antigen- expressing cells via natural complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC). A CD44-binding protein described herein can include complement binding effector domain, such as the Fc portions from IgG1, -2, or -3 or corresponding portions of IgM which bind complement. In one embodiment, a population of target cells is *ex vivo* treated with a CD44-binding antibody and appropriate effector cells. The treatment can be supplemented by the addition of complement or serum containing complement. Further, phagocytosis of target cells that express CD44 and are coated with a CD44-binding antibody can be improved by binding of complement proteins. In another embodiment target, cells coated with the protein ligand which includes a complement binding effector domain are lysed by complement.

**[0287]** A CD44-binding antibody can also be used for prophylaxis. For example, the antibody can be used to prevent or delay development or progression of cancers, e.g.,, by inhibiting or killing a CD-44 expressing cell.

**[0288]** Use of the therapeutic methods described herein to treat cancers has a number of benefits. Since the protein ligands specifically recognize CD44, other tissue is spared and high levels of the agent are delivered directly to the site where therapy is required. Treatments can be effectively monitored with clinical parameters.

Alternatively, these parameters can be used to indicate when such treatment should be employed.

[0289] CD44-binding proteins can be administered in combination with one or more of the existing modalities for treating cancers, including, but not limited to: surgery; radiation therapy, and chemotherapy.

[0290] CD44-binding proteins can be administered in combination with one or more of the existing modalities for treating an inflammatory disease or disorder. Exemplary inflammatory diseases or disorders include: acute and chronic immune and autoimmune pathologies, such as, but not limited to, rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), psoriasis, graft versus host disease (GVHD), scleroderma, diabetes mellitus, allergy; asthma, acute or chronic immune disease associated with an allogenic transplantation, such as, but not limited to, renal transplantation, cardiac transplantation, bone marrow transplantation, liver transplantation, pancreatic transplantation, small intestine transplantation, lung transplantation and skin transplantation; chronic inflammatory pathologies such as, but not limited to, sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, and Crohn's pathology or disease; vascular inflammatory pathologies, such as, but not limited to, disseminated intravascular coagulation, atherosclerosis, Kawasaki's pathology and vasculitis syndromes, such as, but not limited to, polyarteritis nodosa, Wegener's granulomatosis, Henoch-Schonlein purpura, giant cell arthritis and microscopic vasculitis of the kidneys; chronic active hepatitis; Sjogren's syndrome; psoriatic arthritis; enteropathic arthritis; reactive arthritis and arthritis associated with inflammatory bowel disease; and uveitis. A CD44-binding protein can be used to treat or prevent one of the foregoing diseases or disorders. For example, the protein can be administered (locally or systemically) in an amount effective to ameliorate at least one symptom of the respective disease or disorder. The protein may also ameliorate inflammation, e.g., an indicator of inflammation, e.g., such as local temperature, swelling (e.g., as measured), redness, local or systemic white blood cell count, presence or absence of neutrophils, elastase activity, and so forth.

**[0291]** Cell Grafting and Transplantation

**[0292]** In one aspect, a CD44 binding antibody that has agonist activity is used to treat a subject (e.g., a human patient) prior to introducing exogenous cells into the subject. The antibody may be used, e.g., to decrease the rate of rejection of the exogenous cells, e.g., graft rejection. For example, the antibody can be used for hematopoietic stem cell transplantation (HSCT), e.g., a non-myeloablative HSCT regimen. The antibody can be administered prior to the transplantation, e.g., to sensitize cells prior to irradiating the subject. For example, the subject may have a hematopoietic cancer, e.g., a leukemia, such as chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML), multiple myeloma (MM), or a non-Hodgkin lymphoma (NHL). The human subject may be elderly (e.g., older than 60, 65, 70, 75, 80, 85, or 90 years of age) or may have additional co-morbidities.

**[0293]** Prior to transplantation, the subject is irradiated, e.g., with a low dose of total body irradiation (TBI), for example, to less than 500, 400, 300, 250, 200, 180, 160, 140, 100, or 50 cGy or less. In one implementation, TBI can be given at between 5-10 cGy/minute, e.g., from a dual cobalt 60 source or a linear accelerator. In other implementations, TBI may not be necessary. For example, alternate means can be used to achieve cell killing, e.g., NK cell ablation.

**[0294]** The cells used for transplantation can be allogenic (from the same species as the subject) or xenogenic (from another species). In one embodiment, the cells are matched for one or more antigens, e.g., MHC antigens. In another embodiment, unmatched cells are used.

**[0295]** After transplantation, the subject can be further treated with an immunosuppressant. For example, the subject can be treated with mycophenolate mofetil (MMF) and/or cyclosporine.

**[0296]** The outcome of transplantation can be evaluated by determining the degree of chimerism after transplantation. For example, fluorescence in situ hybridization to detect X or Y chromosomes for sex-mismatched transplants or PCR to

detect other genetic polymorphisms can be used. Between 1% and 95% PB donor T cells can be considered to be mixed chimerism.

**[0297]** In one embodiment, the HSCT regimen includes infusing peripheral blood stem cells (PBSCs) within zero, one or two days of TBI. For example, granulocyte colony stimulating factor (G-CSF) mobilized PBSCs from a donor can be used. After chimerism is detected, e.g., after about 20, 50, 80, 100, 150, 200, 250, or 300 days later, donor leukocytes can be infused, e.g., about  $10^6$ ,  $10^7$ , or  $10^8$  CD3<sup>+</sup> cells/kg, or ranges therebetween.

**[0298]** In one embodiment, the subject receives fludarabine in addition to the CD44-binding antibody prior to TBI. In other embodiments, other treatments can also be used in combination with sensitization with a CD44-binding antibody. Examples of such other treatments include: anti-lymphocyte globulin (ALG), anti-CD8 antibodies, or an alkylating agent such as cyclophosphamide.

**[0299]** In one aspect, a CD44-binding antibody that has agonist activity is used to modulate (e.g., control) graft-versus-host disease (GVHD), and host-versus-graft reactions (HVG) (e.g., a residual HVG after immunosuppression). The antibody can be used in a method that includes administering the antibody one or more times, before, during, or after transplantation of an exogenous cell, e.g., donor hematopoietic cells, e.g., leukocytes.

**[0300]** Other exemplary cells that can be introduced into a recipient subject include: xenogeneic, allogeneic, genetically engineered syngeneic, or genetically engineered autologous stem cells. For example, the stem cells can include an exogenous nucleic acid that expresses a cell surface protein, e.g., an MHC protein, e.g., an MHC Class I or Class II protein, e.g., matched or unmatched to the recipient. Exemplary sources of xenogeneic cells include porcine cells, primate cells, and human cells. It is also possible to use cells that are removed from the recipient, i.e., the recipient's own cells, wherein the removed cells are subsequently modified, e.g., by introduction of an exogenous nucleic acid, e.g., that expresses a cell surface protein.

**[0301]** Retroviral transformation allows production of transgenic bone marrow cells, preferably autologous bone marrow cells, expressing allogeneic or xenogeneic

MHC genes. Expression of the transgenic MHC genes confers tolerance to grafts which exhibit the products of these or closely related MHC genes. Thus, these methods provide for the induction of specific transplantation tolerance by somatic transfer of MHC genes. See, e.g., US 2002-0168348.

**[0302]** Without intending to be bound by theory, an S5-like CD44-binding antibody may improve success of engraftment after introduction of exogenous cells by one or more mechanisms. The antibody may sensitize host NK cells and prime them for ablation, e.g., by low dose irradiation. The antibody may enhance hematopoiesis of donor cells.

**[0303]** The methods described herein can be used to induce tolerance for any introduction of exogenous cells. Examples of cell engraftments include: solid organ transplantation (e.g., liver, kidney, lung, or heart), hematologic disorders, including aplastic anemia, severe combined immunodeficiency (SCID) states, thalassemia, diabetes and other autoimmune disease states, sickle cell anemia, and some enzyme deficiency states. A specific example of cell engraftment that can be achieved is partial engraftment of allogeneic or even xenogeneic bone marrow that creates a mixed host/donor chimeric state with preservation of immunocompetence and resistance to GVHD.

#### **[0304] Diagnostic Uses**

**[0305]** Protein ligands that bind to CD44 (e.g., those described herein) have *in vitro* and *in vivo* diagnostic, therapeutic and prophylactic utilities.

**[0306]** In one aspect, the invention provides a diagnostic method for detecting the presence of a CD44, *in vitro* (e.g., a biological sample, such as tissue, biopsy, e.g., a cancerous tissue) or *in vivo* (e.g., *in vivo* imaging in a subject).

**[0307]** The method includes: (i) contacting a sample with CD44-binding ligand; and (ii) detecting formation of a complex between the CD44-binding ligand and the sample. The method can also include contacting a reference sample (e.g., a control sample) with the ligand, and determining the extent of formation of the complex between the ligand and the sample relative to the same for the reference sample. A change, e.g., a

statistically significant change, in the formation of the complex in the sample or subject relative to the control sample or subject can be indicative of the presence of CD44 in the sample.

**[0308]** Another method includes: (i) administering the CD44-binding ligand to a subject; and (iii) detecting formation of a complex between the CD44-binding ligand, and the subject. The detecting can include determining location or time of formation of the complex.

**[0309]** The CD44-binding ligand can be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.

**[0310]** Complex formation between the CD44-binding ligand and CD44 can be detected by measuring or visualizing either the ligand bound to the CD44 or unbound ligand. Conventional detection assays can be used, e.g., an enzyme-linked immunosorbent assays (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. Further to labeling the CD44-binding ligand, the presence of CD44 can be assayed in a sample by a competition immunoassay utilizing standards labeled with a detectable substance and an unlabeled CD44-binding ligand. In one example of this assay, the biological sample, the labeled standards and the CD44 binding agent are combined and the amount of labeled standard bound to the unlabeled ligand is determined. The amount of CD44 in the sample is inversely proportional to the amount of labeled standard bound to the CD44 binding agent.

**[0311]** Fluorophore and chromophore labeled protein ligands can be prepared. Since antibodies and other proteins absorb light having wavelengths up to about 310 nm, the fluorescent moieties should be selected to have substantial absorption at wavelengths above 310 nm and preferably above 400 nm. A variety of suitable fluoresters and chromophores are described by Stryer (1968) *Science*, 162:526 and Brand, L. et al. (1972) *Annual Review of Biochemistry*, 41:843-868. The protein ligands can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Patent Nos. 3,940,475, 4,289,747, and 4,376,110. One group of fluoresters

having a number of the desirable properties described above is the xanthene dyes, which include the fluoresceins and rhodamines. Another group of fluorescent compounds are the naphthylamines. Once labeled with a fluorophore or chromophore, the protein ligand can be used to detect the presence or localization of the CD44 in a sample, e.g., using fluorescent microscopy (such as confocal or deconvolution microscopy).

**[0312]        Histological Analysis.** Immunohistochemistry can be performed using the protein ligands described herein. For example, in the case of an antibody, the antibody can be synthesized with a label (such as a purification or epitope tag), or can be detectably labeled, e.g., by conjugating a label or label-binding group. For example, a chelator can be attached to the antibody. The antibody is then contacted to a histological preparation, e.g., a fixed section of tissue that is on a microscope slide. After an incubation for binding, the preparation is washed to remove unbound antibody. The preparation is then analyzed, e.g., using microscopy, to identify if the antibody bound to the preparation.

**[0313]**        Of course, the antibody (or other polypeptide or peptide) can be unlabeled at the time of binding. After binding and washing, the antibody is labeled in order to render it detectable.

**[0314]        Protein Arrays.** The CD44-binding ligand can also be immobilized on a protein array. The protein array can be used as a diagnostic tool, e.g., to screen medical samples (such as isolated cells, blood, sera, biopsies, and the like). Of course, the protein array can also include other ligands, e.g., that bind to CD44 or to other target molecules, such as hyaluronic acid.

**[0315]**        Methods of producing polypeptide arrays are described, e.g., in De Wildt *et al.* (2000) *Nat. Biotechnol.* 18:989-994; Lueking *et al.* (1999) *Anal. Biochem.* 270:103-111; Ge (2000) *Nucleic Acids Res.* 28, e3, I-VII; MacBeath and Schreiber (2000) *Science* 289:1760-1763; WO 01/40803 and WO 99/51773A1. Polypeptides for the array can be spotted at high speed, e.g., using commercially available robotic apparatus, e.g., from Genetic Microsystems or BioRobotics. The array substrate can be, for example, nitrocellulose, plastic, glass, e.g., surface-modified glass. The array can also include a porous matrix, e.g., acrylamide, agarose, or another polymer.



[0316] For example, the array can be an array of antibodies, e.g., as described in De Wildt, *supra*. Cells that produce the protein ligands can be grown on a filter in an arrayed format. Polypeptide production is induced, and the expressed polypeptides are immobilized to the filter at the location of the cell.

[0317] A protein array can be contacted with a labeled target to determine the extent of binding of the target to each immobilized polypeptide from the diversity strand library. If the target is unlabeled, a sandwich method can be used, e.g., using a labeled probed, to detect binding of the unlabeled target.

[0318] Information about the extent of binding at each address of the array can be stored as a profile, e.g., in a computer database. The protein array can be produced in replicates and used to compare binding profiles, e.g., of a target and a non-target. Thus, protein arrays can be used to identify individual members of the diversity strand library that have desired binding properties with respect to one or more molecules.

[0319] **FACS. (Fluorescent Activated Cell Sorting).** The CD44-binding ligand can be used to label cells, e.g., cells in a sample (e.g., a patient sample). The ligand is also attached (or attachable) to a fluorescent compound. The cells can then be sorted using fluorescent activated cell sorted (e.g., using a sorter available from Becton Dickinson Immunocytometry Systems, San Jose CA; see also U.S. Patent No. 5,627,037; 5,030,002; and 5,137,809). As cells pass through the sorter, a laser beam excites the fluorescent compound while a detector counts cells that pass through and determines whether a fluorescent compound is attached to the cell by detecting fluorescence. The amount of label bound to each cell can be quantified and analyzed to characterize the sample.

[0320] The sorter can also deflect the cell and separate cells bound by the ligand from those cells not bound by the ligand. The separated cells can be cultured and/or characterized.

[0321] **In vivo Imaging.** In still another embodiment, the invention provides a method for detecting the presence of a CD44-expressing cancerous tissues *in vivo*. The method includes (i) administering to a subject (e.g., a patient having a cancer or neoplastic disorder) a CD44-binding antibody, conjugated to a detectable marker; (ii)

exposing the subject to a means for detecting said detectable marker to the CD44-expressing tissues or cells. For example, the subject is imaged, e.g., by NMR or other tomographic means.

**[0322]** Examples of labels useful for diagnostic imaging include radiolabels such as  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{123}\text{I}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ , and  $^{188}\text{Rh}$ , fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, positron emitting isotopes detectable by a positron emission tomography (“PET”) scanner, chemiluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes can also be employed. The protein ligand can be labeled with such reagents using known techniques. For example, see Wensel and Meares (1983) *Radioimmunoimaging and Radioimmunotherapy*, Elsevier, New York for techniques relating to the radiolabeling of antibodies and D. Colcher et al. (1986) *Meth. Enzymol.* 121: 802-816.

**[0323]** A radiolabeled ligand-labelled CD44-binding antibody can also be used for *in vitro* diagnostic tests. The specific activity of a isotopically-labeled ligand depends upon the half-life, the isotopic purity of the radioactive label, and how the label is incorporated into the antibody.

**[0324]** Procedures for labeling polypeptides with the radioactive isotopes (such as  $^{14}\text{C}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{131}\text{I}$ ) are generally known. For example, tritium labeling procedures are described in U.S. Patent No. 4,302,438. Iodinating, tritium labeling, and  $^{35}\text{S}$  labeling procedures, e.g., as adapted for murine monoclonal antibodies, are described, e.g., by Goding, J.W. (*Monoclonal antibodies : principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry, and immunology* 2nd ed. London ; Orlando : Academic Press, 1986. pp 124-126) and the references cited therein. Other procedures for iodinating polypeptides, such as antibodies, are described by Hunter and Greenwood (1962) *Nature* 144:945, David et al. (1974) *Biochemistry* 13:1014-1021, and U.S. Patent Nos. 3,867,517 and 4,376,110. Radiolabeling elements which are useful in imaging include  $^{123}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ , and  $^{99\text{m}}\text{Tc}$ , for example. Procedures for iodinating antibodies are described by Greenwood, F. et al. (1963) *Biochem. J.*

89:114-123; Marchalonis, J. (1969) *Biochem. J.* 113:299-305; and Morrison, M. et al. (1971) *Immunochemistry* 289-297. Procedures for  $^{99m}\text{Tc}$ -labeling are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), *Tumor Imaging: The Radioimmunochemical Detection of Cancer*, New York: Masson 111-123 (1982) and the references cited therein. Procedures suitable for  $^{111}\text{In}$ -labeling antibodies are described by Hnatowich, D.J. et al. (1983) *J. Immunol. Methods*, 65:147-157, Hnatowich, D. et al. (1984) *J. Applied Radiation*, 35:554-557, and Buckley, R. G. et al. (1984) *F.E.B.S.* 166:202-204.

**[0325]** In the case of a radiolabeled ligand, the ligand is administered to the patient, is localized to the tumor bearing the antigen with which the ligand reacts, and is detected or “imaged” *in vivo* using known techniques such as radionuclear scanning using e.g., a gamma camera or emission tomography. See e.g., A.R. Bradwell et al., “Developments in Antibody Imaging”, *Monoclonal Antibodies for Cancer Detection and Therapy*, R.W. Baldwin et al., (eds.), pp 65-85 (Academic Press 1985). Alternatively, a positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can be used where the radiolabel emits positrons (e.g.,  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{15}\text{O}$ , and  $^{13}\text{N}$ ).

**[0326] MRI Contrast Agents.** Magnetic Resonance Imaging (MRI) uses NMR to visualize internal features of living subject, and is useful for prognosis, diagnosis, treatment, and surgery. MRI can be used without radioactive tracer compounds for obvious benefit. Some MRI techniques are summarized in EP-A-0 502 814. Generally, the differences related to relaxation time constants T1 and T2 of water protons in different environments are used to generate an image. However, these differences can be insufficient to provide sharp high resolution images.

**[0327]** The differences in these relaxation time constants can be enhanced by contrast agents. Examples of such contrast agents include a number of magnetic agents paramagnetic agents (which primarily alter T1) and ferromagnetic or superparamagnetic (which primarily alter T2 response). Chelates (e.g., EDTA, DTPA and NTA chelates) can be used to attach (and reduce toxicity) of some paramagnetic substances (e.g.,  $\text{Fe}^{+3}$ ,  $\text{Mn}^{+2}$ ,  $\text{Gd}^{+3}$ ). Other agents can be in the form of particles, e.g., less than 10  $\mu\text{m}$  to about 10 nM in diameter). Particles can have ferromagnetic, antiferromagnetic or

superparamagnetic properties. Particles can include, e.g., magnetite ( $\text{Fe}_3\text{O}_4$ ),  $\gamma\text{-Fe}_2\text{O}_3$ , ferrites, and other magnetic mineral compounds of transition elements. Magnetic particles may include: one or more magnetic crystals with and without nonmagnetic material. The nonmagnetic material can include synthetic or natural polymers (such as sepharose, dextran, dextrin, starch and the like

**[0328]** The CD44-binding ligands can also be labeled with an indicating group containing of the NMR-active  $^{19}\text{F}$  atom, or a plurality of such atoms inasmuch as (i) substantially all of naturally abundant fluorine atoms are the  $^{19}\text{F}$  isotope and, thus, substantially all fluorine-containing compounds are NMR-active; (ii) many chemically active polyfluorinated compounds such as trifluoroacetic anhydride are commercially available at relatively low cost, and (iii) many fluorinated compounds have been found medically acceptable for use in humans such as the perfluorinated polyethers utilized to carry oxygen as hemoglobin replacements. After permitting such time for incubation, a whole body MRI is carried out using an apparatus such as one of those described by Pykett (1982) *Scientific American*, 246:78-88 to locate and image cancerous tissues.

**[0329]** Information obtained from evaluating a CD44-binding ligand, e.g., a ligand described herein, can be store as a computer representation, e.g., in a database, e.g., a database of images for one or a plurality of subjects. The database can be a relational database. The term “computer representation” refers to information which is in a form that can be manipulated by a computer. The act of storing a computer representation refers to the act of placing the information in a form suitable for manipulation by a computer.

**[0330]** Kits

**[0331]** Also within the scope of the invention are kits that include a composition described herein, e.g., a composition that contains a CD44-binding protein. In one embodiment, the kit includes (a) a composition that includes the CD44-binding protein, and, optionally, (b) informational material. The informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the compound for the methods described herein, e.g., a

treatment, prophylactic, or diagnostic use. For example, the informational material describes methods for administering the composition to treat a disorder, e.g., a neoplastic disorder or an inflammatory disorder, or a disorder characterized by excessive CD44 activity.

**[0332]** In another example, the composition includes a CD44-binding cell agonist or a CD44-binding cell sensitizing agent. The informational material can describes methods for administering the composition to sensitize a cell, e.g., an NK cell or to prepare a subject to receive exogenous cells, e.g., allogenic, xenogenic, matched, or unmatched cells.

**[0333]** In one embodiment, the informational material can include instructions to administer the compound in a suitable manner, e.g., in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein). In another embodiment, the informational material can include instructions for identifying a suitable subject, e.g., a human, e.g., a human having, or at risk for a disorder characterized by excessive elastase activity. The informational material can include information about production of the compound, molecular weight of the compound, concentration, date of expiration, batch or production site information, and so forth. The informational material of the kits is not limited in its form. Information about the compound can include structural information, e.g., amino acid sequence, tradename, FDA approved name, antibody isotype, and so forth. In many cases, the informational material, e.g., instructions, is provided in printed matter, e.g., a printed text, drawing, and/or photograph, e.g., a label or printed sheet. However, the informational material can also be provided in other formats, such as Braille, computer readable material, video recording, or audio recording. In another embodiment, the informational material of the kit is a link or contact information, e.g., a physical address, email address, hyperlink, website, or telephone number, where a user of the kit can obtain substantive information about the compound and/or its use in the methods described herein. The informational material can also be provided in any combination of formats.

**[0334]** In addition to the composition that includes the CD44-binding protein, the the composition itself can include other ingredients, such as a solvent or buffer, a

stabilizer or a preservative, and/or a second agent for treating a condition or disorder described herein, e.g. a neoplastic or inflammatory (e.g., IBD or RA) disorder. Alternatively, such other ingredients can be included in the kit, but in different compositions or containers than the composition that includes the CD44-binding protein. In such embodiments, the kit can include instructions for admixing the compound and the other ingredients, or for using the compound together with the other ingredients.

**[0335]** The composition that includes the CD44-binding protein can be provided in any form, e.g., liquid, dried or lyophilized form. It is preferred that composition be substantially pure and/or sterile. When the composition that includes the CD44-binding protein is provided in a liquid solution, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being preferred. When the composition that includes the CD44-binding protein is provided as a dried form, reconstitution generally is by the addition of a suitable solvent. The solvent, e.g., sterile water or buffer, can optionally be provided in the kit.

**[0336]** The kit can include one or more containers for the composition that includes the CD44-binding protein. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of the CD44-binding protein. For example, the kit includes a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of the compound. The containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight.

**[0337]** Kits can be provided that include a CD44-binding antibody and instructions for diagnostic, e.g., the use of the CD44-binding ligand (e.g., antibody or

antigen-binding fragment thereof, or other polypeptide or peptide) to detect CD44, *in vitro*, e.g., in a sample, e.g., a biopsy or cells from a patient having a cancer or neoplastic disorder, or *in vivo*, e.g., by imaging a subject. The kit can further contain a least one additional reagent, such as a label or additional diagnostic agent. For *in vivo* use the ligand can be formulated as a pharmaceutical composition.

[0338] The following invention is further illustrated by the following non-limiting examples.

[0339] **EXAMPLES**

[0340] **Example 1: Selection and Primary Screening**

[0341] Antibodies that recognize activated CD44 were selected from Dyax Corp.'s CJ phagemid library for binding to neuraminidase treated, soluble, biotinylated-CD44Fc protein immobilized on streptavidin magnetic beads.

[0342] **Construction of Soluble CD44Fc**

[0343] Human blood collected in the presence of sodium heparin was spun down to isolate the mononuclear cell layer. Cells were washed and mixed with RNAZOL™ (Cinna Bioteckx Laboratories) to isolate the RNA, as described in the product insert. Following cDNA production using poly dT priming, the extracellular domain of CD44 and the Fc portion of human IgG<sub>1</sub> were amplified. The extracellular domain of CD44 was cloned upstream of the Fc domain with a Factor X site in between. This construct, named CD44Fc, was cloned into pIRESneo2 (Clontech) to allow expression of soluble CD44Fc in mammalian cells.

[0344] **Expression and purification of CD44Fc**

[0345] HEK293T cells were transfected with endotoxin free DNA (Qiagen) (pIRESneo2CD44Fc) by standard methods using LIPOFECTAMINE™ 2000 (Invitrogen). Supernatants were harvested after 72 and 144 hours. Soluble CD44Fc was then purified from the pooled cell culture supernatant by immobilized Protein A

chromatography and characterized by protein staining using SDS-PAGE, Western Blot and ELISA methods.

**[0346]** CD44Fc biotinylation

**[0347]** Purified CD44-Fc was reacted with a 5-fold molar excess of sulfo-NHS-SS-biotin in 50 mM HEPES, pH 8.0, 100 mM NaCl overnight at 4°C. Free biotin was removed by buffer exchange into PBS, 0.01% Tween 20 using a BIOMAX™ device with a 10 kDa molecular weight cut-off membrane. Protein was quantified by absorbance at 280 nm where 1 mg/mL = 1.039 OD. The number of biotin molecules incorporated per mole of CD44-Fc was determined using the HABA assay as described by the manufacturer (Pierce).

**[0348]** Binding of Hyaluronic Acid (HA) to immobilized CD44Fc:

**[0349]** Biotinylated CD44Fc (b-CD44Fc) was treated with *V. cholerae* neuraminidase (Roche), which was chosen for its broad substrate specificity. Other glycosidase enzymes could have been used providing that, empirically, their activity could produce CD44 (e.g., b-CD44Fc) having increased affinity for HA (e.g., FL-HA). Briefly, 200 µg of CD44Fc plus 0.2 units neuraminidase per ml of PBS were incubated for 18 hours at 37°C. A control sample of b-CD44Fc was treated under identical conditions except without neuraminidase. Dilutions of neuraminidase treated and control b-CD44Fc were mixed with streptavidin coated polystyrene particles (Spherotech) for 1 hour at room temperature, blocked with 10% horse serum in DMEM and washed in HEPES/DMEM with 2% fetal calf serum. The b-CD44Fc coated beads were then incubated with Fluorescein HA (FL-HA), CD44-binding-FITC antibody, or various lectins for 45 minutes on ice. After a few washes, the HA binding activity, relative concentration of CD44 and sialic removal was determined by flow cytometric analysis on a FACSCAN™ (Becton Dickinson). Fluorescein-labeled HA was prepared following the isocyanide procedure as described in De Belder and Wik, Preparation and properties of fluorescein-labeled hyaluronate, *Carbohydr Res* 44(2):251-7 (1975).



**[0350]** Selection and screening for CD44-binding antibodies:

**[0351]** Using Dyax Corp.'s CJ phagemid Fab library, 3 rounds of selection were done with neuraminidase treated b-CD44Fc (100, 50 and 50 µg for 1st, 2nd and 3rd round respectively) immobilized on streptavidin coated magnetic beads (Dynal). The library was depleted against streptavidin coated magnetic beads on each round of selection, and soluble Trail-Fc (a commercially available Fc fusion protein) was included during the selections to remove Fc binders from being selected. Each round of selection included two cycles of streptavidin magnetic bead depletion, a cycle of binding of phage to treated b-CD44Fc coated beads, ten cycles of washes, elution of bound phage, and propagation of enriched phage ready for the next round. Phage bound to biotinylated-CD44Fc coated beads after ten washes were directly amplified, or eluted with 200 µg/mL of HA before amplification. After three rounds of selection, individual clones were grown in 96-well microtiter plates and were screened for CD44 binding activity by phage ELISA, using biotinylated-CD44Fc, Trail-Fc or streptavidin as targets. Numerous isolates (85%) showed reactivity to biotinylated-CD44Fc, but not to Trail-Fc or streptavidin. These isolates were DNA fingerprinted to determine their diversity. More than 10 different clones were identified.

**[0352]** ELISAs:

**[0353]** Individual clones were grown and rescued as described previously (Marks *et al.* (1991), *J. Mol. Biol.* 222:581). For the CD44Fc ELISAs, 96-well IMMULON2 HB™ plates (Thermo Labsystems) were coated with 1 µg/well IMMUNOPURE™ streptavidin (Pierce) in PBS and incubated overnight at 4°C. After three washes with PBS, 100 µL of the b-CD44Fc was added and allowed to bind to streptavidin for 30-60 minutes at room temperature. Next, the b-CD44Fc coated wells were blocked with 300 µL of 2% milk/1x PBS/0.05% Tween (2% MPBST) for two hours at 37°C. The b-CD44Fc coated wells were then incubated with 100 µL of phage culture supernatant that had been blocked with 2% MPBST for one hour at room temperature, washed five times with 1xPBS/Tween 0.1% (PBST), and incubated with 100 µL of anti-M13-HRP secondary antibody at a 1:5,000 dilution for one hour at room temperature. The

b-CD44Fc coated wells were washed five times with PBST before developing with TMB-solution and read at 630 nm.

**[0354]** For the cell ELISAs, cells were washed once in PBS and resuspended at a concentration of  $1 \times 10^6$  to  $2 \times 10^6$  cells/mL of PBS. A final concentration of  $1-2 \times 10^5$  cells per well of a 96-well tissue culture plate (Falcon, VWR) was used. The cells were fixed by adding an equal volume of 0.2% glutaraldehyde (Sigma-Aldrich) and incubating at 37°C for 12 minutes. They were then washed three times with PBS using an automated plate washer (Bio-Tek Instruments, Inc.) and blocked with 200 µL of 2% MPBST for one hour at room temperature. The rest of the ELISA was performed as described above except that 1xPBS/Tween 0.05% was used for the washes and incubations. For the HA inhibition assay, the wells were incubated with 50 µL of blocked phage culture supernatant, followed by overlaying 50 µL of 0.1 µg/ml HA-FITC per well and incubation for another hour at room temperature. After five washes with PBST, the samples were incubated with 100 µL of anti-FITC-HRP secondary antibody (Dako) at 1:800 dilution and incubated for one hour. Alternatively, for the OS/37 Ab competition ELISA, the samples were incubated with 50 µL of the CD44-binding OS/37 antibody (Seikagaku Corporation) at a 1:400 dilution in 2% MPBST for one hour at room temperature, followed by overlaying with 50 µL of blocked phage culture supernatant and incubation for an additional hour at room temperature.

**[0355]** DNA fingerprinting of clones:

**[0356]** Positive isolates were PCR amplified with the oligonucleotide primers M13-reverse and geneIII-forward (Marks *et al.* (1991), *J. Mol. Biol.* 222:581), and the product analyzed by *Bst*NI fingerprinting.

**[0357]** **Example 2: Secondary screening against CD44 expressed on cultured cells**

**[0358]** To verify the binding of selected clones to CD44 expressed on cells, the monocytic cell line KG1a was utilized. Cell ELISAs, as described above, were done

using untreated and neuraminidase treated KG1a cells. *V. cholerae* neuraminidase treated KG1a cells gain higher affinity for HA, as if CD44 has been activated.

**[0359]** The KG1a gain in affinity for HA was confirmed by flow cytometry. KG1a cells were incubated with 10  $\mu$ L CD44-binding-FITC antibody (clone F10-44-2, Biosource), or 10  $\mu$ g/mL FL-HA for 20 minutes on ice. After two washes with PBS, the cells were fixed with 2% paraformaldehyde (Sigma-Aldrich) in PBS, read in a FACS scan flow cytometer (FACSCAN™, BD Biosciences) and analyzed using CELL QUEST™ software (BD Biosciences). For T cells or monocytes,  $1 \times 10^6$  of the isolated cells were incubated with 200  $\mu$ L of heat-inactivated autologous plasma for 10 minutes on ice and washed once in PBS before staining for analysis.

**[0360]** Treatment with neuraminidase increased the binding capacity of CD44 to HA by 84%. There was no change in CD44 expression after treatment. Furthermore, ELISAs performed with these cells showed that several clones bound significantly more to neuraminidase treated KG1a cells than to mock treated cells. B12 is the CD44-binding control and F12 is the HA-FITC control.

**[0361]** Some clones competed directly with HA for binding to neuraminidase treated KG1a cells. FL-HA was incubated with neuraminidase-treated KG1a cells, followed by competition with Fab displaying phage. A number of phage isolates inhibited HA binding in this assay relative to controls.

**[0362]** All cells were grown at 37°C in a 0.5% CO<sub>2</sub> incubator. The monocyte cell line KG1a was grown in Iscove's modified Dulbecco's medium plus 20% fetal bovine serum and 4mM L-glutamine and 1.5 g/L sodium bicarbonate. KG1a cells were treated with neuraminidase from *V. cholerae* (Roche). Briefly, KG1a cells were washed once in a 1:1 solution of RPMI/PBS and resuspended at  $10^7$  cells/mL of RPMI/PBS containing 0.05 units/mL of neuraminidase for 75 minutes. Control cells were treated under identical conditions except without neuraminidase, then they were washed twice in PBS.

[0363] **Example 3: Screening against CD44 expressed on primary leukocytes**

[0364] Since activation of CD44 binding to HA *in vivo* can be accomplished through several mechanisms, we tested the ability of the isolated phage clones to recognize activated CD44 as expressed on the surface of leukocytes. In order to activate CD44 on primary T cells, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and cultured in the presence or absence of PMA and ionomycin for 18 hours. T cells were isolated by magnetic depletion of the non-T cell population. FACS analysis confirmed activation of CD44 in the T cell population. There was a 44% increase in FL-HA binding by T cells after treatment. As published previously in Brown *et al.* (2001), *J. Immunol* 167(9):5367-74; Maiti *et al.* (1998), *Science* 282:941-3, there was also a 14% increase in CD44 expression in these cells. When the same CD44-binding antibody (clone F10-44-2) was used in the ELISA, the difference in CD44 signal was not significantly different between the PMA/ionomycin treated cells and the untreated controls. Several Fab-expressing phage clones showed an increased signal to activated T cells when compared to unstimulated PBMC cells.

[0365] The PBMC isolation and culture was done as described previously (Brown *et al.* (2001), *J. Immunol* 167(9):5367-74). Briefly, whole blood (200-400 mL) from healthy volunteers was collected and treated with sodium heparin. The PBMCs were separated by centrifugation over a FICOLL-PLAQUE PLUS™ (Amersham Biosciences) density gradient. Contaminating red blood cells in the buffy coat were lysed using a human erythrocyte lysis kit from R&D Systems. The PBMCs were cultured at  $2.5 \times 10^6$  cells/mL in RPMI 1640/10% FBS with or without the following treatments: 500 units/mL IFN- $\gamma$  (R&D Systems) for 72 hours, or 1 ng/mL PMA plus 500 ng/mL ionomycin (both from Sigma-Aldrich) for 18 hours. Cells were seeded into 6-well ultra low attachment plates (Corning, VWR) for all applications except for stimulation of the T cell population with PMA and ionomycin where they were seeded into 6-well tissue culture plates (Falcon, VWR). After incubation the T cells or the CD14-positive monocyte/macrophage populations were isolated using the Pan T cell Isolation Kit or anti-CD14 MICROBEADS™, respectively (Miltenyi Biotech).

[0366] PBMCs were also stimulated with IFN-gamma for 72 hours, after which the monocyte/macrophage population was isolated using anti-CD14 MICROBEADS™. This population had an increase in FL-HA binding of 75% when compared to non-stimulated cells, as determined using FACS analysis. The CD44 levels did not change significantly after stimulation as detected by this method. ELISA results demonstrated a similar increase in FL-HA binding to activated CD14-positive cells, while the CD44 expression levels were not significantly different. Phage reactivity to the activated monocytes/macrophages was moderately increased as compared to their reactivity towards unstimulated PBMCs.

**[0367] Example 4: Screening against murine CD44**

[0368] We analyzed the reactivity of the CD44 binding clones to murine CD44 as expressed in a surface lymphocyte cell line. ELISA reactivity to BW5147.3, which expresses constitutively active CD44, was compared to the CD44-negative murine cell line AKR-1. Several clones show species cross reactivity.

[0369] All cells were grown at 37°C in a 0.5% CO<sub>2</sub> incubator. Mouse cell line BW5147.3 was grown in DMEM plus 10% horse serum and 1 mM sodium pyruvate. The mouse cell line AKR-1 was grown in DMEM (Mediatech) plus 10% horse serum.

**[0370] Example 5: Screening of soluble Fabs against CD44 expressed on cultured human cells and screening for inhibition of HA binding**

[0371] Four Fabs -- A2, A3, G2, H10 -- were tested for their ability to bind to human CD44+ cells and their ability to inhibit hyaluronan (HA) binding. The A2 Fab is a negative control.

**[0372] Methods**

[0373] Binding by the Fabs was analyzed as follows:

1. Cells incubated with varying concentrations of Fabs at 4°C for 15-20 min.
2. washed once

3. incubated with a detection antibody (either anti-cmyc or anti-6His) for 20 min at 4°C,
4. washed 1x
5. incubated with a secondary antibody: goat anti-mouse (GxM) FITC antibody for 20 min at 4°C
6. washed twice
7. analyzed on a FACSCAN™ machine (Becton Dickinson).

**[0374]** Fabs were detected with (1) a murine anti-cmyc tag antibody (9E10) and GxM FITC secondary antibody; or (2) a murine anti-6His mAb and GxM FITC secondary antibody. Later experiments predominantly used the anti-6His antibody because its signal was better. A mouse anti-human CD44 mAb that inhibits HA binding was used as a positive control. Binding by this monoclonal could be directly detected with the GxM FITC secondary antibody.

**[0375]** HA binding and inhibition was assessed by binding fluorescently labeled HA (FL-HA) to cells in the presence or absence of Fabs. FL-HA binding was also detected using FACS. Binding data are represented graphically as either amount of fluorescence (FL-1, arbitrary units) or as % inhibition of FL-HA binding.

**[0376] Results.** At low concentrations (0.1-1 µg/mL), the Fabs demonstrated low binding (Table 4) to KG1a cells and no inhibition of HA binding (Table 5).

**Table 4: Fab Binding at Low Concentration**

Antibody	FL Counts*
Positive Control	272
A2	6
A3	9
G2	10
H10	9

\*Values are FL counts in arbitrary units.

**Table 5: Inhibition of HA binding at Low Concentration**

Antibody	% Inhibition
Positive Control	83.00
A2	7.00
A3	20.00
G2	10.00
H10	16.00

[0377] Increasing the concentration of Fabs to 10 and 20 µg/mL increased binding to KG1a (Table 6, columns 2 and 3) and SR91 cells (a human myelo-monocytic cell line) (Table 6, columns 4 and 5). Binding by the G2 Fab was particularly evident at these concentrations (values being at least 4 times background). Similar results were seen at higher concentrations (Table 7).

**Table 6: CD44+ Cell Binding at Intermediate Concentrations (I)**

<i>Antibody</i>	<b>KG1a-HA+ Cells</b>		<b>SR91 Cells</b>	
	10µg/mL	20µg/mL	10µg/mL	20µg/mL
A2	2.68	3.53	2.09	2.24
A3	2.74	3.98	2.33	1.94
G2	9.37	15.48	4.35	9.1
H10	2.88	3.46	2.2	2.42
2° Ab control	2.08		2.08	

\*Values are FL counts in arbitrary units.

[0378] Dose dependent Fab binding and dose dependent inhibition of HA binding was observed for the G2 Fab at concentrations between 25 and 100 µg/mL. See Table 7 and Table 8.

**Table 7: CD44+ Cell Binding at Intermediate Concentrations (II)**

Antibody	25 µg/mL	50 µg/mL	100 µg/mL
9E10+gxm	29	29	29
A2	30	32	34
A3	33	31	33
G2	46	72	89
H10	34	30	32

\*Values are FL counts in arbitrary units.

**Table 8: HA Blocking by Fabs at Varying Concentrations**

Antibody*	25 µg/mL	50 µg/mL	100 µg/mL
HA	161		
Positive Control	20		
A2	199	171	181
A3	174	173	149
G2	146	117	93
H10	198	185	145

\*Except row 1 (HA).

[0379] Similar results were obtained for binding in assays that used the 6HIS mAb for detection of Fab binding. See Table 9. G2 bound in a dose dependent manner at concentrations between 20-100 µg/mL. H10 binding was observed at 100-1000 µg/mL.

[0380] KG1a cells were selected for hi HA binding (HA+) or lo HA binding (HA-). The lo HA binding cells express lower levels of CD44, but still bind significant levels of HA. Binding correlated with the level of CD44 as less binding was observed low CD44-expressing cells.

**Table 9: Fab Binding using anti-6His Ab Detection**

Fab: Conc. in µg/mL	G2 Fab		H10 Fab	
	KG1a-HA+	KG1a-HA-	KG1a-HA+	KG1a-HA-
(anti-6His/gxm-FITC)	6	6	6	6
20	43	48	9	7
50	134	99	12	12
100	240	213	39	34
1000			108	132



**[0381]** The results in Table 10 indicated that G2 binding to KG1a hi HA binding cells saturated at 125 µg/mL, but is dose dependent for KG1a HA lo selected cells. H10 binding was dose dependent for both cell types.

**[0382]** Both G2 and H10 exhibited significant inhibition of HA binding, although the H10 Fab did not bind as well as the G2 Fab. However, direct comparison of binding of Fabs with positive control mAb was not possible in this assay since the control mAb was detected using GxM FITC and whereas the Fabs were detected by anti-6His and GxM FITC.

**[0383]** G2 inhibited the binding of HA to CD44+ KG1a cells to 60-80% inhibition at 100 µg/mL (Table 11). The H10 Fab exhibited significant inhibition (~60%) at concentrations above 250 µg/mL. These results indicated that G2 has a higher affinity for CD44 than H10. With undiluted TCS, ~90% inhibition was observed for the positive control antibody whereas maximal inhibition by the G2 Fab was ~80%.

**Table 10: Binding Titration**

	KG1a-HA+				KG1a-HA-			
	125µg/mL	250 µg/mL	500 µg/mL	1 mg/mL	125 µg/mL	250 µg/mL	500 µg/mL	1mg/mL
2° Ab control	7	7	7	7	7	7	7	7
Positive C	289	328	448	332	331	345	407	352
G2	872	629	619	864	387	521	674	846
H10	65	92	106	176	46	74	108	117

• Values are arbitrary fluorescence units.

• The concentration of Fabs is 125-1000 µg/ml as listed below the cell type, and the concentration for the positive control is (from left to right) 1/8, 1/4, 1/2, or 1/1dilution of tissue culture supernatant.

**Table 11: Titration for HA Inhibition**

	KG1a-HA+				KG1a-HA-			
	125µg/mL	250 µg/mL	500 µg/mL	1 mg/mL	125 µg/mL	250 µg/mL	500 µg/mL	1mg/mL
Positive C	32.7	58.9	85.0	94.4	73.8	52.9	32.0	24.5
G2	66.4	67.3	72.0	77.6	46.9	46.2	42.4	37.9
H10	11.2	48.6	57.0	65.4	91.0	61.1	54.4	47.7

Values are % inhibition of HA binding.

• the conc. of FABS is 125-1000µg/mL and the conc. for the positive control is 1/1-1/8 dilution of tissue culture supernatant (TCS)

**[0384] Example 6: Affinity of Fabs and IgGs for CD44**

**[0385]** Divalent IgG4 antibodies (Abs) were produced using the full light chain and heavy chain variable region of the Fabs A2, A3, G2 and H10. The affinities of the Fabs and the corresponding divalent IgG4 Abs for human CD44-Fc and neuraminidase-treated (activated) CD44-Fc were evaluated in BIACORE™ analysis. The data are summarized in Table 13. For the divalent IgG4 Abs except H10, increased affinities relative to the parental Fabs were observed.

**Table 12: Antibody Affinities for CD44**

CD44-binding Antibody	K <sub>D</sub> (nM)	
	CD44-Fc	CD44-Fc(Activated)
A2 Fab	2820	249
A2 IgG4	2	1.5
A3 Fab	>500	>500
A3 IgG4	125	131
G2 Fab	239	353
G2 IgG4	123	173
H10 Fab	487	388
H10 IgG4	2348	3448

[0386] **Example 7: Titration of IgGs against CD44 expressed on cultured human cells and titration for inhibition of HA binding**

[0387] Divalent IgG4 antibodies (Abs) A2, A3, G2 and H10 were produced. Human myeloid cells (KG1a) were incubated with different concentrations (100, 75, 50, 12.5, 6.2, 3.1, 1.5, 0.75, 0.37, 0.18, 0.09, 0.04, 0.02, 0.01, 0.005  $\mu\text{g/mL}$ ) of A2, A3 or G2 antibodies on ice for 20 min or with 400, 200, 100, 75, 50, 12.5, 6.2, 3.1, 1.5, 0.75, 0.37, 0.18, 0.09, or 0.04  $\mu\text{g/mL}$  of A2 or H10 Abs on ice for 20min. Cells were washed once then incubated with secondary antibodies, goat anti human-FITC (Jackson Immune Research) 1/50 dilution for A2, A3, G2 and H10 antibodies or goat anti mouse-FITC (Southern Biotech) 1/50 dilution for a positive control antibody for 20 min. on ice. Cells were washed once and then analyzed on FACSCAN™. Results are summarized in Table 13. Because the positive control was a mouse anti-human Ab and a different secondary Ab was used to detect it, the highest mean fluorescence values for each antibody were converted to 100 and other values were calculated as a percentage of the highest value. Each graph depicts an average of three or four experiments.

[0388] HA binding inhibition was assessed by adding different concentrations of antibodies or PBS in control wells to cells incubated for 10 min. on ice, then HA-FITC 1/100 dilution was also added and incubated for 20 min. Cells were washed once, then binding and blocking of HA-FITC to cells was detected using FACSCAN™. Results are summarized in Table 13. Using the 50% binding concentrations of the antagonist IgG4s for human CD44 expressed on KG1a cells to calculate estimated  $\text{IC}_{50}$  values, the  $\text{IC}_{50}$ s are as follows: HAE-A3 IgG4:  $4.2 \times 10^{-9}$  M; HAE-G2 IgG4:  $1.0 \times 10^{-9}$  M; HAE-H10 IgG4:  $6.9 \times 10^{-8}$  M; Positive control mouse anti-human IgG:  $4.2 \times 10^{-9}$  M. Accordingly, antibodies with  $\text{IC}_{50}$ 's less than 200, 100, 50, 10, or 5 nM can be used.

**Table 13: CD44 Binding and HA Inhibition Titration**

<b>IgG Tested</b>	<b>Titration parameter</b>	<b>Initial Saturation Conc. (µg/mL)</b>	<b>50% CD44 Binding or HA Blocking Conc. (µg/mL)</b>
A3 IgG4	Binding to CD44 on cells	25	0.75
	Block HA binding to CD44 on cells	6	0.75
G2 IgG4	Binding to CD44 on cells	0.75 – 1.5	0.18
	Block HA binding to CD44 on cells	0.75	0.18
Positive control M anti-H IgG	Binding to CD44 on cells	12.5	0.75
	Block HA binding to CD44 on cells	6	0.5
H10 IgG4	Binding to CD44 on cells	100	12.5
	Block HA binding to CD44 on cells	50	6.2
Positive control M anti-H IgG	Binding to CD44 on cells	12.5	0.75
	Block HA binding to CD44 on cells	6	0.2
Negative control A2 IgG4	Binding to CD44 on cells	No binding	No blocking
	Block HA binding to CD44 on cells	No binding	No blocking

**[0389] Example 8: Assay of IgGs for binding to human endothelial cells and T cells and assay for inhibition of HA binding**

**[0390]** The binding of IgG4 Abs to human endothelial cells and CD44-transfected Jurkat T cells was determined by FACS analysis. Inhibition of HA binding by these cells was determined by measuring the ability of the antibodies to block binding of fluoresceinated hyaluronan (HA-FITC).

**[0391]** Human cells ( $2 \times 10^5$ ) in 50 µL volume were incubated with saturating concentrations (as determined for KG1a in Example 7), or above, of each antibody for 20 min. on ice, i.e., 50 µg/mL of A3 and A2, 6.2 µg/mL of G2 and 100 µg/mL of H10. In some cases, these amounts were titrated to examine binding and % HA inhibition. Cells were washed 1x then incubated with fluoresceinated secondary antibodies: 1/50 goat anti-human Ig FITC (Jackson Immune Research), or 1/50 goat anti-mouse Ig FITC (Southern Biotech) for 20 minutes on ice. Cells were washed once and then analyzed on

FACSCAN™ using CELL QUEST™ software (BD Biosciences). HA binding and inhibition was assessed by adding different concentrations of antibodies or PBS in control wells to cells incubated for 10 minutes on ice, then 50 µL 1/100 dilution of HA-FITC was added and incubated for 20 min. on ice. Cells were washed once then binding of HA-FITC to cells was detected by FACSCAN™.

**[0392] Results:** For the cell types assayed, levels of fluorescence between the control anti-human CD44 monoclonal antibody (HuCON) and the IgG4 antibodies are not necessarily comparable since different secondary detection antibodies were used.

**[0393] Human microvascular endothelial cell line (HMEC)**

**[0394]** HMECs express human CD44 but have low binding capacity for HA. All IgG4 antibodies except A2 bound well to these cells: A3 at 50, 25, and 12.5µg/mL; G2 at 6.2, 3.1, and 1.5 µg/mL; H10 at 100, 50, and 25 µg/mL. The positive control monoclonal antibody bound well at 12.5, 6.2 and 3.1 µg/mL. The antibodies A3, G2, H10 and the positive control all partially reduced HA binding. As HA binding by HMEC was poor, it was difficult to get a precise value both for HA binding and % inhibition with these cells, however, A3, G2 and H10 acted like the positive control.

**[0395] Human umbilical vein endothelial cell line (HUVEC)**

**[0396]** HUVEC express human CD44 and have low to medium binding capacity for HA. All IgG4 antibodies except A2 bound well to these cells: A3 at 50 µg/mL; G2 at 6.2 µg/mL; and H10 at 100 µg/mL. The antibodies G2, A3, H10 and the positive control substantially reduced the ability of HUVEC cells to bind to HA.

**[0397] Human Jurkat T cell line**

**[0398]** Jurkat T cells do not express human CD44 and do not bind HA. The IgG4 antibodies that bind CD44, like the positive control, did not bind to this CD44-negative cell line further substantiating that the antibodies are specific for human CD44.

**[0399] Human Jurkat T cells transfected with human CD44-H or CD44-R1**

**[0400]** These transfected cell lines express either the isoform of human CD44 that predominates on resting cells (CD44-H) or the isoform that is predominantly present on the myeloid cell line KG1a (CD44-R1). Neither of these transfected lines bind significant levels of HA. All IgG4 antibodies except A2 bound to these cells. For example, A3 bound at concentrations of 50, 25, and 12.5 µg/mL; G2 at 6.2, 3.1, and 1.5 µg/mL; and H10 at 100, 50, and 25 µg/mL. The positive control monoclonal antibody bound at 12.5, 6.2 and 3.1 µg/mL. The G2 antibody was the best binder.

**[0401] Human Jurkat T cells transfected with human CD44 point mutant**

**[0402]** This transfected cell line expresses an isoform of human CD44 that binds HA to a greater extent than the CD44-H or CD44-R1 isoforms. All IgG4 antibodies except A2 bound well to these cells and substantially inhibited HA binding: A3 at 50 µg/mL; G2 at 6.2 µg/mL; H10 at 100 µg/mL.

**[0403] Overall conclusions for binding to human cells**

**[0404]** Lack of binding to CD44-negative Jurkat T cells and binding to CD44-transfected Jurkat T cells demonstrates that Abs A3, G2 and H10 are specific for human CD44. These antibodies bind to CD44 expressed on human cells, irrespective of HA binding ability and bind to both CD44-H and CD44-R1 isoforms. When cells bind HA in CD44-dependent manner, antibodies A3, G2 and H10, like the positive control antibody, can substantially inhibit HA binding. Though antibody A2 binds CD44-Fc in BIACORE™ analysis (Example 6), it does not bind to CD44+ or CD44- human cells.

**[0405] Example 9:**

**[0406]** To identify CD44 binding clones that potentially recognize the overlapping CD44 epitopes bound by the S5 mouse anti-canine CD44 monoclonal antibody and the IM7 rat CD44-binding monoclonal antibody, phage isolates that showed reactivity to biotinylated-CD44Fc were screened by competition phage ELISA, a modification of the phage ELISA of Example 1. The b-CD44Fc coated wells were incubated with 450 ng of S5 or IM7 antibody in 100 µl of 2% MPBST for one hour at

room temperature, then 50 µl of phage culture supernatant was added for an additional incubation period of one hour at room temperature. Wells were then washed, incubated with anti-M13-HRP antibody, washed again and developed with TMB-solution as described in Example 1. Clones that were blocked from binding b-CD44Fc by either the S5 or IM7 antibody or both (Table 14) underwent DNA fingerprinting and sequencing analysis and several unique candidate agonist isolates were identified.

**Table 14: Blocking by S5 Monoclonal Antibody**

	CD44+S5	CD44
BE-A11	0.261	1.083
BE-B12	0.303	0.785
BE-D7	0.327	0.598
BE-H10	0.359	1.081

[0407] Clones inhibited by IM7 include: BE-B12, BE-D7, BE-H10, BE-H9, BE-A11, HAE-B8, HAE-F1, HAE-H-H10. Clones inhibited by S5 include: BE-B12, BE-D7, BE-H10, BE-H9, BE-A11.

[0408] **Example 10**

[0409] In vitro functional assays are also used to evaluate antibodies that recognize CD44. Exemplary assays include: 1. A static leukocyte-endothelial cell adhesion assay. The ability of antibodies to affect adherent cells in fluorescence microplate assay is evaluated. The analysis is used to determine the ability of antibodies to disrupt adherence between HMEC cells and KG1a cells. 2. Cell migration and wound healing assay. The ability of antibodies to modulate measured migration of cells (particularly endothelial cells after wound infliction) or in response to a particular signal is evaluated. 3. Cellular flow rolling and adhesion assay. Cells in medium are mixed with each antibody. The ability of each antibody to inhibit rolling on and adhesion to either hyaluronan or endothelial cells immobilized on a flow chamber surface is evaluated.

[0410] Other embodiments are within the following claims.